Benzenesulfonamide derivatives and uses thereof as protein binders
Patent Information
- Application Number
- PCT/IB2024/000099
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-07-18
- Filing Date
- 2024-02-21
- Publication Date
- 2024-12-05
AI Technical Summary
Covalent small molecule binders often suffer from off-target modifications due to susceptibility to nucleophilic metabolism by glutathione (GSH), leading to reduced efficacy and increased toxicity.
Development of benzenesulfonamide derivatives with a warhead group that selectively interacts with target proteins, such as Bruton’s tyrosine kinase (BTK), epidermal growth factor receptor (EGFR), and others, at ortho or meta positions relative to sulfur-containing groups, minimizing interaction at para-positions and reducing reactivity with GSH.
The compounds exhibit enhanced selectivity for target proteins over GSH, maintaining stability and efficacy, with reduced off-target effects and increased therapeutic potential.
Smart Images

Figure IB2024000099_05122024_PF_FP_ABST
Abstract
Description
BENZENESULFONAMIDE DERIVATIVES AND USES THEREOFCROSS-REFERENCE
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 486,622, filed February 23, 2023, U.S. Provisional Application No. 63 / 486,623, filed February 23, 2023, and U.S. Provisional Application No. 63 / 514,309, filed July 18, 2023, which are hereby incorporated by reference in their entirety herein.BACKGROUND
[0002] Chemical modification is an important tool to alter structure and function of proteins. One way to achieve chemical modification of proteins is to use protein binders, such as covalent small molecule binder (e.g., inhibitors). As a result, protein binders (e.g., covalent small molecule binders (e.g., inhibitors of proteins)) are considered to be useful in multiple applications, including therapeutics.BRIEF SUMMARY OF THE DISCLOSURE
[0003] Many covalent small molecule binders, specifically the warhead group of such compounds, are susceptible to off-target (e.g., covalent) modification, such as before reaching a target protein. In some instances, a warhead group of such a binder covalently modifies a protein (e.g., an off-target protein) or is metabolized, such as via nucleophilic metabolism by glutathione (GSH), and is neutralized before it has a chance to (e.g., covalently) modify its target protein. A warhead group that is more selective for a target protein and / or more stable to off-target (e.g., covalent) modification, such as modification via nucleophilic metabolism by glutathione (GSH), would help decrease off-target effects, such as resulting from covalent binding of the warhead to an off-target protein, and increase efficacy of (e.g., on-target effects of) covalent small molecule binders.
[0004] Provided herein are protein binders (e.g., covalent small molecule protein binders (e.g., inhibitors)). In some instances, the protein binders provided herein comprise a warhead group. In some instances, the warhead group directs covalent and / or irreversible interaction with a (e.g., cysteine residue of a) protein (e.g., described herein, such as a target protein). In some instances, the warhead group directs covalent and / or irreversible interaction with a (e.g., cysteine residue of a) target protein and is stable to off-target (e.g., covalent) modification, such as modification via nucleophilic metabolism by glutathione (GSH). In some instances, the warhead group directs covalent and / or irreversible interaction of a (e.g., cysteine residue of a) protein (e.g., described herein, such as a target protein) to a position of the warhead group that is ortho or meta to a sulfur- containing group (e.g., sulfone, sulfide, sulfoxide, or the like). In some instances, the protein does not covalently and / or irreversibly interact with the warhead group at a para-position. In someinstances, the protein covalently and / or irreversibly interacts with the warhead group at either an ortho-position or a meta-position, such as a position of the warhead that is ortho or meta relative to the sulfur containing group. In some instances, the warhead comprises a blocking group (e.g., hydrogen, CN, NO2, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, or the like). In some embodiments, the blocking group is at a position of the warhead that is para relative to the sulfur-containing group. In some embodiments, the blocking group directs covalent and / or irreversible interaction of a (e.g., cysteine residue of a) protein (e.g., described herein) to a position of the warhead that is ortho or meta relative to the sulfur-containing group.
[0005] In some instances, a compound provided herein (or a warhead group thereof) does not substantially bind to glutathione (GSH). In some instances, a compound provided herein is stable. In some instances, a compound provided herein (or a warhead group thereof) is stable to GSH. In some instances, a warhead of a compound provided herein is stable (e.g., to metabolism by GSH). In some instances, a warhead of a compound provided herein is stable to GSH. In some instances, a compound provided herein (or a warhead group thereof) does not bind to GSH. In some instances, a warhead of a compound provided herein does not bind to GSH. In some instances, a compound provided herein (or a warhead group thereof) has reduced reactivity with GSH. In some instances, a compound provided herein (or a warhead group thereof) forms covalent bond(s) with a polypeptide (e.g., a protein, such as Bruton’s tyrosine kinase (BTK), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), aurora kinase A (AURKA), proto- oncogene c-KIT (KIT), BMX non-receptor tyrosine kinase (BMX), transcriptional enhancer factor TEF (TEAD), Janus kinase 3 (JAK3), a KRAS protein or a mutant thereof (e.g., KRAS G12C, KRAS C118A, or KRAS G12C / C118A)) without substantially binding to GSH. In some instances, a compound provided herein (or a warhead group thereof) forms covalent bond(s) with a sulfur atom of a cysteine residue of a target protein without substantially covalently binding to the sulfur-containing GSH. In some instances, a compound provided herein (or a warhead group thereof) is selective for a polypeptide, such as a (target) protein described herein, relative to GSH. In some instances, GSH has minimal to no reactivity with a compound described herein (or a warhead group thereof), such that GSH is unable to react with (e.g., a warhead of) a compound provided herein. In some instances, GSH has a binding affinity (e.g., Kd) with a compound described herein (or a warhead group thereof) of more than 0.1 μM (e.g., 1 pm, 10 pm, 100 pm, or 1000 pm or more). In some instances, GSH has a binding affinity (e.g., Kd) with a compound described herein (or a warhead group thereof) of more than 10 pm.
[0006] In some embodiments, the compound (or a warhead group thereof) is selective for the polypeptide (e.g., a protein, such as Bruton’s tyrosine kinase (BTK), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), aurora kinase A (AURKA), proto-oncogene c-KIT (KIT), BMX non-receptor tyrosine kinase (BMX), transcriptional enhancer factor TEF (TEAD), Janus kinase 3 (JAK3), a KRAS protein or a mutant thereof (e.g., KRAS G12C, KRAS C118A, or KRAS G12C / C118A)). In some embodiments, the compound (or a warhead group thereof) is selective for the polypeptide (e.g., a protein, such as Bruton’s tyrosine kinase (BTK), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), aurora kinase A (AURKA), proto-oncogene c-KIT (KIT), BMX non-receptor tyrosine kinase (BMX), transcriptional enhancer factor TEF (TEAD), Janus kinase 3 (JAK3), a KRAS protein or a mutant thereof (e.g., KRAS G12C, KRAS Cl 18A, or KRAS G12C / C118A)) relative to GSH. In some embodiments, the compound (or a warhead group thereof) is selective for (e.g., covalent) binding to the polypeptide relative to GSH. In some embodiments, the compound (or a warhead group thereof) is selective for the polypeptide relative to GSH at a ratio of at least 10: 1 (e.g., 20: 1 or more, 50: 1 or more, 100: 1 or more, 500: 1 or more, 1000: 1 or more). In some embodiments, the compound (or a warhead group thereof) is selective for the polypeptide relative to GSH at a ratio of about 10: 1 to about 100: 1.
[0007] In some embodiments, the compound (or a warhead group thereof) is at least 2-fold (e.g., 2-fold or more, 5-fold or more, 10-fold or more, 25-fold or more) selective for the polypeptide relative to GSH.
[0008] In some embodiments, the compound has an ICso for the polypeptide of at least 10 pM and a GSH half life of greater than about 10 minutes. In some embodiments, the compound has an ICso for the polypeptide of at least 1 μM and a GSH half life of greater than about 10 minutes. In some embodiments, the compound has an IC50 of at least 0.1 μM and a GSH half life of greater than about 100 minutes.
[0009] In some embodiments, the compound (or a warhead group thereof) does not covalently bind with (e.g., the thiol of) GSH (e.g., at Y2or a position ortho or meta to Y2). In some embodiments, the compound (or a warhead group thereof) does not covalently bind with (e.g., the thiol of) GSH.
[0010] In some embodiments, a warhead group described herein is provided in Table A.
[0011] Provided in some embodiments herein is a compound having a structure of Formula (A):Formula (A)or a salt thereof, wherein,X1is absent or O;X is absent, O, or NRA;Q1is Rxor L-G;Q2is L-G or Y2;Y2is a blocking group (e.g., a group that directs (e.g., covalent and / or irreversible) binding (of a cysteine residue) of a protein to a position other than Y2);Rxis substituted or unsubstituted alkyl or NRyRz;RA, Ry, and Rzare each independently hydrogen or substituted or unsubstituted alkyl;L is a linker; andG is an organic residue; wherein one and only one of Q1or Q2is L-G.
[0012] In some embodiments, Q1is not substituted or unsubstituted methoxy phenyl.
[0013] Provided in some embodiments herein is a compound having a structure of Formula (I):Formula (I) or salt thereof, wherein,X2is absent, O, or NRA;RAis hydrogen or substituted or unsubstituted alkyl;Y2is a blocking group (e.g., a group that directs (e.g., covalent and / or irreversible) binding (of a cysteine residue) of a protein to a position other than Y2);L is a linker; andG is a protein-binding ligand (e.g., a radical of a compound that interacts with a protein or a mutant thereof, comprising one or more cyclic group wherein the one or more cyclic groups are individually linked by one or more linker).
[0014] In some embodiments, G is or comprises a protein-binding ligand selected from a BTK-, EGFR-, FGFR-, AURKA-, TEAD-, JAK3- KRAS-, and BMX-binding ligand. In some embodiments, G is or comprises a BTK-binding ligand. In some embodiments, G is or comprisesa EGFR-binding ligand. In some embodiments, G is or comprises a FGFR-binding ligand. In some embodiments, G is or comprises a AURKA-binding ligand. In some embodiments, G is or comprises a TEAD-binding ligand. In some embodiments, G is or comprises a JAK3-binding ligand. In some embodiments, G is or comprises KRAS-binding ligand. In some embodiments, G is or comprises a BMX-binding ligand.
[0015] Provided in some embodiments herein is a compound having a structure of Formula (I-A):Formula (LA) or a salt thereof, wherein,X is absent, O, or NRA;RAis hydrogen or substituted or unsubstituted alkyl;2Y is a blocking group (e.g., a group that directs (e.g., covalent and / or irreversible) binding (of a cysteine residue) of KRAS or a mutant thereof to a position other than Y2(e.g., a position ortho or meta to Y2));L is a linker; andG is a KRAS-binding ligand (e.g., a radical of a compound that interacts with a KRAS protein or a mutant thereof (e.g., KRAS G12C, KRAS C118A, or KRAS G12C / C118A) (e.g., an (e.g., unsaturated) unsubstituted or substituted carbocycle or an (e.g., unsaturated) unsubstituted or substituted heterocycle)).
[0016] Provided in some embodiments herein is a compound having a structure of Formula (I-Formula (LB) or a salt thereof, wherein,2X is absent, O, or NRA;RAis hydrogen or substituted or unsubstituted alkyl;2Y is a blocking group (e.g., a group that directs (e.g., covalent and / or irreversible) binding (of a cysteine residue) of JAK3 or a mutant thereof to a position other than Y2(e.g., a position ortho or meta to Y2));L is a linker; andG is a JAK3 -binding ligand (e.g., a radical of a compound that interacts with a JAK3 protein or a mutant thereof (e.g., an unsubstituted or substituted heterocycle)).
[0017] In some embodiments, the JAK3-binding ligand is an unsubstituted or substituted pyrrolopyrimidine, an unsubstituted or substituted pyrrolopyridine, an unsubstituted or substituted pyrazolopyrimidine, an unsubstituted or substituted pyrazolopyridine, or an unsubstituted or substituted benzimidazole. In some embodiments, the JAK3-binding ligand is a pyrrolopyrimidine described herein, such as a 7H-pyrrolo[2,3-t / ]pyrimidine described herein. In some embodiments, the JAK3 -binding ligand is a pyrrolopyridine described herein, such as a 1H- pyrrolo[2,3-b]pyridine described herein. In some embodiments, the JAK3-binding ligand is a pyrazolopyridine described herein, such as a pyrazolo[l,5-a]pyridine described herein.
[0018] In some embodiments, X2is O. In some embodiments, at least one of X1or X2is O.
[0019] In some embodiments, the compound (e.g., covalently and / or irreversibly) interacts with a protein or a mutant thereof (e.g., a cysteine residue of the protein or the mutant thereof) at a position other than Y2(e.g., a position ortho or meta to Y2).
[0020] In some embodiments, Y2is a group that directs (e.g., covalent and / or irreversible) binding (e.g., of a cysteine residue) of a protein (e.g., BTK, EGFR, FGFR, AURKA, BMX, TEAD, JAK3 KRAS) or a mutant thereof to a position other than Y2(e.g., a position ortho or meta to Y2).
[0021] In some embodiments, Y2is not halo. In some embodiments, Y2is not fluoro.
[0022] In some embodiments, Y2is hydrogen, CN, NO2, hydroxy, substituted or unsubstituted amino (e.g., -NRxaRya-, where Rxais hydroxy or substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo) and Ryais hydrogen or substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo)), substituted or unsubstituted alkyl (e.g., fluoroalkyl), substituted or unsubstituted alkoxy (e.g., fluoroalkoxy), or substituted or unsubstituted heteroalkyl (e.g., alkylamine substituted with oxo and / or hydroxy)). In some embodiments, Y2is hydrogen, CN, NO2, amino, hydroxy, substituted or unsubstituted alkoxy (e.g., methoxy), unsubstituted or substituted heteroalkyl (e.g., alkylamine or heteroalkyl substituted with oxo, such as Me2N(CO)O, MeNHCO-, Me2NCO-, and MeCONH-), unsubstituted alkyl (e.g., methyl), or substituted alkyl(e.g., alkyl substituted with hydroxy or amino (e.g., -NH2), alkyl substituted with oxo an amino (e.g., -C(O)NH2), alkyl substituted with hydroxy and oxo (e.g., -COOH), alkyl substituted with oxo and heterocyclyl (e.g., azetidinyl), alkyl substituted with halo (e.g., fluoroalkyl (e.g., methyl substituted with one, two, or three fluoro))). In some embodiments, Y2is hydrogen, CN, NO2, or substituted alkyl (e.g., alkyl substituted with halo (e.g., fluoroalkyl (e.g., methyl substituted with one, two, or three fluoro))).
[0023] In some embodiments, Y2is hydrogen, CN, NO2, or CF3.
[0024] In some embodiments, Y2is CN, NO2, or CF3.
[0025] In some embodiments, Y2is CN or NCh.
[0026] In some embodiments, such as when Y2is hydrogen, thiol, substituted thioether, substituted alkoxy (e.g., fluoroalkoxy), substituted amino, or NO2, the compound (e.g., covalently and / or irreversibly) interacts with a protein or a mutant thereof (e.g., a cysteine residue of the protein or the mutant thereof) at a position other than Y2(e.g., a position ortho or meta to Y2).
[0027] In some embodiments, G comprises an optionally substituted cyclic group, optionally substituted with one or more L’-G’, wherein each L’ individually selected from a linker and is connected to another G’ .
[0028] In some embodiments, G or G’ is a radical of a compound that interacts with a protein (e g., BTK, EGFR, FGFR, AURKA, BMX, TEAD, JAK3, KRAS) or a mutant thereof.
[0029] In some embodiments, G or G’ is amino, hydroxyl, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, alkoxy, or comprises one or more cyclic groups wherein the one or more cyclic groups are individually linked by one or more linker (e.g., L or L’).
[0030] In some embodiments, G or G’ comprises one or more cyclic group wherein the one or more cyclic groups are individually linked by one or more linker (e.g., L or L’).
[0031] In some embodiments, G or G’ comprises an optionally substituted cyclic group, optionally substituted with -(L’-G’)nL’-G’, wherein n is 0 to 4.
[0032] In some embodiments, n is 1 to 3.
[0033] In some embodiments, G or G’ is or comprises an (e.g., unsaturated) unsubstituted or substituted carbocycle or an (e.g., unsaturated) unsubstituted or substituted heterocycle)).
[0034] In some embodiments, G or G’ comprises a substituted or unsubstituted carbocycle.
[0035] In some embodiments, G or G’ comprises a substituted or unsubstituted heterocycle. In some embodiments, G is a substituted heterocycle.
[0036] In some embodiments, G or G’ comprises one or more (e.g., one, two, or three) nitrogen atoms (e.g., within its (e.g., fused) ring system).
[0037] In some embodiments, G or G’ comprises one or more (e.g., fused) rings.
[0038] In some embodiments, G or G’ is aromatic or partially aromatic.
[0039] In some embodiments, G or G’ comprises one or more (e.g., one, two, or three) substituted or unsubstituted (e.g., fused) aromatic ring(s). In some embodiments, G or G’ comprises two or more substituted or unsubstituted aromatic or partially aromatic rings.
[0040] In some embodiments, G or G’ comprises two or more substituted or unsubstituted aromatic or partially aromatic rings, each aromatic or partially aromatic ring independently being a carbocycle or a heterocycle. In some embodiments, G or G’ comprises one or more substituted or unsubstituted carbocycle and one or more substituted or unsubstitued heterocycle, each of the one or more substituted or unsubstituted carbocycle and the one or more substituted or unsubstitued heterocycle independently being linked (e.g., fused) to a substituted or unsubstituted carbocycle or a substituted or unsubstitued heterocycle by a bond. In some embodiments, G or G’ comprises two (or more) substituted or unsubstituted heteroaromatic rings, the heteroaromatic rings being linked (e.g., fused) by a bond, each heteroaromatic ring being aromatic or partially aromatic. In some embodiments, the heteroaromatic rings are selected from the group consisting of benzimidazole, indole, indolizine, pyridine, and pyridopyrimidinone (e.g., pyrido[2,3- d]pyrimidin-2(lH)-one).
[0041] In some embodiments, G or G’ comprises two (or more) substituted or unsubstituted phenyl rings, the phenyl being linked by a bond.
[0042] In some embodiments, G or G’ is or comprises a substituted or unsubsituted quinazoline, a substituted or unsubstituted tetrahydropyridopyrimidine (e.g., 5, 6,7,8- tetrahydropyrido[3,4-d]pyrimidine), a substituted or unsubsituted quinoline, a substituted or unsubstituted pyridopyrazinone (e.g., pyrido[2,3-b]pyrazin-3(4H)-one), a substituted or unsubstituted benzimidazole, a substituted or unsubstituted pyrrolopyrimidine (e.g., a 7H- pyrrolo[2,3-t / ]pyrimidine), a substituted or unsubstituted pyrazolopyridine (e.g., a pyrazolo[l,5- a]pyridine), or a substituted or unsubstituted pyrrolopyridine (e.g., a lH-pyrrolo[2,3-Z>]pyridine). In some embodiments, G or G’ is or comprises a substituted pyrrolopyridine (e.g., a 1H- pyrrolo[2,3-Z>]pyridine).
[0043] In some embodiments, G or G’ is a substituted quinazoline, a substituted tetrahydropyridopyrimidine (e.g., 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine), a substituted quinoline, a substituted pyridopyrazinone (e.g., pyrido[2,3-b]pyrazin-3(4H)-one). In some embodiments, G is a substituted tetrahydropyridopyrimidine (e.g., 5,6,7,8-tetrahydropyrido[3,4- d]pyrimidine).
[0044] In some embodiments, G or G’ has a structure shown in Table 1 A, Table IB, or Table 1C.
[0045] In some embodiments, G or G’ is a substituted carbocycle. In some embodiments, G is a substituted phenyl.
[0046] In some embodiments, G or G’ is a substituted heterocycle. In some embodiments, G or G’ is a substituted or unsubsituted quinazoline or a substituted pyrazolopyrimidine (e.g., 1H- pyrazolo[3,4-d]pyrimidine). In some embodiments, G or G’ is an unsubsituted quinazoline. In some embodiments, G is a substituted quinazoline or a substituted pyrazolopyrimidine (e.g., 1H- pyrazolo[3,4-d]pyrimidine). In some embodiments, G or G’ is a substituted pyridine. In some embodiments, G or G’ is a substituted pyrazole.
[0047] In some embodiments, the linker (e.g., L or L’) is a bond, amino, substituted or unsubstituted alkyl(ene), substituted or unsubstituted alkoxy, substituted or unsubstituted heteroalkyl(ene), substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl. In some embodiments, the linker (e.g., L or L’) is amino, substituted or unsubstituted heteroalkyl(ene), or substituted or unsubstituted heterocyclyl.
[0048] In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted C1-C6 alkylene. In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted C1-C6 heteroalkylene.
[0049] In some embodiments, the linker (e.g., L or L’) comprises a carbonyl. In some embodiments, the linker (e.g., L or L’) comprises an ester. In some embodiments, the linker (e.g., L or L’) comprises a ketone. In some embodiments, the linker (e.g., L or L’) comprises an amide.
[0050] In some embodiments, the linker (e.g., L or L’) comprises one or more N atom(s).
[0051] In some embodiments, the linker (e.g., L or L’) is amino. In some embodiments, the linker (e.g., L or L’) is -NR2-, where R2is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted carbocyclyl. In some embodiments, the linker (e.g., L or L’) is -NH- or -NCH3-.
[0052] In some embodiments, the linker (e.g., L or L’) is substituted or unsubstituted alkylamine. In some embodiments, the linker (e.g., L or L’) comprises a C1-C6 alkylamine. In some embodiments, the linker (e.g., L or L’) is -NR3R4-, where R3is substituted or unsubstituted alkyl(ene), substituted or unsubstituted heteroalkyl(ene), substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocycyl and R4is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted carbocyclyl. In some embodiments, the linker (e.g., L or L’) is methylamine, ethylamine, propylamine, or butylamine. In some embodiments, the linker (e.g., L or L’) is methylamine, ethylamine, or propylamine. In some embodiments, L is - NH(heterocyclyl)-. In some embodiments, L is -NH(azetidinyl)-.
[0053] In some embodiments, the linker (e.g., L or L’) is substituted or unsubstituted heterocyclyl. In some embodiments, NR5R6-, -NR5R6-NR7-, -NR5R6-C(O)-, -NR5R6-CH2NR7-, - NR5R6-CH2NR7C(O)-, -C(O)NR5R6-NR7-, or -C(O)NR5R6CH2-NR7-, where R5and R6are taken together to form a substituted or unsubstituted heterocyclyl, and R7is H, substituted orunsubstituted alkyl (e.g., alkyl substituted with oxo), or alkoxy. In some embodiments, the linker (e.g., L or L’) is -NR5R6-, where R5and R6are taken together to form a substituted or unsubstituted heterocyclyl. In some embodiments, L or L’ is substituted or unsubstituted piperazinyl or substituted or unsubstituted piperidinyl. In some embodiments, L is substituted or unsubstituted piperazinyl (e.g., piperazinyl substituted with methyl). In some embodiments, -NR5R6- is substituted or unsubstituted piperazinyl (e.g., piperazinyl substituted with methyl), substituted or unsubstituted piperidinyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted azepanyl, or diazepanyl (e.g., 1,4-diazepanyl). In some embodiments, -NR5R6- is substituted or unsubstituted piperidinyl or substituted or unsubstituted azetidinyl and -NR7- is -NH-, -NCH3-, -NC(O)CH3-, or -NCH2CH2OCH3-. In some embodiments, L or L’ is -NR5R6-C(O)- and -NR5R6- is unsubstituted 1,4-diazepanyl. In some embodiments, L or L’ is -C(O)NR5R6-NR7-, -NR5R6- is unsubstituted piperidinyl or unsubstituted pyrrolidinyl, and -NR7- is -NH-. In some embodiments, L or L’ is -NR5R6-CH2NR7C(O)-, -NR5R6- is unsubstituted pyrrolidinyl, and -NR7- is -NH-. In some embodiments, L or L’ is -NR5R6-CH2NR7- , -NR5R6- is unsubstituted azetidinyl or azepanyl, and -NR7- is -NH-. In some embodiments, L or L’ is -NR5R6-CH2NR7C(O)-, -NR5R6- is unsubstituted azetidinyl, and -NR7- is -NH-.
[0054] In some embodiments, the linker (e.g., L or L’) comprises two N atom(s) (e.g., (substituted or unsubstituted) diaminoalkyl, (substituted or unsubstituted) diamino-cycloalkyl, (substituted or unsubstituted) amino-heterocyclyl (e.g., the heterocyclyl being nitrogen containing), (substituted or unsubstituted) heterocyclyl (e.g., containing 2 nitrogen atoms), the heterocyclyl being optionally fused or spirocyclic). In some embodiments, L or L’ is or comprises -C(O)-diaminoalkyl-, each amino group of the diaminoalkyl being independently unsubstituted or substituted, such as being substituted with methyl.
[0055] In some embodiments, the linker (e.g., L or L’) comprises one or more (e.g., fused or spirocyclic) rings. In some embodiments, L or L’ is or comprises a spirocyclic ring, such as 1,7- diazaspiro[4.5]decane.
[0056] In some embodiments, L or L’ is or comprises substituted or unsubstituted phenyl.
[0057] In some embodiments, L or L’ is or comprises substituted phenyl, the phenyl being substituted with substitued halo, cyano, amino, alkylamino, heteroalkyl (e.g., substituted alkanolamine or substituted diaminoalkyl), -N-(substituted heterocyclyl), or substituted heterocyclyl, such as wherein the substituted heterocyclyl is piperidinyl or pyrrolidinyl substituted with amino or alkylamine.
[0058] In some embodiments, L or L’ is -NH-(unsubstituted phenyl)-, -NH-(unsubstituted phenyl)-C(O)-, -NH-(substituted phenyl)-C(O)-, -NH-(unsubstituted phenyl)-C(O)NH-, or-NH- (substituted phenyl)-C(O)NH-.
[0059] In some embodiments, the linker (e.g., L or L’) is a bond.
[0060] In some embodiments, the compound is represented by a structure of Table 2A, Table2B, Table 2C, or Table 2D.
[0061] Also provided herein are pharmaceutical compositions comprising the compounds described herein, and methods for using said compounds for the treatment of diseases. Provided herein are pharmaceutical compositions comprising the compounds provided herein. Also provided herein are pharmaceutical compositions that are at least partially stable to glutathione (GSH).
[0062] Also provided in some embodiments herein is a pharmaceutically acceptable composition comprising a compound disclosed herein, or a salt, solvate, tautomer, or regioisomer thereof, and one or more pharmaceutically acceptable excipients.
[0063] In some embodiments, provided herein is a pharmaceutical composition comprising a compound represented by a structure provided herein, such as the structure of Formula (A), Formula (I), Formula (I-A), Formula (I-B), or provided in Table 2A, Table 2B, Table 2C, or Table 2D.
[0064] In some embodiments provided herein is a pharmaceutical composition comprising a compound represented by a structure provided herein, such as the structure of Formula (A), Formula (I), Formula (I-A), Formula (I-B), or provided in Table 2A, Table 2B, Table 2C, or Table 2D, wherein the compound is selective for a polypeptide (e.g., a protein) relative to glutathione (GSH).
[0065] In some embodiments, provided herein is a pharmaceutical composition that is (e.g., at least partially) stable to glutathione (GSH).
[0066] In some embodiments, the pharmaceutical composition is (e.g., at least partially) stable to glutathione (GSH) in the presence of a polypeptide.
[0067] Provided herein in some embodiments is a pharmaceutical composition comprising a compound represented by a structure provided herein, such as the structure of Formula (A), Formula (I), Formula (I-A), Formula (I-B), or provided in Table 2A, Table 2B, Table 2C, or Table 2D, the compound having reduced reactivity with GSH.
[0068] In some embodiments, disclosed herein is a protein modified with a compound disclosed herein, or a salt, solvate, tautomer, or regioisomer thereof, wherein the compound forms a covalent bond with a sulfur atom of a cysteine residue of the protein.
[0069] Also provided herein are methods of modifying polypeptides, such as proteins, by contacting the polypeptides with the compounds provided herein. In some embodiments, provided herein are methods of selectively modifying polypeptides in the presence of glutathione with the compounds provided herein comprising contacting the polypeptides with the compound.
[0070] In some embodiments, disclosed herein is a method of modifying (e.g., attaching to and / or degrading) a polypeptide with a compound, comprising contacting the polypeptide with a compound disclosed herein, or a salt, solvate, tautomer, or regioisomer thereof, to form a covalent bond with a sulfur atom of a cysteine residue of the polypeptide.
[0071] In some embodiments, disclosed herein is a method of binding a compound to a polypeptide, comprising contacting the polypeptide with a compound disclosed herein, or a salt, solvate, tautomer, or regioisomer thereof.
[0072] In some embodiments, disclosed herein is a method of disrupting a polypeptide (e.g. the function thereof), comprising contacting the polypeptide with a compound disclosed herein, or a salt, solvate, tautomer, or regioisomer thereof.
[0073] Provided in some embodiments herein is a method of (e.g., selectively) modifying (e.g., covalently) a polypeptide (e.g., a protein) (e.g., intracellularly) with a compound (e.g., wherein the selectivity is for a sulfur-containing nucleophile of the protein over other (e.g., intracellular) sulfur-containing nucleophiles (e.g., in a biological system)), comprising contacting the polypeptide with the compound described herein, or a salt thereof. In some embodiments, the compound contacts the polypeptide intracellularly (e.g., in an individual).
[0074] In some cases, the present disclosure provides a KRAS protein or an active fragment thereof modified with a compound described herein, or a salt, solvate, tautomer, or regioisomer thereof, wherein the compound forms a covalent bond with a sulfur atom of a cysteine residue of the KRAS protein or an active fragment thereof (e.g., a polypeptide thereof).
[0075] In some cases, the present disclosure provides a method of modifying (e.g., attaching to and / or degrading) KRAS protein or an active fragment thereof with a compound, comprising contacting the polypeptide with a compound described herein, or a salt, solvate, tautomer, or regioisomer thereof, to form a covalent bond with a sulfur atom of a cysteine residue of the KRAS protein or an active fragment thereof (e.g., polypeptide thereof).
[0076] In some cases, the present disclosure provides a method of binding a compound to KRAS protein or an active fragment thereof, comprising contacting the KRAS protein or an active fragment thereof (e.g., polypeptide thereof) with a compound described herein, or a salt or solvate or tautomer or regioisomer thereof.
[0077] In some cases, the present disclosure provides a method of disrupting KRAS protein or an active fragment thereof (e.g., a function thereof), comprising contacting the KRAS protein or an active fragment thereof (e.g., polypeptide thereof) with a compound described herein, or a salt or solvate or tautomer or regioisomer thereof.
[0078] Provided in some embodiments herein is a method of (e.g., selectively) modifying (e.g., covalently) KRAS (or a mutant thereof) (e.g., intracellularly) with a compound provided herein(e.g., wherein the selectivity is for a sulfur-containing nucleophile of KRAS (or the mutant thereof) over other (e.g., intracellular) sulfur-containing nucleophiles (e.g., in a biological system))), comprising contacting KRAS (or the mutant thereof) with the compound provided herein, or a salt thereof. In some embodiments, the compound contacts KRAS (or the mutant thereof) intracellularly (e.g., in an individual).
[0079] Provided in some embodiments herein is a method for (e.g., selectively) modifying a polypeptide (e.g., a protein) with a compound represented by a structure provided herein, such as the structure of Formula (A) Formula (I), Formula (I- A), or Formula (I-B), the method comprising contacting the polypeptide with the compound, the compound having reduced reactivity with glutathione (GSH).
[0080] Provided in some embodiments herein is a method for (e.g., selectively) modifying a polypeptide (e.g., a protein) in the presence of glutathione (GSH) with a compound represented by a structure provided herein, such as the structure of Formula (A), Formula (I), Formula (I- A), or Formula (I-B), the method comprising contacting the polypeptide with the compound (e.g., to form a covalent bond with (e.g., a sulfur atom of a cysteine residue of) the polypeptide) without the compound substantially covalently binding to GSH (e.g., as demonstrated by the lack of covalent binding of GSH to the compound).
[0081] Provided herein in some embodiments, is a method for (e.g., selectively) modifying a polypeptide (e.g., a protein) in the presence of glutathione (GSH) with a compound represented by a structure provided herein, such as the structure of Formula (A), Formula (I), Formula (I- A), or Formula (I-B), the method comprising contacting the polypeptide with the compound, wherein the compound is selective for the polypeptide relative to GSH.
[0082] In some embodiments, the polypeptide covalently binds to the compound (e.g., wherein the polypeptide comprises a thiol (e.g., a cysteine residue) that covalently binds to the compound). In some embodiments, the polypeptide contacts (e.g., covalently binds) the compound in the absence of covalent binding of GSH to the compound.
[0083] In some embodiments, the polypeptide is a sulfur containing polypeptide, such as a cysteine containing polypeptide. In some embodiments, the polypeptide is Bruton’s tyrosine kinase (BTK), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), aurora kinase A (AURKA), proto-oncogene c-KIT (KIT), BMX non-receptor tyrosine kinase (BMX), transcriptional enhancer factor TEF (TEAD), Janus kinase 3 (JAK3), KRAS, or a mutant thereof (e.g., KRAS G12C, KRAS C118A, or KRAS G12C / C118A).
[0084] In some embodiments, the method further comprises inhibiting, deactivating, or degrading the polypeptide.INCORPORATION BY REFERENCE
[0085] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference for the specific purposes identified herein.BRIEF DESCRIPTION OF THE DRAWINGS
[0086] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also “Figure” and “FIG.” herein), of which:
[0087] FIG. 1A illustrates an example of a warhead portion, a linker portion, and a protein- binding ligand portion of a compound provided herein.
[0088] FIG. IB illustrates an example of a warhead portion, a linker portion, and a KRAS- binding ligand portion of a compound provided herein.
[0089] FIG. 1C illustrates an example of a warhead portion, a linker portion, and a JAK3- binding ligand portion of a compound provided herein.
[0090] FIG. 2 shows the amino acid sequence of KRAS G12C.
[0091] FIG. 3 shows the amino acid sequence of KRAS G12C Commercial.
[0092] FIG. 4 shows the amino acid sequence of KRAS G12C Lite.
[0093] FIG. 5 shows an exemplary warhead reaction progress curve used to calculate 50% warhead reaction (WRso) values, as described herein.DETAILED DESCRIPTION OF THE DISCLOSURE
[0094] As used herein and in the appended claims, the singular forms "a," "and," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an agent" includes a plurality of such agents, and reference to "the cell" includes reference to one or more cells (or to a plurality of cells) and equivalents thereof known to those skilled in the art, and so forth. When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulae, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. The term "about" when referring to a number or a numerical range means that the number or numerical range referred to is an approximation within experimental variability (or within statistical experimental error), and thus the number or numerical range, in some instances, will vary between 1% and 15% of the stated number or numerical range. In some embodiments, about is within 10% of the stated number or numerical range. In some embodiments, about is within 5% of the stated number or numerical range. In some embodiments, about is within 1% of the stated number or numericalrange. The term "comprising" (and related terms such as "comprise" or "comprises" or "having" or "including") is not intended to exclude that in other certain embodiments, for example, an embodiment of any composition of matter, composition, method, or process, or the like, described herein, "consist of' or "consist essentially of the described features.Definitions
[0095] As used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated below.
[0096] “KRAS protein” refers to a wild-type KRAS protein or a mutant thereof.
[0097] “KRAS-binding ligand” refers to a ligand binding to a KRAS protein or a mutant thereof, for example KRAS G12C, KRAS C118A, or KRAS G12C / C118A.
[0098] “Amino” refers to the -NH2 moiety.
[0099] “Cyano” refers to the -CN radical.
[0100] “Nitro” refers to the -NO2 radical.
[0101] “Hydroxy” or “hydroxyl” refers to the -OH moiety.
[0102] "Alkyl" generally refers to a non-aromatic straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, partially or fully saturated, cyclic or acyclic, having from one to fifteen carbon atoms (e.g., C1-C14 alkyl). Unless otherwise state, alkyl is saturated or unsaturated (e.g., an alkenyl, which comprises at least one carbon-carbon double bond). Disclosures provided herein of an “alkyl” are intended to include independent recitations of a saturated “alkyl,” unless otherwise stated. Alkyl groups described herein are generally monovalent, but may also be divalent (which may also be described herein as “alkylene” or “alkylenyl” groups). In certain embodiments, an alkyl comprises one to thirteen carbon atoms (e.g., C1-C12 alkyl). In certain embodiments, an alkyl comprises one to eight carbon atoms (e.g., Ci-Cs alkyl). In other embodiments, an alkyl comprises one to five carbon atoms (e.g., C1-C5 alkyl). In other embodiments, an alkyl comprises one to four carbon atoms (e.g., C1-C4 alkyl). In other embodiments, an alkyl comprises one to three carbon atoms (e.g., C1-C3 alkyl). In other embodiments, an alkyl comprises one to two carbon atoms (e.g., C1-C2 alkyl). In other embodiments, an alkyl comprises one carbon atom (e.g., Ci alkyl). In other embodiments, an alkyl comprises five to fifteen carbon atoms (e.g., C5-C15 alkyl). In other embodiments, an alkyl comprises five to eight carbon atoms (e.g., Cs-Cs alkyl). In other embodiments, an alkyl comprises two to five carbon atoms (e.g., C2-C5 alkyl). In other embodiments, an alkyl comprises three to five carbon atoms (e.g., C3-C5 alkyl). In other embodiments, the alkyl group is selected from methyl, ethyl, 1 -propyl ( / / -propyl), 1 -methylethyl ( / .w-propyl), 1 -butyl ( / / -butyl), 1 -methylpropyl (sec-butyl), 2-methylpropyl ( / .w-butyl), 1,1 -dimethylethyl (tert-butyl), 1 -pentyl ( / / -pentyl). The alkyl is attached to the rest of the molecule by a single bond. In general, alkyl groups are eachindependently substituted or unsubstituted. Each recitation of “alkyl” provided herein, unless otherwise stated, includes a specific and explicit recitation of an unsaturated “alkyl” group. Similarly, unless stated otherwise specifically in the specification, an alkyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)N(Ra)2, - N(Ra)C(O)ORa, -OC(O)-N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)S(O)tRa(where t is 1 or 2), -S(O)tORa(where t is 1 or 2), -S(O)tRa(where t is 1 or 2) and -S(O)tN(Ra)2(where t is 1 or 2) where each Rais independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl). In certain embodiments, an alkyl includes alkenyl, alkynyl, cycloalkyl, carbocycloalkyl, cycloalkylalkyl, haloalkyl, and fluoroalkyl, as defined herein.
[0103] "Alkenyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon double bond, and having from two to twelve carbon atoms. In certain embodiments, an alkenyl comprises two to eight carbon atoms. In other embodiments, an alkenyl comprises two to four carbon atoms. The alkenyl is attached to the rest of the molecule by a single bond, for example, ethenyl (z.e., vinyl), prop-l-enyl (z.e., allyl), but-l-enyl, pent-l-enyl, penta- 1,4-dienyl, and the like. Unless stated otherwise specifically in the specification, an alkenyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -OC(O)- N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)S(O)tRa(where t is 1 or 2), -S(O)tORa(where t is 1 or 2), -S(O)tRa(where t is 1 or 2) and -S(O)tN(Ra)2(where t is 1 or 2) where each Rais independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), cycloalkyl alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocycloalkylalkyl(optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl).
[0104] "Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation and having from one to twelve carbon atoms, for example, methylene, ethylene, propylene, ^-butylene, and the like. The alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group are through one carbon in the alkylene chain or through any two carbons within the chain. In certain embodiments, an alkylene comprises one to eight carbon atoms (e.g., Ci-Cs alkylene). In other embodiments, an alkylene comprises one to five carbon atoms (e.g., C1-C5 alkylene). In other embodiments, an alkylene comprises one to four carbon atoms (e.g., C1-C4 alkylene). In other embodiments, an alkylene comprises one to three carbon atoms (e.g., C1-C3 alkylene). In other embodiments, an alkylene comprises one to two carbon atoms (e.g., C1-C2 alkylene). In other embodiments, an alkylene comprises one carbon atom (e.g., Ci alkylene). In other embodiments, an alkylene comprises five to eight carbon atoms (e.g., Cs-Cs alkylene). In other embodiments, an alkylene comprises two to five carbon atoms (e.g., C2-C5 alkylene). In other embodiments, an alkylene comprises three to five carbon atoms (e.g., C3-C5 alkylene). Unless stated otherwise specifically in the specification, an alkylene chain is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -ORa, -SIU, -OC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -OC(O)-N(Ra)2, - N(Ra)C(O)Ra, -N(Ra)S(O)tRa(where t is 1 or 2), -S(O)tORa(where t is 1 or 2), -S(O)tRa(where t is 1 or 2) and -S(O)tN(Ra)2 (where t is 1 or 2) where each Rais independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), cycloalkyl alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl).
[0105] "Alkoxy" refers to a radical bonded through an oxygen atom of the formula -O-alkyl, where alkyl is as defined above. Unless stated otherwise specifically in the specification, an alkoxy group is optionally substituted, as defined above for an alkyl group.
[0106] "Alkoxyalkyl" refers to an alkyl moiety comprising at least one alkoxy substituent, where alkyl is as defined above. Unless stated otherwise specifically in the specification, an alkoxyalkyl group is optionally substituted, as defined above for an alkyl group.
[0107] "Alkylamino" refers to a moiety of the formula -NHRaor -NRaRbwhere Raand Rbare each independently an alkyl group as defined above. Unless stated otherwise specifically in the specification, an alkylamino group is optionally substituted, as defined above for an alkyl group.
[0108] "Alkylaminoalkyl" refers to an alkyl moiety comprising at least one alkylamino substituent. The alkylamino substituent can be on a tertiary, secondary or primary carbon. Unless stated otherwise specifically in the specification, an alkylaminoalkyl group is optionally substituted, as defined above for an alkyl group.
[0109] “Aminoalkyl” refers to an alkyl moiety comprising at least one amino substituent. The amino substituent can be on a tertiary, secondary or primary carbon. Unless stated otherwise specifically in the specification, an aminoalkyl group is optionally substituted, as defined above for an alkyl group.
[0110] "Aryl" refers to a radical derived from an aromatic monocyclic or multicyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom. The aromatic monocyclic or multicyclic hydrocarbon ring system contains only hydrogen and carbon from five to eighteen carbon atoms, where at least one of the rings in the ring system is fully unsaturated, z.e., it contains a cyclic, delocalized (4n+2) ^-electron system in accordance with the Hiickel theory. The ring system from which aryl groups are derived include, but are not limited to, groups such as benzene, fluorene, indane, indene, tetralin and naphthalene. Unless stated otherwise specifically in the specification, the term "aryl" or the prefix "ar-" (such as in "aralkyl") is meant to include aryl radicals optionally substituted by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -Rb-ORa, -Rb-OC(O)-Ra, -Rb-OC(O)-ORa, -Rb-OC(O)- N(Ra)2, -Rb-N(Ra)2, -Rb-C(O)Ra, -Rb-C(O)ORa, -Rb-C(O)N(Ra)2, -Rb-O-Rc-C(O)N(Ra)2, -Rb- N(Ra)C(O)ORa, -Rb-N(Ra)C(O)Ra, -Rb-N(Ra)S(O)tRa(where t is 1 or 2), -Rb-S(O)tRa(where t is 1 or 2), -Rb-S(O)tORa(where t is 1 or 2) and -Rb-S(O)tN(Ra)2 (where t is 1 or 2), where each Rais independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, ortrifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), each Rbis independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rcis a straight or branched alkylene or alkenylene chain, and where each of the above substituents is unsubstituted unless otherwise indicated.
[0111] “Arylene” refers to a divalent aryl group which links one part of the molecule to another part of the molecule. Unless stated specifically otherwise, an arylene is optionally substituted, as defined above for an aryl group.
[0112] "Aralkyl" refers to a radical of the formula -Rc-aryl where Rcis an alkylene chain as defined above, for example, methylene, ethylene, and the like. The alkylene chain part of the aralkyl radical is optionally substituted as described above for an alkylene chain. The aryl part of the aralkyl radical is optionally substituted as described above for an aryl group.
[0113] The term “carbocycle” or “carbocyclic” refers to a ring or ring system where the atoms forming the backbone of the ring are all carbon atoms. The term thus distinguishes carbocyclic group from a “heterocycle” or “heterocyclic” in which the ring backbone contains at least one atom which is different from carbon. In some embodiments, carbocycles are monocyclic, bicyclic, polycyclic, spirocyclic or bridged compounds. Carbocycle includes aromatic and partially or fully saturated ring systems. In some embodiments, carbocycle comprises cycloalkyl and aryl. In some embodiments, a carboxycle provided herein is optionally substituted (e.g., carbocycle substituted with one or more carbocycle substitutent, each carbocycle substituent being independently selected from the group consisting of alkyl, oxo, halo, hydroxyl, heteroalkyl, alkoxy, aryl, and heteroaryl). In some embodiments, a heterocycle provided herein is optionally substituted (e.g., heterocycle substituted with one or more heterocycle substitutent, each heterocycle substituent being independently selected from the group consisting of alkyl, oxo, halo, hydroxyl, heteroalkyl, alkoxy, aryl, and heteroaryl).
[0114] "Cyclic ring" refers to a carbocycle or heterocycle, including aromatic, non- saturated, and saturated carbocycle and heterocycle. A "cyclic ring" is optionally monocyclic or polycyclic (e.g., bicyclic).
[0115] "Cycloalkyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which includes fused or bridged ring systems, having from three to fifteen carbon atoms. In certain embodiments, a cycloalkyl comprises three to ten carbon atoms. In other embodiments, a cycloalkyl comprises five to seven carbon atoms. The cycloalkyl is attached to the rest of the molecule by a single bond. Cycloalkyl is saturated (z.e., containing single C-C bonds only) or unsaturated (z.e., containing one or more double bonds or triple bonds). Examples of monocyclic cycloalkyls include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. An unsaturated cycloalkyl is also referred to as "cycloalkenyl." Examples of monocyclic cycloalkenyls include, e.g., cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Polycyclic cycloalkyl radicals include, for example, adamantyl, norbomyl (z.e., bicyclo[2.2.1]heptanyl), norbornenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, the term "cycloalkyl" is meant to include cycloalkyl radicals that are optionally substituted by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -Rb-ORa, -Rb-OC(O)-Ra, -Rb-OC(O)-ORa, -Rb-OC(O)-N(Ra)2, -Rb- N(Ra)2, -Rb-C(O)Ra, -Rb-C(O)ORa, -Rb-C(O)N(Ra)2, -Rb-O-Rc-C(O)N(Ra)2, -Rb-N(Ra)C(O)ORa, -Rb-N(Ra)C(O)Ra, -Rb-N(Ra)S(O)tRa(where t is 1 or 2), -Rb-S(O)tRa(where t is 1 or 2), -Rb- S(O)tORa(where t is 1 or 2) and -Rb-S(O)tN(Ra)2(where t is 1 or 2), where each Rais independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), each Rbis independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rcis a straight or branched alkylene or alkenylene chain, and where each of the above substituents is unsubstituted unless otherwise indicated.
[0116] "Cycloalkylalkyl" refers to a radical of the formula -Rc-cycloalkyl where Rcis an alkylene chain as defined above. The alkylene chain and the cycloalkyl radical is optionally substituted as defined above.
[0117] " Halo" or "halogen" refers to bromo, chloro, fluoro or iodo substituents. A “haloalkyl” refers to an alkyl radical, as described herein, that is substituted with one or more halo radical, such as described above.
[0118] "Fluoroalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more fluoro radicals, as defined above, for example, trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, l-fluoromethyl-2-fluoroethyl, and the like. In some embodiments, the alkyl part of the fluoroalkyl radical is optionally substituted as defined above for an alkyl group.
[0119] The term “heteroalkyl” refers to an alkyl group as defined above in which one or more skeletal carbon atoms of the alkyl are substituted with a heteroatom (with the appropriate number of substituents or valencies - for example, -CH2- may be replaced with -NH- or -O-). For example, each substituted carbon atom is independently substituted with a heteroatom, such as wherein the carbon is substituted with a nitrogen, oxygen, sulfur, or other suitable heteroatom. In some instances, each substituted carbon atom is independently substituted for an oxygen, nitrogen (e.g. -NH-, -N(alkyl)-, or -N(aryl)- or having another substituent contemplated herein), or sulfur (e.g. -S-, -S(=O)-, or -S(=O)2-). In some embodiments, a heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. In some embodiments, a heteroalkyl is attached to the rest of the molecule at a heteroatom of the heteroalkyl. In some embodiments, a heteroalkyl is a Ci -Ci 8 heteroalkyl. In some embodiments, a heteroalkyl is a C1-C12 heteroalkyl. In some embodiments, a heteroalkyl is a C1-C6 heteroalkyl. In some embodiments, a heteroalkyl is a Ci- C4 heteroalkyl. In some embodiments, heteroalkyl includes alkylamino, alkylaminoalkyl, aminoalkyl, heterocycloalkyl, heterocycloalkyl, heterocyclyl, and heterocycloalkylalkyl, as defined herein. Unless stated otherwise specifically in the specification, heteroalkyl does not include alkoxy as defined herein. Unless stated otherwise specifically in the specification, a heteroalkyl group is optionally substituted as defined above for an alkyl group.
[0120] “Heteroalkylene” refers to a divalent heteroalkyl group defined above which links one part of the molecule to another part of the molecule. Unless stated specifically otherwise, a heteroalkylene is optionally substituted, as defined above for an alkyl group.
[0121] The term “heterocycle” or “heterocyclic” refers to heteroaromatic rings (also known as heteroaryls) and heterocycloalkyl rings (also known as heteroalicyclic groups) that includes at least one heteroatom selected from nitrogen, oxygen and sulfur, wherein each heterocyclic group has from 3 to 12 atoms in its ring system, and with the proviso that any ring does not contain twoadjacent O or S atoms. In some embodiments, heterocycles are monocyclic, bicyclic, polycyclic, spirocyclic or bridged compounds. Non-aromatic heterocyclic groups (also known as heterocycloalkyls) include rings having 3 to 12 atoms in its ring system and aromatic heterocyclic groups include rings having 5 to 12 atoms in its ring system. The heterocyclic groups include benzo-fused ring systems. Examples of non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, oxazolidinonyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, pyrrolin-2-yl, pyrrolin-3-yl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3- azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3 h-indolyl, indolin-2-onyl, isoindolin-1- onyl, isoindoline- 1, 3-dionyl, 3,4-dihydroisoquinolin-l(2H)-onyl, 3,4-dihydroquinolin-2(lH)- onyl, isoindoline- 1, 3-dithionyl, benzo[d]oxazol-2(3H)-onyl, lH-benzo[d]imidazol-2(3H)-onyl, benzo[d]thiazol-2(3H)-onyl, and quinolizinyl. Examples of aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. The foregoing groups are either C-attached (or C-linked) or TV-attached where such is possible. For instance, a group derived from pyrrole includes both pyrrol-l-yl (TV-attached) or pyrrol-3-yl (C-attached). Further, a group derived from imidazole includes imidazol-l-yl or imidazol-3-yl (both TV-attached) or imidazol-2-yl, imidazol-4-yl or imidazol-5-yl (all C-attached). The heterocyclic groups include benzo-fused ring systems. Non-aromatic heterocycles are optionally substituted with one or two oxo (=0) moieties, such as pyrrolidin-2-one. Heterocycle includes aromatic and partially or fully saturated ring systems. In some embodiments, at least one of the two rings of a bicyclic heterocycle is aromatic. In some embodiments, both rings of a bicyclic heterocycle are aromatic.
[0122] "Heterocycloalkyl" refers to a stable 3- to 18-membered non-aromatic ring radical that comprises two to twelve carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur. Unless stated otherwise specifically in the specification, the heterocycloalkyl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which optionally includes fused or bridged ring systems. The heteroatoms in the heterocycloalkyl radical are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocycloalkylradical is partially or fully saturated. The heterocycloalkyl is attached to the rest of the molecule through any atom of the ring(s). In some embodiments, heterocycloalkyl comprises 2-12 C atoms, 0-6 N atoms, 0-4 O atoms, and 0-4 S atoms. In some embodiments, heterocycloalkyl comprises 2-10 C atoms, 0-4 N atoms, 0-2 O atoms, and 0-2 S atoms. In some embodiments, heterocycloalkyl comprises 2-8 C atoms, 0-3 N atoms, 0-1 0 atoms, and 0-1 S atoms. In some embodiments, heterocycloalkyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic, or 13-16 membered polycyclic (e.g., tricyclic or tetracyclic) ring system having 1, 2, 3, or 4 heteroatom ring members each independently selected from N, O, and S. In some embodiments, heterocycloalkyl comprises 1 or 2 heteroatom ring members each independently selected from N, O, and S. Examples of heterocycloalkyl radicals include, but are not limited to, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in the specification, the term "heterocycloalkyl" is meant to include heterocycloalkyl radicals as defined above that are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -Rb-0Ra, -Rb-OC(O)-Ra, -Rb-OC(O)-ORa, -Rb-OC(O)-N(Ra)2, -Rb- N(Ra)2, -Rb-C(O)Ra, -Rb-C(O)ORa, -Rb-C(O)N(Ra)2, -Rb-O-Rc-C(O)N(Ra)2, -Rb-N(Ra)C(O)ORa, -Rb-N(Ra)C(O)Ra, -Rb-N(Ra)S(O)tRa(where t is 1 or 2), -Rb-S(O)tRa(where t is 1 or 2), -Rb- S(O)tORa(where t is 1 or 2) and -Rb-S(O)tN(Ra)2(where t is 1 or 2), where each Rais independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, ortrifluoromethyl), each Rbis independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rcis a straight or branched alkylene or alkenylene chain, and where each of the above substituents is unsubstituted unless otherwise indicated.
[0123] " / ' / -heterocycloalkyl" or “TV-attached heterocycloalkyl” refers to a heterocycloalkyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocycloalkyl radical to the rest of the molecule is through a nitrogen atom in the heterocycloalkyl radical. An A -heterocycloalkyl radical is optionally substituted as described above for heterocycloalkyl radicals. Examples of such A-heterocycloalkyl radicals include, but are not limited to, 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, 1-pyrrolidinyl, pyrazolidinyl, imidazolinyl, and imidazolidinyl.
[0124] " C-heterocycloalkyl" or “C-attached heterocycloalkyl” refers to a heterocycloalkyl radical as defined above containing at least one heteroatom and where the point of attachment of the heterocycloalkyl radical to the rest of the molecule is through a carbon atom in the heterocycloalkyl radical. A C-heterocycloalkyl radical is optionally substituted as described above for heterocycloalkyl radicals. Examples of such C-heterocycloalkyl radicals include, but are not limited to, 2-morpholinyl, 2- or 3- or 4-piperidinyl, 2-piperazinyl, 2- or 3-pyrrolidinyl, and the like.
[0125] "Heteroaryl" refers to a radical derived from a 3- to 18-membered aromatic ring radical that comprises two to seventeen carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur. As used herein, the heteroaryl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, wherein at least one of the rings in the ring system is fully unsaturated, z.e., it contains a cyclic, delocalized (4n+2) ^-electron system in accordance with the Hiickel theory. Heteroaryl includes fused or bridged ring systems. The heteroatom(s) in the heteroaryl radical is optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heteroaryl is attached to the rest of the molecule through any atom of the ring(s). Examples of heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3 -benzodi oxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[Z>][l,4]dioxepinyl, benzo[b][l,4]oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl, 6,7-dihydro-5H- benzo[6,7]cyclohepta[l,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, furo[3,2-c]pyridinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidinyl,5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, 5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyri dinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl,5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1 -phenyl- 1 / 7-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl,5.6.7.8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl,6.7.8.9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-c]pridinyl, and thiophenyl (i.e. thienyl). Unless stated otherwise specifically in the specification, the term "heteroaryl" is meant to include heteroaryl radicals as defined above which are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -Rb-0Ra, -Rb-0C(0)-Ra, -Rb-0C(0)-0Ra, -Rb-0C(0)-N(Ra)2, -Rb-N(Ra)2, -Rb- C(0)Ra, -Rb-C(0)0Ra, -Rb-C(0)N(Ra)2, -Rb-0-Rc-C(0)N(Ra)2, -Rb-N(Ra)C(0)0Ra, -Rb- N(Ra)C(0)Ra, -Rb-N(Ra)S(O)tRa(where t is 1 or 2), -Rb-S(O)tRa(where t is 1 or 2), -Rb-S(O)tORa(where t is 1 or 2) and -Rb-S(O)tN(Ra)2(where t is 1 or 2), where each Rais independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), each Rbis independently a direct bond or a straight or branched alkylene oralkenylene chain, and Rcis a straight or branched alkylene or alkenylene chain, and where each of the above substituents is unsubstituted unless otherwise indicated.
[0126] “Heteroarylene” refers to a divalent heteroaryl group which links one part of the molecule to another part of the molecule. Unless stated specifically otherwise, a heteroarylene is optionally substituted, as defined above for a heteroaryl group.
[0127] In general, optionally substituted groups are each independently substituted or unsubstituted. Each recitation of an optionally substituted group provided herein, unless otherwise stated, includes an independent and explicit recitation of both an unsubstituted group and a substituted group (e.g., substituted in certain embodiments, and unsubstituted in certain other embodiments). Unless otherwise stated, a substituted group provided herein (e.g., substituted alkyl) is substituted by one or more substituent, each substituent being independently selected from the group consisting of halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -OC(O)-N(Ra)2, - N(Ra)C(O)Ra, -N(Ra)S(O)tRa(where t is 1 or 2), -S(O)tORa(where t is 1 or 2), -S(O)tRa(where t is 1 or 2) and -S(O)tN(Ra)2(where t is 1 or 2), where each Rais independently hydrogen, alkyl (e.g., optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, carbocyclyl (e.g., optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), carbocyclylalkyl (e.g., optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (e.g., optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (e.g., optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (e.g., optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (e.g., optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (e.g., optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (e.g., optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl). Unless described otherwise, a substituent of a substituted group or an optionally substituted group recited herein is not further substituted.
[0128] The compounds disclosed herein, in some embodiments, contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that are defined, in terms of absolute stereochemistry, as (R)- or (5)-. Unless stated otherwise, it is intended that all stereoisomeric forms of the compounds disclosed herein are contemplated by this disclosure. When the compounds described herein contain alkene double bonds, and unless specified otherwise, it is intended that this disclosure includes both E and Z geometric isomers (e.g., cis or trans.) Likewise, all possible isomers, as well as their racemic and optically pure forms, and all tautomeric forms are also intended to be included. The term “geometric isomer” refers to E or Z geometric isomers (e.g., cis or trans) of an alkene doublebond. The term “positional isomer” refers to structural isomers around a central ring, such as ortho-, meta-, and para- isomers around a benzene ring.
[0129] "Pharmaceutically acceptable salt" includes both acid and base addition salts. A pharmaceutically acceptable salt of any one of the compounds described herein is intended to encompass any and all pharmaceutically suitable salt forms. Exemplary pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0130] "Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts that are formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and. aromatic sulfonic acids, etc. and include, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Exemplary salts thus include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinate suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like. Also contemplated are salts of amino acids, such as arginates, gluconates, and galacturonates (see, for example, Berge S.M. et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66: 1-19 (1997)). Acid addition salts of basic compounds are, in some embodiments, prepared by contacting the free base forms with a sufficient amount of the desired acid to produce the salt according to methods and techniques with which a skilled artisan is familiar.
[0131] "Pharmaceutically acceptable base addition salt" refers to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Pharmaceutically acceptable base addition salts are, in some embodiments, formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Salts derived fromorganic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, A,A-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N- methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. See Berge et al., supra.
[0132] "Pharmaceutically acceptable solvate" refers to a composition of matter that is the solvent addition form. In some embodiments, solvates contain either stoichiometric or non- stoichiometric amounts of a solvent, and are formed during the process of making with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of compounds described herein are conveniently prepared or formed during the processes described herein. The compounds provided herein optionally exist in either unsolvated as well as solvated forms.
[0133] The term “individual,” “subject,” or “patient” encompasses mammals. Examples of mammals include, but are not limited to, any member of the Mammalian class: humans, non- human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. In one aspect, the mammal is a human.
[0134] As used herein, “treatment” or “treating,” or “palliating” or “ameliorating” are used interchangeably. These terms refer to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and / or a prophylactic benefit. By “therapeutic benefit” is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient is still afflicted with the underlying disorder. For prophylactic benefit, the compositions are, in some embodiments, administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease has not been made. Protein Binding
[0135] Chemical modification is an important tool to alter structure and function of proteins. One way to achieve chemical modification of proteins is to use protein binders (e.g., a (e.g.,covalent) small molecule inhibitor). As a result, binders (e.g., covalent small molecule binders (e.g., inhibitors) of proteins) are considered to be useful in multiple applications, including therapeutics. Covalent binding (e.g., inhibition) of a target protein may minimize the required systemic drug exposure. In some embodiments, protein (e.g., functional) activity can only be restored by de novo protein synthesis, resulting in a prolonged therapeutic effect long after the compound is cleared from the blood. Strategically placing an electrophilic moiety on the protein binder (e.g., inhibitor) will allow it to undergo attack by a nucleophilic amino acid residue upon binding to the target protein, forming a reversible or irreversible bond that is much stronger than typical noncovalent interactions. However, the ability to form a covalent bond with the target enzyme has raised concerns about indiscriminate reactivity with off-target proteins, even though some of the most prescribed drugs are covalent irreversible binders. This led to the disfavor of covalent modifiers as drug candidates until the recent successful development of irreversible covalent kinase inhibitors ibrutinib and afatinib, which form an irreversible covalent bond between an acrylamide warhead and a nonconserved cysteine residue on the ATP -binding site but also with nontargeted cellular thiols. The ability to form covalent adducts with off-target proteins has been linked to an increased risk of unpredictable idiosyncratic toxicity along with the increased daily drug dose administered to patients. Accordingly, there is a need to reduce the risk of non-target covalent interactions by incorporating less reactive electrophilic moieties into binders (e.g., to form covalent small molecule binders (e.g., inhibitors). In some embodiments, described herein is a protein binder, such as a covalent small molecule binder (e.g., inhibitor). In some embodiments, described herein is a covalent small molecule protein binder which acts functionally as a protein. In some embodiments, described herein is a covalent small molecule binder which acts functionally as an inhibitor. In some embodiments, the warhead group directs covalent and / or irreversible interaction with a (e.g., cysteine residue of a) protein (e.g., described herein). In some embodiments, the warhead group directs covalent and / or irreversible interaction of a (e.g., cysteine residue of a) protein (e.g., described herein) to a position of the warhead group that is ortho or meta to a sulfur-containing group (e.g., sulfone, sulfide, sulfoxide, or the like). In some embodiments, the protein does not covalently and / or irreversibly interact with the warhead group at a para-position. In some embodiments, the protein covalently and / or irreversibly interacts with the warhead group at either an ortho-position or a meta-position, such as a position of the warhead that is ortho or meta relative to the sulfur containing group. In some embodiments, the warhead comprises a blocking group (e.g., hydrogen, CN, NO2, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, or the like). In some embodiments, the blocking group is at a position of the warhead that is para relative to the sulfur-containing group. In some embodiments, the blocking group directs covalent and / or irreversible interaction of a (e.g., cysteine residue of a)protein (e.g., described herein) at a position of the warhead that is ortho or meta relative to the sulfur-containing group. In some embodiments, described herein is a pharmaceutical composition comprising a protein binder (e.g., a covalent small molecule binder (e.g., inhibitor) and one or more pharmaceutically acceptable excipients. In other embodiments, a protein binder (e.g., covalent small molecule binder (e.g., inhibitor)) is used to treat or prevent a disease or condition in a subject in need thereof.
[0136] In some embodiments, a protein binder provided herein, such as a covalent small molecule binder (e.g., inhibitor) is a benzenesulfonamide derivative compound. In some embodiments, a benzenesulfonamide derivative compound as described herein is used to treat or prevent a disease or condition in a subject in need thereof.
[0137] In some instances, a protein binder provided herein, such as any compound provided herein, such as a compound of Table 1A, Table IB, or Table 1C, binds to, (e.g., covalently) interacts with, modulates (e.g., inhibits), destabilizes, imparts a conformational change, (functionally) disrupts a protein described herein, such as, for example, epidermal growth factor receptor (EGFR), Bruton’s tyrosine kinase (BTK), Fibroblast Growth Factor Receptor (FGFR) (e.g., FGFR4), Aurora kinase A (AURKA), tyrosine-protein kinase KIT (KIT), Cytoplasmic tyrosine-protein kinase (BMX)), transcriptional enhancer factor TEF (TEAD), Janus kinase 3 (JAK3), KRAS, or a mutant thereof (e.g., by interacting with the protein at a position of a warhead (e.g., of the compound) that is ortho or meta relative to a sulfur-containing group (e.g., of the compound)). In some instances, a protein binder provided herein binds to BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof (e.g., by interacting with the protein at a position of a warhead (e.g., of the compound) that is ortho or meta relative to a sulfur- containing group (e.g., of the compound)). In some instances, a protein binder provided herein interacts with BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof (e.g., by interacting with the protein at a position of a warhead (e.g., of the compound) that is ortho or meta relative to a sulfur-containing group (e.g., of the compound)). In some instances, a protein binder provided herein covalently interacts with BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof. In some instances, a protein binder provided herein modulates BTK, EGFR, FGFR, AURKA, KIT BMX, TEAD, JAK3, KRAS, or a mutant thereof (e.g., by interacting with the protein at a position of a warhead (e.g., of the compound) that is ortho or meta relative to a sulfur-containing group (e.g., of the compound)). In some instances, a protein binder provided herein inhibits BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof (e.g., by interacting with the protein at a position of a warhead (e.g., of the compound) that is ortho or meta relative to a sulfur- containing group (e.g., of the compound)). In some instances, a protein binder provided hereindestabilizes BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a muta’t the’eof (e.g., by interacting with the protein at a position of a warhead (e.g., of the compound) that is ortho or meta relative to a sulfur-containing group (e.g., of the compound)). In some instances, a protein binder provided herein imparts a conformational change to BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof (e.g., by interacting with the protein at a position of a warhead (e.g., of the compound) that is ortho or meta relative to a sulfur-containing group (e.g., of the compound)). In some instances, a protein binder provided herein disrupts BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof (e g., by interacting with the protein at a position of a warhead (e.g., of the compound) that is ortho or meta relative to a sulfur-containing group (e.g., of the compound)). In some instances, a protein binder provided herein functionally disrupts BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof (e.g., by interacting with the protein at a position of a warhead (e.g., of the compound) that is ortho or meta relative to a sulfur-containing group (e.g., of the compound)).
[0138] In some instances, an inhibitor is a protein binder that degrades and / or disrupts the functionality of a protein described herein, such as BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof (e.g., by interacting with the protein at a position of a warhead (e.g., of the compound) that is ortho or meta relative to a sulfur-containing group (e.g., of the compound)).
[0139] In some embodiments, a compound provided herein interacts with the protein at a position of a warhead (e.g., of the compound) that is ortho or meta relative to a sulfur-containing group (e.g., of the compound).
[0140] In some instances, a compound provided herein is an irreversible binder (e.g., inhibitor). In some instances, mass spectrometry, enzyme kinetics, discontinuous exposure (e.g., jump dilution), or any combination thereof are used to determine the amount a compound modifies a target protein. In some instances, mass spectrometry (e.g., of the protein drug target modified (e g., BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof) in the presence of a compound provided herein) is used to determine if a compound is an irreversible binder (e.g., inhibitor). In some instances, a protein (e.g., BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof) modulated (e.g., inhibited) by a compound provided herein is subjected to mass spectral analysis (e.g., to assess the formation of permanent, irreversible covalent adducts). In some instances, analytical methods to examine peptide fragments (e.g., generated upon tryptic cleavage of a protein (e.g., BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof) include, but are not limited to mass spectroscopy. In some instances, such methods identify permanent, irreversible covalent proteinadducts (e.g., by observing a mass peak that corresponds to the mass of a control sample plus the mass of an irreversible adduct).
[0141] In some instances, such as when a protein described herein interacts (e.g., is bound (e.g., covalently and / or irreversibly bound)) with a compound provided herein, binding of a protein described herein leads to functional inhibition of the protein target (e.g., in a cellular environment).
[0142] In some embodiments, a compound provided herein (e.g., selectively) modifies (e.g., covalently) a polypeptide (e.g., a protein) (e.g., intracellularly) (e.g., wherein the selectivity is for a sulfur-containing nucleophile of the protein over other (e.g., intracellular) sulfur-containing nucleophiles (e.g., in a biological system)).
[0143] Provided in some embodiments herein is a method of (e.g., selectively) modifying (e.g., covalently) a polypeptide (e.g., a protein) (e.g., intracellularly) with a compound (e.g., wherein the selectivity is for a sulfur-containing nucleophile of the protein over other (e.g., intracellular) sulfur-containing nucleophiles (e.g., in a biological system)), comprising contacting the polypeptide with the compound described herein, or a salt thereof. In some embodiments, the compound contacts the polypeptide intracellularly (e.g., in an individual).
[0144] In some embodiments, a measure of (e.g., GSH or protein) modification is relative (e.g., GSH or protein) modification over a period of time. In some embodiments, a measure of (e.g., GSH or protein) modification is relative (e.g., GSH or protein) modification over a period of time of at least 0.5 minutes (e.g., at least 1 minutes, at least 5 minutes, at least 10 minutes, at least 30 minutes). In some embodiments, a measure of (e.g., GSH or protein) modification is relative (e.g., GSH or protein) modification over a period of time of at most 200 minutes (e.g., at most 150 minutes, at most 100 minutes, at most 50 minutes). In some embodiments, the relative (e.g., GSH or protein) modification over a period of time is measured using a method described herein, such as a GSH or GST assay described in Example IV1.
[0145] In some embodiments, a compound provided herein comprises a group (e.g., a warhead) that irreversibly or covalently binds to a protein (e.g., BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof). In some instances, a warhead provided herein is a functional group that covalently binds (e.g., at a position ortho or meta of the warhead that is ortho or meta to a sulfur-containing group of the compound) to an amino acid residue (such as cysteine, lysine, histidine, or other residues capable of being covalently modified), present in or near the binding pocket of a target protein (e g., BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof). In some instances, a warhead provided herein irreversibly inhibits BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof. In some instances, a warhead provided herein covalently and irreversibly inhibits BTK, EGFR, FGFR,AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof either alone or in combination with L (e.g., warhead-L-).
[0146] In some embodiments, a compound provided herein is selective for a KRAS protein or a mutant thereof, e.g., selective for KRAS G12C, KRAS C118A, or KRAS G12C / C118A. In some cases, provided herein are small molecule binders (e.g., inhibitors) that bind effectively to a KRAS protein (a.k.a., K-Ras) or a mutant thereof (e.g., KRAS G12C), e.g., by a covalent bond, which are useful for treating cancer, as mutant KRAS proteins are major drivers of human cancers. Also provided herein are pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases such as cancers.
[0147] In some embodiments, provided herein is a compound that interacts with KRAS or a mutant thereof at a position other than Y2. In some embodiments, provided herein is a compound that covalently and / or irreversibly interacts with KRAS or a mutant thereof at a position other than Y2. In some embodiments, provided herein is a compound that covalently and / or irreversibly interacts with a cysteine residue of KRAS or the mutant thereof at a position other than Y2. In some embodiments, provided herein is a compound that covalently and / or irreversibly interacts with a cysteine residue of KRAS or the mutant thereof at a position ortho or meta to Y2.
[0148] In some embodiments, a compound provided herein irreversibly and covalent modifies KRAS G12C at cysteine-12 and / or cysteine-118 in the full-length protein.
[0149] In some embodiments, a compound provided herein interacts with a protein as described in the Examples, such as shown in Tables 3-10F.
[0150] In some embodiments, provided herein is a compound (e.g., of Formula (A), Formula (I), Formula (LA), or Formula (I-B)), wherein the compound (e.g., of Formula (A), Formula (I), Formula (LA), or Formula (I-B)) has a warhead, such as wherein the warhead is the part of the compound identified with a box around it in FIG. 1 A, FIG. IB, or FIB. 1C.
[0151] In some embodiments, the warhead comprises a para-activating group, such as a para- activating group that directs binding to, disruption of, and / or modification of a protein (e.g., BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof) either alone or in combination with the linker (e.g., L or L’).
[0152] In some embodiments, provided herein is a compound (e.g., of Formula (A), Formula (I), Formula (I-A), or Formula (I-B)), wherein the compound (e.g., of Formula (A), Formula (I), Formula (I-A), or Formula (I-B)) comprises a protein-binding ligand (e.g., G or G’) of any one of the structures of Table 1A, Table IB, or Table 1C, such as wherein the protein-binding ligand (e.g., G or G’) is the part of the compound identified with a box around it in FIG. 1 A, FIG. IB, or FIB. 1C.
[0153] In some embodiments, a compound of any one of the formulas provided herein, such as Formula (A), Formula (I), Formula (I-A), or Formula (I-B) has a G or G’ as described in any of the compounds of Table 2A, Table 2B, Table 2C, or Table 2D. For example, a compound of any one of the formulas (e.g., Formula (A), Formula (I), Formula (I-A), or Formula (I-B)) provided herein has a G or G’ as identified with a box in FIG. 1 A, FIG. IB, or FIG. 1C.
[0154] In some embodiments, a protein-binding ligand provided herein binds to, disrupts, and / or modifies a protein (e.g, BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof) either alone or in combination with a warhead radical provided herein and / or a linker (e.g, L or L’) provided herein. In some instances, a protein-binding ligand provided herein has activity such that a compound provided herein binds to, disrupts, and / or modifies a protein (e g, BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof) at a concentration of about 10 mM or less (e.g, 500 uM or less, 100 uM or less, or 10 uM or less). In some instances, a protein binding ligand provided herein has activity such that a compound provided herein has Ki to a protein (e.g, BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof) of about 250 uM or less (e.g, about 50 uM or less or about 1 uM or less).
[0155] In some embodiments, the linker (e.g, L or L’) is a non-releasable linker.
[0156] In some instances, the linker (e.g, L or L’) does not decompose (e.g, hydrolyze) or release the warhead radical (or a free form thereof), the radical of the protein-binding ligand (or a free form thereof), or any other portion of the compound (e.g, a radical of any Formula provided herein) (or a free form thereof)).
[0157] In some embodiments, the linker (e.g, L or L’) comprises one or more linker group, each linker group being independently selected from the group consisting of a bond, -O-, (substituted or unsubstituted) amino (e.g, -NH-, -NCEE-, methylamine, or dimethylamine), substituted or unsubstituted (e.g, acyclic (e.g, straight or branched) or cyclic) alkyl(ene) (e.g, straight unsubstituted alkyl (e.g, methylene, ethylene, or the like) or straight alkylene substituted with oxo, amino (e.g, -NH-, -NCEE-, or methylamine), heterocyclyl (e.g, (methylene) piperidinyl or piperazinyl), and / or aryl (e.g, (methylene) phenyl)), substituted or unsubstituted (e.g, acyclic (e.g, straight or branched) or cyclic) heteroalkyl(ene) (e.g, cyclic heteroalkylene (e.g, piperazinyl or 1,4-diazepanyl) substituted with alkyl (e.g, methyl) and / or oxo, or straight heteroalkylene substituted with oxo, heterocyclyl (e.g, azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl), aryl (e.g, phenyl), and / or heteroaryl (e.g, substituted or unsubstituted oxazolyl, pyridinyl, imidazolyl, or pyrazolyl)), substituted or unsubstituted alkoxy (e.g, unsubstituted alkoxy (e.g, methoxy, ethoxy, or the like) or alkoxy substituted with oxo, amino (e.g, -NH-, - NCH3-, substituted (e.g, methylamine) or -NH-azetidinyl-), cycloalkyl (e.g, cyclobutylsubstituted with amino (e.g., -NH-, -NCH3-, or methylamine)), and / or heterocyclyl (e.g., azetidinyl or pyrrolidinyl)), and substituted or unsubstituted aryl (e.g., aryl substituted with alkyl (e.g., methyl)).
[0158] In some embodiments, the linker (e.g., L or L’) comprises one or more linker group, each linker group being independently selected from the group consisting of -O-, substituted or unsubstituted amino, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, and substituted or unsubstituted alkoxy.
[0159] In some embodiments, the linker (e.g., L or L’) comprises one or more linker group, each linker group being independently selected from the group consisting of -O-, substituted or unsubstituted amino and substituted or unsubstituted heteroalkylene. In some embodiments, the linker (e.g., L or L’) comprises one or more linker group, each linker group being independently selected from the group consisting of -O-, substituted or unsubstituted amino and substituted or unsubstituted acyclic (e.g., straight or branched) heteroalkylene. In some embodiments, the linker (e.g., L or L’) comprises one or more linker group, each linker group being independently selected from the group consisting of -O-, substituted or unsubstituted amino and substituted or unsubstituted cyclic heteroalkylene. In some embodiments, the linker (e.g., L or L’) comprises one or more linker group, each linker group being independently selected from the group consisting of -O-, substituted or unsubstituted amino and substituted or unsubstituted heterocyclyl.
[0160] In some embodiments, the linker (e.g., L or L’) comprises one or more linker group, each linker group being independently selected from the group consisting of substituted or unsubstituted amino and substituted or unsubstituted heteroalkylene. In some embodiments, the linker (e.g., L or L’) comprises one or more linker group, each linker group being independently selected from the group consisting of substituted or unsubstituted amino and substituted or unsubstituted acyclic (e.g., straight or branched) heteroalkylene. In some embodiments, the linker (e.g., L or L’) comprises one or more linker group, each linker group being independently selected from the group consisting of substituted or unsubstituted amino and substituted or unsubstituted cyclic heteroalkylene. In some embodiments, the linker (e.g., L or L’) comprises one or more linker group, each linker group being independently selected from the group consisting of substituted or unsubstituted amino and substituted or unsubstituted heterocyclyl.
[0161] In some embodiments, the linker (e.g., L or L’) comprises -O-.
[0162] In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted amino.
[0163] In some embodiments, the linker (e.g., L or L’) comprises -NH-.
[0164] In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted alkylene. In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstitutedC1-C6 alkylene. In some embodiments, the linker (e.g., L or L’) comprises substituted Ci-Ce alkylene. In some embodiments, the linker (e.g., L or L’) comprises unsubstituted C1-C6 alkylene.
[0165] In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted heteroalkylene. In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted C1-C6 heteroalkylene. In some embodiments, the linker (e.g., L or L’) comprises substituted C1-C6 heteroalkylene. In some embodiments, the linker (e.g., L or L’) comprises unsubstituted C1-C6 heteroalkylene.
[0166] In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted alkoxyalkyl. In some embodiments, the linker (e.g., L or L’) comprises substituted alkoxyalkyl. In some embodiments, the linker (e.g., L or L’) comprises unsubstituted alkoxyalkyl. In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted alkoxyheteroalkyl. In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted Ci-Ce alkoxyheteroalkyl. In some embodiments, the linker (e.g., L or L’) comprises substituted Ci-Ce alkoxyheteroalkyl .
[0167] In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted amino. In some embodiments, the linker (e.g., L or L’) is -NH-. In some embodiments, the linker (e.g., L or L’) comprises an alkylamine. In some embodiments, the linker (e.g., L or L’) comprises a C1-C6 alkylamine.
[0168] In some embodiments, the linker (e.g., L or L’) is a bond.
[0169] In some embodiments, the linker (e.g., L or L’) comprises a carbonyl. In some embodiments, the linker (e.g., L or L’) comprises an ester. In some embodiments, the linker (e.g., L or L’) comprises a ketone. In some embodiments, the linker (e.g., L or L’) comprises an amide.
[0170] In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted alkylene. In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted acyclic (e.g., straight or branched) alkylene. In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted cyclic alkylene.
[0171] In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted heteroalkylene. In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted acyclic (e.g., straight or branched) heteroalkylene. In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted cyclic heteroalkylene (e.g., heterocycyl).
[0172] In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted heterocycyl.
[0173] In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted heterocycloalkyl. In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted C4-C7 heterocycloalkyl. In some embodiments, the linker (e.g., L or L’) comprisessubstituted C4-C7 heterocycloalkyl. In some embodiments, the linker (e.g., L or L’) comprises unsubstituted C4-C7 heterocycloalkyl. In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted piperazine (e.g., piperazine substituted with methyl). In some embodiments, the linker (e.g., L or L’) comprises substituted piperazine. In some embodiments, the linker (e.g., L or L’) comprises piperazine substituted with one or more methyl, alkoxy, alkoxyalkyl, alkoxyheteroalkyl, or heteroalkyl.
[0174] In some embodiments, the linker (e.g., L or L’) comprises substituted or unsubstituted alkoxy.
[0175] In some embodiments, provided herein is a compound (e.g., of Formula (A), Formula (I), Formula (I-A), or Formula (I-B)), wherein the compound (e.g., of Formula (A), Formula (I), Formula (I-A), or Formula (I-B)) comprises a linker (e.g., L or L’) of any one of the compounds of Table 1 A, Table IB, or Table 1C, such as wherein the linker (e.g., L or L’) is the part of the compound identified with a box around it in FIG. 1 A, FIG. IB, or FIG. 1C.
[0176] In some instances, such as when then linker (e.g., L or L’) is substituted or unsubstituted heterocyclyl, the linker is part of the protein-binding ligand and / or the warhead.
[0177] In some embodiments, a covalent small molecule protein binder (e.g., inhibitor) provided herein is a benzenesulfonamide derivative compound. In some embodiments, a benzenesulfonamide derivative compound as described herein is used to treat or prevent a disease or condition in a subject in need thereof.
[0178] In other embodiments, a pharmaceutical composition comprising a benzenesulfonamide derivative compound as described herein and one or more pharmaceutically acceptable excipients is used to treat or prevent a disease or condition in a subject in need thereof.
[0179] In some embodiments, disclosed herein is a method of treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of a benzenesulfonamide derivative compound as described herein.
[0180] In other embodiments, disclosed herein is a method of treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a benzenesulfonamide derivative compound as described herein and one or more pharmaceutically acceptable excipients.
[0181] In some embodiments, disclosed herein is a protein modified with a benzenesulfonamide derivative compound as described herein, wherein the compound forms a covalent bond with a sulfur atom of a cysteine residue of the protein (e.g., as described elsewhere herein). In some embodiments, disclosed herein is a method of modifying (e.g., attaching to and / or degrading) a polypeptide with a benzenesulfonamide derivative compound as described herein, comprising contacting the polypeptide with the compound to form a covalent bond with a sulfuratom of a cysteine residue of the polypeptide (e.g., as described elsewhere herein). In some embodiments, disclosed herein is a method of binding a compound to a polypeptide, comprising contacting the polypeptide with a benzenesulfonamide derivative compound as described herein (e.g., as described elsewhere herein).
[0182] In one aspect, provided herein is a benzenesulfonamide derivative compound. In some embodiments, a benzenesulfonamide derivative compound is a protein-binding compound. In some embodiments, a benzenesulfonamide derivative compound is a protein-binding ligand inhibitory compound.
[0183] In some embodiments, the warhead comprises a para-activating group, such as a para- activating group that directs binding to, disruption of, and / or modification of KRAS or a mutant thereof either alone or in combination with L.
[0184] In some embodiments, the warhead is a selective warhead. In some embodiments, the warhead is a selective over other cysteine containing selectivity protein S0S1. In some embodiments, the warhead is selective for KRAS, such as over wild-type KRAS.
[0185] In some embodiments, the warhead covalently modifies KRAS (e.g., KRAS G12C (SEQ ID NO: 1 or SEQ ID NO: 2) and / or a mutant KRAS G12C Lite (SEQ ID NO: 3)).Sequence of KRAS G12C:MHHHHHHSSG RENLYFQGMT EYKLVVVGAC GVGKSALTIQ LIQNHFVDEY DPTIEDSYRK QVVIDGETCL LDILDTAGQE EYSAMRDQYM RTGEGFLCVF AINNTKSFED IHHYREQIKR VKDSEDVPMV LVGNKCDLPS RTVDTKQAQD LARSYGIPFI ETSAKTRQGV DDAFYTLVRE IRI<HI<EI< (SEQ ID NO: 1)
[0186] Sequence of KRAS G12C Commercial:HHHHHHSSG RENLYFQGMT EYKLVVVGAC GVGKSALTIQ LIQNHFVDEY DPTIEDSYRK QVVIDGETCL LDILDTAGQE EYSAMRDQYM RTGEGFLCVFAINNTKSFED IHHYREQIKR VKDSEDVPMV LVGNKCDLPS RTVDTKQAQD LARSYGIPFI ETSAKTRQGV DDAFYTLVRE IRI<HI<EI< (SEQ ID NO:2)
[0187] Sequence of KRAS G12C Lite:MHHHHHHSSG RENLYFQGMT EYKLVVVGAC GVGKSALTIQ LIQNHFVDEY DPTIEDCYRK QVVIDGETSL LDILDTAGQE EYSAMRDQYM RTGEGFLSVF AINNTKSFED IHHYREQIKR VKDSEDVPMV LVGNKSDLPS RTVDTKQAQD LARPYGIPFI ETSAKTRQGV DDAFYTLVRE IRI<HI<EI< (SEQ ID NO:3)
[0188] KRAS G12C Lite (SEQ ID NO: 3) is FL KRAS mutated at all the cysteines except G12C (K-Ras(C51S / C80L / C118S) described in reference : Ostrem, J. M. L.; Shokat, K. M. Direct Small- Molecule Inhibitors of KRAS: From Structural Insights to Mechanism-Based Design. Nature Reviews Drug Discovery. Nature Publishing Group November 1, 2016, pp 771-785.
[0189] In some embodiments, the warhead does not covalently modify KRAS WT protein. In some embodiments, the warhead does not substantially covalently modify KRAS WT protein.
[0190] In some embodiments, the binds to, disrupts, and / or modifies KRAS G12C (SEQ ID NO: 1 or SEQ ID NO: 2) and / or a mutant KRAS G12C Lite (SEQ ID NO: 3), such as in vitro, such as using differential scanning fluorimetry (DSF), such as described in the Examples.
[0191] In some embodiments, provided herein is a compound (e.g., of Formula (LA)), wherein the compound (e.g., of Formula (I- A)) comprises a KRAS-binding ligand (e.g., G) of any one of the structures of Table IB, such as wherein the KRAS-binding ligand (e.g., G) is the part of the compound identified with a box around it in FIG. IB.
[0192] In some embodiments, a KRAS-binding ligand provided herein binds to, disrupts, and / or modifies KRAS either alone or in combination with a warhead radical provided herein and / or a linker provided herein. In some instances, a KRAS-binding ligand provided herein has activity such that a compound provided herein binds to, disrupts, and / or modifies KRAS (e.g., KRAS G12C) at a concentration of about 10 mM or less (e.g., 500 uM or less, 100 uM or less, or 10 uM or less). In some instances, a KRAS-binding ligand provided herein has activity such that a compound provided herein has Ki to KRAS (e.g., KRAS G12C) of about 250 uM or less (e.g., about 50 uM or less or about 1 uM or less).
[0193] In some embodiments, the warhead comprises a para-activating group, such as a para- activating group that directs binding to, disruption of, and / or modification of JAK3 or a mutant thereof either alone or in combination with L.
[0194] In some embodiments, the warhead covalently modifies JAK3.
[0195] In some embodiments, the binds to, disrupts, and / or modifies JAK3, such as in vitro, such as using differential scanning fluorimetry (DSF), such as described in the Examples.
[0196] In some embodiments, provided herein is a compound (e.g., of Formula (LB)), wherein the compound (e.g., of Formula (LB)) comprises a JAK3 -binding ligand (e.g., G) of a structure of Table 1A or Table 1C, such as wherein the JAK3-binding ligand (e.g., G) is the part of the compound identified with a box around it in FIG. 1C.
[0197] In some embodiments, a JAK3 -binding ligand provided herein binds to, disrupts, and / or modifies JAK3 either alone or in combination with a warhead radical provided herein and / or a linker provided herein. In some instances, a JAK3 -binding ligand provided herein has activity such that a compound provided herein binds to, disrupts, and / or modifies JAK3 at a concentrationof about 10 mM or less (e.g., 500 uM or less, 100 uM or less, or 10 uM or less). In some instances, a JAK3 -binding ligand provided herein has activity such that a compound provided herein has Ki to JAK3 of about 250 uM or less (e.g., about 50 uM or less or about 1 uM or less).
[0198] Provided in some embodiments herein is a compound having a structure of Formula (A):Formula (A).
[0199] In some embodiments, X1is absent or O. In some embodiments, X1is O. In some embodiments, X2is absent, O, or NRA. In some embodiments, X2is absent. In some embodiments, X2is O. In some embodiments, X2is NRA. In some embodiments, Q1is Rxor L-G. In some embodiments, Q1is Rx. In some embodiments, Q1is L-G. In some embodiments, Q2is L-G or Y2. In some embodiments, Q2is L-G. In some embodiments, Q2is Y2. In some embodiments, Y2is a blocking group. In some embodiments, a blocking group is a group that directs (e.g., covalent and / or irreversible) binding (e.g., of a cysteine residue) of a protein to a position other than Y2. In some embodiments, Rxis substituted or unsubstituted alkyl or NRyRz. In some embodiments, Rxis substituted or unsubstituted alkyl. In some embodiments, Rxis substituted alkyl. In some embodiments, Rxis unsubstituted alkyl. In some embodiments, Rxis NR^R2. In some embodiments, RA, Ry, and Rzare each independently hydrogen or substituted or unsubstituted alkyl. In some embodiments, RAis hydrogen or unsubstituted alkyl. In some embodiments, RAis hydrogen. In some embodiments, RAis unsubstituted alkyl. In some embodiments, Ryis hydrogen or substituted or unsubstituted alkyl. In some embodiments, Ryis hydrogen. In some embodiments, Ryis substituted alkyl. In some embodiments, Ryis unsubstituted alkyl. In some embodiments, Rzis hydrogen or substituted or unsubstituted alkyl. In some embodiments, Rzis hydrogen. In some embodiments, Rzis substituted alkyl. In some embodiments, Rzis unsubstituted alkyl. In some embodiments, L is a linker. In some embodiments, G is an organic residue. In specific embodiments, one and only one of Q1or Q2is L-G. In some embodiments, one of Q1or Q2is L-G.
[0200] In some embodiments, Rxis substituted or unsubstituted alkyl. In some embodiments, Rxis unsubstituted alkyl. In some embodiments, Rxis C1-C6 alkyl. In some embodiments, Rxis methyl.
[0201] In some embodiments, Rxis substituted or unsubstituted aryl.
[0202] In some embodiments, Rxis substituted or unsubstituted heteroaryl.
[0203] In some embodiments, Rxis NRyRz. In some embodiments, Ryand Rzare each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In some embodiments, Ryand Rzare each independently hydrogen or substituted or unsubstituted alkyl. In some embodiments, Ryand Rzare hydrogen. In some embodiments, Ryand Rzare each independently substituted or unsubstituted alkyl. In some embodiments, Ryis substituted or unsubstituted alkyl and Rzis hydrogen.
[0204] In some embodiments, X1is absent.
[0205] In some embodiments, X1is O.
[0206] In some embodiments, at least one of X1or X2is O.
[0207] In some embodiments, Q1is not substituted or unsubstituted methoxy phenyl. In some instances, Q1is not phenyl, such as specifically not methoxy phenyl.
[0208] In some embodiments, Q2is not substituted or unsubstituted methoxy phenyl. In some instances, Q2is not phenyl, such as specifically not methoxy phenyl.
[0209] Provided in some embodiments herein is a compound having a structure of Formula (I):Formula (I).
[0210] In some embodiments, X2is absent, O, or NRA. In some embodiments, RAis hydrogen or substituted or unsubstituted alkyl. In some embodiments, Y2is a blocking group (e.g., a group that directs (e.g., covalent and / or irreversible) binding (of a cysteine residue) of a protein to a position other than Y2). In some embodiments, L is a linker. In some embodiments, G is a protein- binding ligand (e.g., a radical of a compound that interacts with a protein or a mutant thereof, comprising one or more cyclic group wherein the one or more cyclic groups are individually linked by one or more linker). In some embodiments, G is a KRAS-binding ligand. In some embodiments, the compound is a salt.
[0211] In some embodiments, X2is O.
[0212] In some embodiments, X2is absent.
[0213] In some embodiments, X2is NRA. In some embodiments, RAis hydrogen or substituted or unsubstituted C1-C6 alkyl.
[0214] In some embodiments, G or G’ is an organic residue. In some embodiments, G or G’ is a radical of a protein-binding ligand, such as a protein-binding ligand provided elsewhere herein.
[0215] In some embodiments, G or G’ is a radical of a compound that interacts with a protein (e g., BTK, EGFR, FGFR, AURKA, BMX, TEAD, JAK3, KRAS) or a mutant thereof.
[0216] In some embodiments, G or G’ is or comprises a protein-binding ligand selected from a BTK-, EGFR-, FGFR-, AURKA-, TEAD-, JAK3- KRAS-, and BMX-binding ligand.
[0217] In some embodiments, G or G’ is a radical of a BTK-binding ligand. In some embodiments, G or G’ is a radical of an EGFR-binding ligand. In some embodiments, G or G’ is a radical of a FGFR-binding ligand. In some embodiments, G or G’ is a radical of a BMX-binding ligand. In some embodiments, G or G’ is a radical of an AURKA-binding ligand. In some embodiments, G or G’ is a radical of a TEAD-binding ligand.
[0218] In some embodiments, G is a radical of a KRAS-binding ligand, such as a KRAS-binding ligand provided elsewhere herein.
[0219] In some embodiments, G is a radical of a KRAS-binding protein.
[0220] Provided in some embodiments herein is a compound having a structure of Formula (I-A):Formula (LA)2
[0221] In some embodiments, X is absent, O, or NRA. In some embodiments, RAis hydrogen or 2 substituted or unsubstituted alkyl. In some embodiments, Y is a blocking group. In some 2 embodiments, Y is a group that directs (e.g., covalent and / or irreversible) binding (of a cysteine residue) of KRAS or a mutant thereof to a position other than Y2(e.g., a position ortho or meta to Y2)). In some embodiments, L is a linker described herein. In some embodiments, G is a KRAS- binding ligand described herein, such as a radical of a compound that interacts with a KRAS protein or a mutant thereof (e.g., KRAS G12C, KRAS C118A, or KRAS G12C / C118A). In some embodiments, the compound is a salt.
[0222] In some embodiments, G is a radical of a JAK3-binding ligand, such as a JAK3-binding ligand provided elsewhere herein.
[0223] In some embodiments, G is a radical of a JAK3 -binding protein.
[0224] Provided in some embodiments herein is a compound having a structure of Formula (I-Formula (I-B)2
[0225] In some embodiments, X is absent, O, or NRA. In some embodiments, RAis hydrogen2 or substituted or unsubstituted alkyl. In some embodiments, Y is a blocking group. In some 2 embodiments, Y is a group that directs (e.g., covalent and / or irreversible) binding (of a cysteine residue) of KRAS or a mutant thereof to a position other than Y2(e.g., a position ortho or meta to Y2)). In some embodiments, L is a linker described herein. In some embodiments, G is a JAK3- binding ligand described herein, such as a radical of a compound that interacts with a JAK3 protein or a mutant thereof. In some embodiments, the compound is a salt.
[0226] In some embodiments, the JAK3-binding ligand is an unsubstituted or substituted heterocycle. In some embodiments, the JAK3-binding ligand is an unsubstituted or substituted pyrrolopyrimidine, an unsubstituted or substituted pyrrolopyridine, an unsubstituted or substituted pyrazolopyrimidine, an unsubstituted or substituted pyrazolopyridine, or an unsubstituted or substituted benzimidazole. In some embodiments, the JAK3-binding ligand is an unsubstituted or substituted pyrrolopyrimidine. In some embodiments, the JAK3-binding ligand is an an unsubstituted or substituted pyrrolopyridine. In some embodiments, the JAK3-binding ligand is an unsubstituted or substituted pyrazolopyrimidine. In some embodiments, the JAK3-binding ligand is an unsubstituted or substituted pyrazolopyridine. In some embodiments, the JAK3- binding ligand is an unsubstituted or substituted benzimidazole. In some embodiments, the JAK3- binding ligand is a pyrrolopyrimidine described herein, such as a 7H-pyrrolo[2,3-J]pyrimidine described herein. In some embodiments, the JAK3-binding ligand is a pyrrolopyridine described herein, such as a lH-pyrrolo[2,3-b]pyridine described herein. In some embodiments, the JAK3- binding ligand is a pyrazolopyridine described herein, such as a pyrazolo[l ,5-a]pyridine described herein. In some embodiments, the JAK3-binding ligand is attached to a linker described herein.
[0227] In some embodiments, G has a structure represented by any one of Formulas (II)-(VII).
[0228] In some embodiments, G or G’ has a structure shown in Table 1 A, Table IB, or Table 1C.
[0229] In some embodiments, G or G’ is or comprises one or more (e.g., unsaturated) unsubstituted or substituted carbocycle and / or one or more (e.g., unsaturated) unsubstituted or substituted heterocycle. In some embodiments, G or G’ is or comprises an (e.g., unsaturated) unsubstituted or substituted carbocycle or an (e.g., unsaturated) unsubstituted or substitutedheterocycle. In some embodiments, G or G’ consists of an (e.g., unsaturated) unsubstituted or substituted carbocycle or an (e.g., unsaturated) unsubstituted or substituted heterocycle. In some embodiments, G or G’ is (e.g., unsaturated) unsubstituted or substituted carbocycle or an (e.g., unsaturated) unsubstituted or substituted heterocycle. In some embodiments, G or G’ is substituted or unsubstituted unsaturated carbocycle or substituted or unsubstituted unsaturated heterocycle. In some embodiments, G or G’ comprises one or more cyclic ring systems selected from substituted or unsubstituted unsaturated carbocycles and substituted or unsubstituted unsaturated heterocycles. In some embodiments, G or G’ comprises two or more cyclic ring systems selected from substituted or unsubstituted unsaturated carbocycles and substituted or unsubstituted unsaturated heterocycles.
[0230] In some embodiments, G or G’ comprises one or more cyclic ring systems selected from substituted or unsubstituted carbocycles and substituted or unsubstituted heterocycles. In some embodiments, G or G’ comprises two or more cyclic ring systems selected from substituted or unsubstituted carbocycles and substituted or unsubstituted heterocycles.
[0231] In some embodiments, G or G’ is amino, hydroxyl, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or alkoxy. In some embodiments, G or G’ is amino. In some embodiments, G or G’ is hydroxyl. In some embodiments, G or G’ is substituted or unsubstituted alkyl. In some embodiments, G or G’ is substituted or unsubstituted heteroalkyl. In some embodiments, G or G’ is alkoxy.
[0232] In some embodiments, G or G’ comprises one or more cyclic group. In some embodiments, G or G’ comprises one or more cyclic groups wherein the one or more cyclic groups are individually linked by one or more linker (e.g., L or L’). In other words, G or G’ comprises one or more cyclic groups, wherein each of the one or more cyclic group are individually linked to another of the one or more cyclic groups by a linker, such as a bond. For example, FIG. IB shows a G’ that comprises a cyclic group (e.g., a heterocyclyl described herein) linked to another cyclic group (e.g., a heteroaryl described herein) via a bond.
[0233] In some embodiments, G or G’ comprises an optionally substituted cyclic group, optionally substituted with one or more L’-G’, wherein each L’ is individually selected from a linker, such as a linker provided elsewhere herein, and is connected to another G’. In some embodiments, G’ comprises G as described elsewhere herein. In some instances, G’ and G are the same. In some instances, G’ and G are different. In some embodiments, G or G’ comprises an optionally substituted cyclic group, optionally substituted with -(L’-G’)nL’-G’, wherein n is 0 to 4. In some embodiments, n is 1 to 3.
[0234] In some embodiments, G is substituted with L’-G’. In some instances, G is substituted with one or more, such as 2 or 3, L’-G’ on a single G. In some embodiments G is substituted with2 L’-G’, such as on a single G. In some embodiments, G is substituted with -(L’-G’)n-L’-G’. In some embodiments, G is substituted with one or more, such as 2 or 3, -(L’-G’)n-L’-G’ on a single G. In some embodiments, G is substituted with 2 -(L’-G’)n-L’-G’ on a single G.
[0235] In some embodiments, the two or more cyclic ring systems are connected via a bond. In some embodiments, the two or more cyclic ring systems are connected via one or more linker (e.g., L or L’) and / or bond. In some embodiments, the linker (e.g., L or L’) is -O-, -NR8-, - N(R8)2+-, -S-, -S(=O)-, -S(=O)2-, -CH=CH-, =CH-, -C=C-, -C(=O)-, -C(=O)O-, -OC(=O)-, - OC(=O)O-, -C(=O)NR8-, -NR8C(=O)-, -OC(=O)NR8-, -NR8C(=O)O-, -NR8C(=O)NR8-, - NR8S(=O)2-, -S(=O)2NR8-, -C(=O)NR8S(=O)2-, -S(=O)2NR8C(=O)-, substituted or unsubstituted C1-C4 alkylene, substituted or unsubstituted Ci-Cs heteroalkylene, -(C1-C4 alkylene)-O-, -O-(Ci- C4 alkylene)-, -(C1-C4 alkylene)-NR8-, -NR8-(CI-C4 alkylene)-, -(C1-C4 alkylene)-N(R8)2+-, or - N(R8)2+-(CI-C4alkylene)-; and each R8is independently hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, substituted or unsubstituted C1-C4 heteroalkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C5 alkynyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C2-C7 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0236] In some embodiments, the cyclic ring system comprises substituted or unsubstituted monocyclic aryl or substituted or unsubstituted monocyclic heteroaryl. In some embodiments, the cyclic ring system comprises substituted or unsubstituted bicyclic aryl or substituted or unsubstituted bicyclic heteroaryl.
[0237] In some embodiments, G or G’ comprises one or more nitrogen atoms. In some embodiments, G or G’ comprises one or more nitrogen ring atoms. In some embodiments, G or G’ comprises one or more nitrogen atoms within its ring system. In some embodiments, G or G’ comprises one or more nitrogen atoms within its fused ring system. In some embodiments, G or G’ comprises one, two, or three nitrogen atoms (e.g., within its (e.g., fused) ring system).
[0238] In some embodiments, G or G’ comprises one or more (e.g., fused) rings. In some embodiments, G or G’ comprises one or more fused rings.
[0239] In some embodiments, G or G’ is aromatic or partially aromatic. In some embodiments, G or G’ is aromatic. In some embodiments, G or G’ is partially aromatic.
[0240] In some embodiments, G or G’ comprises one or more substituted or unsubstituted aromatic ring(s). In some embodiments, G or G’ comprises one substituted or unsubstituted aromatic ring. In some embodiments, G or G’ comprises two substituted or unsubstituted aromatic rings. In some embodiments, G or G’ comprises three substituted or unsubstituted aromatic rings.
[0241] In some embodiments, G or G’ comprises two or more substituted or unsubstituted aromatic or partially aromatic rings. In some embodiments, each aromatic or partially aromatic ring independently is a carbocycle or a heterocycle.
[0242] In some embodiments, G or G’ comprises one or more substituted or unsubstituted carbocycle and one or more substituted or unsubstitued heterocycle. In some embodiments, each of the one or more substituted or unsubstituted carbocycle and the one or more substituted or unsubstitued heterocycle are independently linked (e.g., fused) to a substituted or unsubstituted carbocycle or a substituted or unsubstitued heterocycle by amino or a bond. In some embodiments, G or G’ comprises one or more substituted or unsubstituted carbocycle and one or more substituted or unsubstitued heterocycle, each of the one or more substituted or unsubstituted carbocycle and the one or more substituted or unsubstitued heterocycle independently being linked (e.g., fused) to a substituted or unsubstituted carbocycle or a substituted or unsubstitued heterocycle by a bond.
[0243] In some embodiments, G or G’ comprises a substituted or unsubstituted carbocycle and a substituted or unsubstitued heterocycle, the substituted or unsubstituted carbocycle and the substituted or unsubstitued heterocycle being linked (e.g., fused) by a bond.
[0244] In some embodiments, G or G’ comprises two (or more) substituted or unsubstituted heteroaromatic rings, the heteroaromatic rings being linked (e.g., fused) by a bond, each heteroaromatic ring being aromatic or partially aromatic. In some embodiments, the heteroaromatic rings are selected from the group consisting of benzimidazole, indole, indolizine, pyridine, quinoline, indazole, pyrimidine, and pyridopyrimidinone (e.g., pyrido[2,3-d]pyrimidin- 2(lH)-one). In some embodiments, the heteroaromatic rings are selected from the group consisting of benzimidazole, indole, indolizine, pyridine, and pyridopyrimidinone (e.g., pyrido[2,3-d]pyrimidin-2(lH)-one). In some embodiments, G or G’ is a substituted benzimidazole linked to an unsubstituted indolizine by a bond. In some embodiments, G or G’ is a substituted benzimidazole linked to an unsubstituted phenyl by a bond. In some embodiments, G or G’ is a substituted pyrido[2,3-d]pyrimidin-2(lH)-one linked to a substituted pyridine by a bond.
[0245] In some embodiments, G or G’ has a structure of:
[0246] In some embodiments, G or G’ has a structure of:
[0247] In some embodiments, G or G’ has a structure of:
[0248] In some embodiments, G or G’ comprises two (or more) substituted or unsubstituted phenyl rings. In some embodiments, the phenyl is linked by a bond.
[0249] In some embodiments, G or G’ has a structure of:
[0250] In some embodiments, G or G’ comprises one or more (e.g., one, two, or three) substituted or unsubstituted heteroaromatic ring(s).
[0251] In some embodiments, G or G’ comprises a substituted or unsubstituted carbocycle. In some embodiments, G or G’ comprises an unsubstituted carbocycle. In some embodiments, G or G’ comprises a substituted carbocycle.
[0252] In some embodiments, G or G’ comprises a substituted or unsubstituted heterocycle. In some embodiments, G or G’ comprises a substituted heterocycle. In some embodiments, G or G’ comprises an unsubstituted heterocycle.
[0253] In some embodiments, G or G’ is a substituted or unsubstituted N-heterocycle.
[0254] In some embodiments, G or G’ is a substituted or unsubstituted pyridine. In some embodiments, G or G’ is unsubstituted pyridine.
[0255] In some embodiments, G or G’ is a substituted or unsubstituted piperazine. In some embodiments, G or G’ is a substituted piperazine. In some embodiments, G or G’ is an unsubstituted piperazine. In some embodiments, G or G’ is piperazine substituted with methyl.
[0256] In some embodiments, G or G’ is a substituted or unsubstituted piperidine. In some embodiments, G or G’ is a substituted or unsubstituted azetidine.
[0257] In some embodiments, G or G’ is unsubstituted tetrahydrofuran. In some embodiments, G or G’ is unsubstituted tetrahydro-2H-pyran.
[0258] In some embodiments, G or G’ is substituted or unsubstituted IH-pyrazole. In some embodiments, G or G’ is unsubstituted IH-pyrazole. In some embodiments, G or G’ is substituted IH-pyrazole.
[0259] In some embodiments, G or G’ is substituted or unsubstituted isoxazole. In some embodiments, G or G’ is substituted isoxaole, such as isoxazole substituted with methyl. In some embodiments, G or G’ is unsubstituted isoxazole.
[0260] In some embodiments, G or G’ is unsubstituted quinoline.
[0261] In some embodiments, G or G’ is unsubstituted pyrimidine.
[0262] In some embodiments, G or G’ is substituted or unsubstituted IH-indazole. In some embodiments, G or G’ is unsubstituted IH-indazole. In some embodiments, G or G’ is substituted IH-indazole, such as IH-indazole substituted with methyl.
[0263] In some embodiments, G or G’ is a substituted carbocycle.
[0264] In some embodiments, G or G’ is a substituted phenyl.
[0265] In some embodiments, G or G’ is a substituted heterocycle.
[0266] In some embodiments, G or G’ is a substituted or unsubstituted quinazoline or a substituted or unsubstituted pyrazolopyrimidine. In some embodiments, G or G’ is a substituted quinazoline or a substituted pyrazolopyrimidine. In some embodiments, G or G’ is an unsubstituted quinazoline or an unsubstituted pyrazolopyrimidine. In some embodiments, G or G’ is a substituted quinazoline. In some embodiments, G or G’ is an unsubstituted quinazoline. In some embodiments, G or G’ is a substituted pyrazolopyrimidine. In some embodiments, G or G’ is an unsubstituted pyrazolopyrimidine. In some embodiments, G or G’ is a substituted 1H- pyrazolo[3,4-d]pyrimidine. In some embodiments, G or G’ is an unsubstituted lH-pyrazolo[3,4- d]pyrimidine.
[0267] In some embodiments, G or G’ is or comprises a substituted or unsubsituted quinazoline. In some embodiments, G or G’ is or comprises a substituted or unsubstituted tetrahydropyridopyrimidine (e.g., 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine). In some embodiments, G or G’ is or comprises a substituted or unsubsituted quinoline. In some embodiments, G or G’ is or comprises a substituted or unsubstituted pyridopyrazinone (e.g., pyrido[2,3-b]pyrazin-3(4H)-one). In some embodiments, G or G’ is or comprises a substituted or unsubstituted benzimidazole. In some embodiments, G or G’ is or comprises a substituted or unsubstituted pyrrolopyrimidine (e.g., a 7H-pyrrolo[2,3-J]pyrimidine). In some embodiments, G or G’ is or comprises a substituted or unsubstituted pyrazolopyridine (e.g., a pyrazolo[l,5- a]pyridine). In some embodiments, G or G’ is or comprises an unsubstituted pyrrolopyridine (e.g., a lH-pyrrolo[2,3-Z>]pyridine). In some embodiments, G or G’ is or comprises a substituted pyrrolopyridine (e.g., a lH-pyrrolo[2,3-Z>]pyridine).
[0268] In some embodiments, G or G’ is a substituted quinazoline, a substituted tetrahydropyridopyrimidine (e.g., 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine), a substituted quinoline, a substituted pyridopyrazinone (e.g., pyrido[2,3-b]pyrazin-3(4H)-one).
[0269] In some embodiments, G or G’ is a substituted tetrahydropyridopyrimidine (e.g., 5, 6,7,8- tetrahydropyrido[3,4-d]pyrimidine).
[0270] In some embodiments, G or G’ is a substituted quinazoline.
[0271] In some embodiments, G or G’ is a substituted tetrahydropyridopyrimidine (e.g., 5, 6,7,8- tetrahydropyrido[3,4-d]pyrimidine).
[0272] In some embodiments, G or G’ is a substituted quinoline.
[0273] In some embodiments, G or G’ is a substituted pyridopyrazinone (e.g., pyrido[2,3- b]pyrazin-3(4H)-one).
[0274] In some embodiments, G or G’ has a structure represented by Formula (II):Formula (II).
[0275] In some embodiments, Rlx, R2x, R3x, R4x, R5x, R6x, and R7xare each independently selected from the group consisting of hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
[0276] In some embodiments, Rlx, R2x, R3x, R4x, R5x, R6x, and R7xare each independently selected from the group consisting of hydrogen, halogen, and substituted or unsubstituted alkyl.
[0277] In some embodiments, Rlxis hydrogen.
[0278] In some embodiments, R2xis halogen. In some embodiments, R2xis fluoro.
[0279] In some embodiments, R3xis halogen. In some embodiments, R3xis chloro.
[0280] In some embodiments, R3xis substituted aryl. In some embodiments, R3xis aryl substituted with halogen. In some embodiments, R3xis aryl substituted with hydroxy. In some embodiments, R3xis aryl substituted with halogen and hydroxy. In some embodiments, R3xis aryl substituted with fluoro and hydroxy.
[0281] In some embodiments, R4xis substituted or unsubstituted alkyl. In some embodiments, R4Xis methyl.
[0282] In some embodiments, R5xis hydrogen.
[0283] In some embodiments, R6xis hydrogen.
[0284] In some embodiments, R7xis substituted or unsubstituted alkyl. In some embodiments, R7Xis isopropyl.
[0285] In some embodiments, Rlxis hydrogen, R2xis fluoro, R3xis aryl substituted with fluoro and hydroxy, R4xis methyl, R5xis hydrogen, R6xis hydrogen, and R7xis isopropyl.
[0286] In some embodiments, G or G’ has a structure represented by Formula (II-A):Formula (II- A)
[0287] In some embodiments, Rlxis hydrogen, R2xis fluoro, R3xis chloro, R4xis methyl, R5xis hydrogen, R6xis hydrogen, and R7xis isopropyl.
[0288] In some embodiments, G or G’ has a structure represented by Formula (II-B):Formula (II-B)
[0289] In some embodiments, G or G’ has a structure represented by Formula (III):Formula (III)
[0290] In some embodiments, R8ais hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In some embodiments, each R9ais independently selected from the group consisting of halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In some embodiments, each R10ais independently selected from the group consisting of halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In some embodiments, m is 0-6. In some embodiments, n is 0-7.
[0291] In some embodiments, R8ais hydrogen.
[0292] In some embodiments, n is 0 or 1.
[0293] In some embodiments, m is 0.
[0294] In some embodiments, R10ais halogen, hydroxy, or unsubstituted alkoxy. In some embodiments, R10ais chloro, hydroxy, or OMe. In some embodiments, R10ais chloro. In some embodiments, R10ais hydroxy. In some embodiments, R10ais OMe.
[0295] In some embodiments, R8ais hydrogen, m is 0, n is 1, and R10ais chloro.
[0296] In some embodiments, G or G’ has a structure represented by Formula (III-A):Formula (III-A)
[0297] In some embodiments, R8ais hydrogen, m is 0, and n is 0.
[0298] In some embodiments, G or G’ has a structure represented by Formula (III-B):Formula (III-B)
[0299] In some embodiments, R8ais hydrogen, m is 0, n is 1, and R10ais hydroxy.
[0300] In some embodiments, G or G’ has a structure represented by Formula (III-C):Formula (III-C)
[0301] In some embodiments, R8ais hydrogen, m is 0, n is 1, and R10ais -OMe.
[0302] In some embodiments, G or G’ has a structure represented by Formula (III-D):Formula (III-D)
[0303] In some embodiments, G or G’ has a structure represented by Formula (IV):Formula (IV)
[0304] In some embodiments, R11and R12are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In some embodiments, each R13is independently selected from the group consisting of halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In some embodiments, each R14is independently selected from the group consisting of halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In some embodiments, o is 0-3. In some embodiments, p is 0-5.
[0305] In some embodiments, R11is hydrogen.
[0306] In some embodiments, R12is hydrogen.
[0307] In some embodiments, o is 0 or 1.
[0308] In some embodiments, R13is halogen (e.g., chloro). In some embodiments, R13is chloro.
[0309] In some embodiments, each R14is independently alkyl.
[0310] In some embodiments, each R14is independently unsubstituted alkyl. In some embodiments, p is 2 and each R14is methyl.
[0311] In some embodiments, R11is hydrogen, R12is hydrogen, o is 0, p is 2, and each R14is methyl.
[0312] In some embodiments, G or G’ has a structure represented by Formula (IV-A):Formula (IV-A)
[0313] In some embodiments, R11is hydrogen, R12is hydrogen, o is 1, R13is chloro, p is 2, and each R14is independently methyl.
[0314] In some embodiments, G or G’ has a structure represented by Formula (IV-B):Formula (IV-B)
[0315] In some embodiments, G or G’ has a structure represented by Formula (V):Formula (V)
[0316] In some embodiments, R15is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In some embodiments, each R16isindependently selected from the group consisting of halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In some embodiments, each R17is independently selected from the group consisting of halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In some embodiments, r is 0-3. In some embodiments, s is 0-5.
[0317] In some embodiments, R15is hydrogen.
[0318] In some embodiments, r is 1 or 2.
[0319] In some embodiments, each R16is independently halogen. In some embodiments, each R16is independently chloro or fluoro.
[0320] In some embodiments, r is 1 and R16is fluoro.
[0321] In some embodiments, R17is independently halogen (e.g., fluoro) or hydroxyl. In some embodiments, R17is independently fluoro or hydroxyl.
[0322] In some embodiments, R15is hydrogen, r is 1, R16is chloro, s is 1, and R14is fluoro.
[0323] In some embodiments, G or G’ has a structure represented by Formula (V-A):Formula (V-A)
[0324] In some embodiments, G or G’ has a structure represented by Formula (V-B):Formula (V-B)
[0325] In some embodiments, G or G’ has a structure represented by Formula (VI):Formula (VI)
[0326] In some embodiments, each R18is independently selected from the group consisting of halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In some embodiments, each R19is independently selected from the group consisting of halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In some embodiments, each R20is independently selected from the group consisting of halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In some embodiments, R21is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In some embodiments, t is 0-6. In some embodiments, u is 0-7. In some embodiments, v is 0-7.
[0327] In some embodiments, t is 0.
[0328] In some embodiments, u is 1.
[0329] In some embodiments, R19is halogen (e.g., chloro). In some embodiments, R19is chloro.
[0330] In some embodiments, v is 0.
[0331] In some embodiments, R21is unsubstituted alkyl (e.g., methyl). In some embodiments, R21is methyl.
[0332] In some embodiments, t and v are 0, u is 1, R19is chloro, and R21is methyl.
[0333] In some embodiments, G or G’ has a structure represented by Formula (VI- A):Formula (VI- A)
[0334] In some embodiments, G or G’ has a structure represented by Formula (VI-B):Formula (VI-B)
[0335] In some embodiments, G or G’ has a structure represented by Formula (VI-C):Formula (VI-C)
[0336] In some embodiments, G or G’ has a structure represented by Formula (VII):Formula (VII)
[0337] In some embodiments, R22, R23, R24, R25, and R26are each independently selected from the group consisting of hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
[0338] In some embodiments, R22is hydrogen, hydroxy, or substituted or unsubstituted heteroalkyl. In some embodiments, R22is hydrogen. In some embodiments, R22is hydroxy. In some embodiments, R22is substituted or unsubstituted heteroalkyl (e.g., alkylamine substituted with oxo and heterocyclyl, such as cyclopropyl).
[0339] In some embodiments, R23is hydrogen or halogen. In some embodiments, R23is hydrogen. In some embodiments, R23is halogen. In some embodiments, R23is hydrogen or chloro.
[0340] In some embodiments, R24is hydrogen or halogen. In some embodiments, R24is hydrogen. In some embodiments, R24is halogen. In some embodiments, R24is chloro or bromo. In some embodiments, R24is hydrogen, chloro or bromo.
[0341] In some embodiments, R25is hydrogen, halogen (e.g., bromo), or substituted alkyl. In some embodiments, R25is hydrogen. In some embodiments, R25is halogen (e.g., bromo). In some embodiments, R25is chloro. In some embodiments, R25is substituted alkyl.
[0342] In some embodiments, R26is hydrogen, halogen (e.g., chloro), unsubstituted alkoxy, or substituted alkyl. In some embodiments, R26is hydrogen. In some embodiments, R26is halogen. In some embodiments, R26is chloro. In some embodiments, R26is unsubstituted alkoxy. In some embodiments, R26is substituted alkyl.
[0343] In some embodiments, R22is hydrogen, R23is hydrogen, R24is chloro, R25is hydrogen, and R26is chloro.
[0344] In some embodiments, G or G’ has a structure represented by Formula (VII-A):Formula (VII- A)
[0345] In some embodiments, R22is hydrogen, R23is chloro, R24is hydrogen, R25is hydrogen, and R26is chloro.
[0346] In some embodiments, G or G’ has a structure represented by Formula (VII-B):Formula (VII-B)
[0347] In some embodiments, R22is hydrogen, R23is hydrogen, R24is hydrogen, R25is bromo, and R26is chloro.
[0348] In some embodiments, G or G’ has a structure represented by Formula (VII-C):Formula (VII-C)
[0349] In some embodiments, R22is hydrogen, R23is hydrogen, R24is alkylamine substituted with oxo and cycloalkyl (e.g., -C(O)NH-(cyclopropyl)), R25is hydrogen, and R26is hydrogen.
[0350] In some embodiments, G or G’ has a structure represented by Formula (VII-D):Formula (VII-D)
[0351] In some embodiments, G or G’ is substituted pyridine. In some embodiments, G or G’ is pyridine substituted with halo (e.g., chloro). In some embodiments, G or G’ is pyridine substituted with substituted alkyl (haloalkyl) and / or unsubstituted alkyl (e.g., methyl).
[0352] In some embodiments, G or G’ has a structure represented by Formula (VII-E):Formula (VII-E)
[0353] In some embodiments, G or G’ has a structure represented by Formula (VII-F):Formula (VII-F)
[0354] In some embodiments, G or G’ is substituted pyrazole. In some embodiments, G or G’ is pyrazole substituted with heterocyclyl, such as pyrrolidin-2-one.
[0355] In some embodiments, G or G’ has a structure represented by Formula (VII-G):Formula (VII-G)
[0356] In some embodiments, G or G’ is substituted or unsubstituted pyrrolopyridine (e.g., 1H- pyrrolo[2,3-Z>]pyridine). In some embodiments, G or G’ is substituted pyrrolopyridine. In some embodiments, G or G’ is lH-pyrrolo[2,3-Z>]pyridine substituted with substituted alkylamine, such as alkylamine substituted with oxo (e.g., -C(O)NH2). In some embodiments, G or G’ is a JAK3-binding ligand that is a substituted or unsubstituted pyrrolopyridine (e.g., lH-pyrrolo[2,3- Z>]pyridine).
[0357] In some embodiments, G or G’ has a structure represented by Formula (VII-H):Formula (VII-H)
[0358] In some embodiments, G or G’ is unsubstituted or substituted pyrrolopyrimidine (e.g., a 7H-pyrrolo[2,3-J]pyrimidine). In some embodiments, G or G’ is unsubstituted pyrrolopyrimidine (e.g., a 7H-pyrrolo[2,3-J]pyrimidine). In some embodiments, G or G’ is unsubstituted 7H-pyrrolo[2,3-J]pyrimidine. In some embodiments, G or G’ is a JAK3-binding ligand that is an unsubstituted or substituted pyrrolopyrimidine (e.g., a 7H-pyrrolo[2,3- t / ]pyrimidine).
[0359] In some embodiments, G or G’ has a structure represented by Formula (VII-I):Formula (VII-I)
[0360] In some embodiments, G or G’ is unsubstituted or substituted pyrazolopyrimidine (e.g., lH-pyrazolo[3,4-d]pyrimidine). In some embodiments, G or G’ is substituted pyrazolopyrimidine (e.g., lH-pyrazolo[3,4-d]pyrimidine), such as pyrazolopyrimidine (e.g., lH-pyrazolo[3,4- d]pyrimidine) substituted with substituted amino (e.g., amino substituted with alkyl (e.g., methyl) or unsubstituted or substituted heterocyclyl, such as pyrazole substituted with alkoxy). In some embodiments, G or G’ is substituted lH-pyrazolo[3,4-d]pyrimidine. In some embodiments, G or G’ is a JAK3-binding ligand that is an unsubstituted or substituted pyrazolopyrimidine (e.g., 1H- pyrazolo[3,4-d]pyrimidine).
[0361] In some embodiments, G or G’ is substituted or unsubstituted pyrazolopyridine (e.g., a pyrazolo[l,5-a]pyridine). In some embodiments, G or G’ is unsubstituted pyrazolopyridine (e.g., a pyrazolo[l,5-a]pyridine). In some embodiments, G or G’ is unsubstituted a pyrazolo[l,5- a]pyridine. In some embodiments, G or G’ is a JAK3-binding ligand that is an unsubstituted or substituted pyrazolopyridine (e.g., a pyrazolo[l,5-a]pyridine).
[0362] In some embodiments, G or G’ has a structure represented by Formula (VII- J):Formula (VII- J)
[0363] In some embodiments, G or G’ is unsubstituted or substituted benzimidazole. In some embodiments, G or G’ is substituted benzimidazole. In some embodiments, G or G’ is benzimidazole substituted with alkyl (e.g., methyl or fluoroalkyl).
[0364] In some embodiments, G or G’ has a structure represented by Formula (VII-K):Formula (VII-K)
[0365] In some embodiments, G’ is a radical of a protein-binding ligand, such as a protein- binding ligand provided elsewhere herein.
[0366] In some embodiments, G’ is a radical of a compound that interacts with a protein (e.g., BTK, EGFR, KRAS, FGFR, TEAD, JAK3, or BMX) or a mutant thereof.
[0367] In some embodiments, G’ is or comprises a protein-binding ligand selected from a BTK-, EGFR-, FGFR-, KRAS-, TEAD-, JAK3-, or BMX-binding ligand.
[0368] In some embodiments, G’ is a radical of a BTK-binding ligand. In some embodiments, G is a radical of an EGFR-binding ligand. In some embodiments, G is a radical of a FGFR-binding ligand. In some embodiments, G’ is a radical of a BMX-binding ligand. In some embodiments, G’ is a radical of a AURKA-binding ligand. In some embodiments, G’ is a radical of a TEAD- binding ligand. In some embodiments, G’ is a radical of a JAK3 -binding ligand. In some embodiments, G’ is a radical of a KRAS-binding ligand.
[0369] In some embodiments, G’ has a structure represented in Table 1 A, Table IB, or Table 1C. In some embodiments, G’ is or comprises one or more (e.g., unsaturated) unsubstituted or substituted carbocycle and / or one or more (e.g., unsaturated) unsubstituted or substituted heterocycle. In some embodiments, G’ is or comprises an (e.g., unsaturated) unsubstituted or substituted carbocycle or an (e.g., unsaturated) unsubstituted or substituted heterocycle)). In some embodiments, G’ consists of an (e.g., unsaturated) unsubstituted or substituted carbocycle or an (e.g., unsaturated) unsubstituted or substituted heterocycle)). In some embodiments, G’ is (e.g., unsaturated) unsubstituted or substituted carbocycle or an (e.g., unsaturated) unsubstituted or substituted heterocycle. In some embodiments, G’ is substituted or unsubstituted unsaturated carbocycle or substituted or unsubstituted unsaturated heterocycle. In some embodiments, G’comprises one or more cyclic ring systems selected from substituted or unsubstituted unsaturated carbocycles and substituted or unsubstituted unsaturated heterocycles. In some embodiments, G’ comprises two or more cyclic ring systems selected from substituted or unsubstituted unsaturated carbocycles and substituted or unsubstituted unsaturated heterocycles.
[0370] In some embodiments, G’ comprises one or more cyclic ring systems selected from substituted or unsubstituted carbocycles and substituted or unsubstituted heterocycles. In some embodiments, G’ comprises two or more cyclic ring systems selected from substituted or unsubstituted carbocycles and substituted or unsubstituted heterocycles.
[0371] In some embodiments, G’ comprises one or more cyclic group. In some embodiments, G’ comprises one or more cyclic groups wherein the one or more cyclic groups are individually linked by one or more linker (e.g., L or L’).
[0372] In some embodiments, G’ comprises one or more nitrogen atoms. In some embodiments, G’ comprises one or more nitrogen ring atoms. In some embodiments, G’ comprises one or more nitrogen atoms within its ring system. In some embodiments, G’ comprises one or more nitrogen atoms within its fused ring system. In some embodiments, G’ comprises one, two, or three nitrogen atoms (e.g., within its (e.g., fused) ring system).
[0373] In some embodiments, G’ comprises one or more (e.g., fused) rings. In some embodiments, G’ comprises one or more fused rings.
[0374] In some embodiments, G’ is aromatic or partially aromatic. In some embodiments, G is partially aromatic. In some embodiments, G’ is partially aromatic.
[0375] In some embodiments, G’ comprises one or more substituted or unsubstituted aromatic ring(s). In some embodiments, G’ comprises one substituted or unsubstituted aromatic ring. In some embodiments, G’ comprises two substituted or unsubstituted aromatic rings. In some embodiments, G’ comprises three substituted or unsubstituted aromatic rings.
[0376] In some embodiments, G’ comprises one or more (e.g., one, two, or three) substituted or unsubstituted heteroaromatic ring(s).
[0377] In some embodiments, G’ comprises a substituted or unsubstituted carbocycle. In some embodiments, G’ comprises an unsubstituted carbocycle. In some embodiments, G comprises a substituted carbocycle.
[0378] In some embodiments, G’ comprises a substituted or unsubstituted heterocycle. In some embodiments, G’ comprises a substituted heterocycle. In some embodiments, G comprises an unsubstituted heterocycle.
[0379] In some embodiments, G’ is a substituted carbocycle.
[0380] In some embodiments, G’ is a substituted phenyl.
[0381] In some embodiments, G’ is a substituted heterocycle.
[0382] In some embodiments, G’ is a substituted quinazoline or a substituted pyrazolopyrimidine. In some embodiments, G’ is a substituted quinazoline. In some embodiments, G’ is a substituted pyrazolopyrimidine. In some embodiments, G is a substituted lH-pyrazolo[3,4-d]pyrimidine.
[0383] Unless stated specifically otherwise herein, each instance of radical indicates that a hydrogen (i.e., a hydrogen radical (H*)) is removed from a free form of a compound provided herein, such as any protein-binding ligand (e.g., G or G’) or warhead described herein. In some instances, the removal of the hydrogen radical from the compound provided herein, such as any protein-binding ligand (e.g., G or G’) or warhead described herein, provides a radical of a protein- binding ligand or a warhead that is taken together with any point of a linker provided herein (e.g., L or L’) to form a bond (e.g., between the linker and the radical of the protein-binding ligand or the warhead). In some instances, a carbon atom (e.g., of any protein-binding ligand (e.g., a substituted heterocycle or a substituted carbocycle) or warhead described herein) loses an H* to become a point of attachment to L. In some instances, >NH loses an H* to become >N-(point of attachment), such as >N-L-G, >N-L-warhead, >N-DG, or >N-warhead. In some instances, -OH loses an H* to become -O-(point of attachment), such as -O-L-G, -O-L-warhead, -O-G, or -O- warhead. In some instances, -S(=O)gH (where g is 1 or 2) loses an H* to become -S(=O)g-(point of attachment), such as -S(=O)g-L-G, -S(=O)g-L-warhead, -S(=O)g-G, or -S(=O)g-warhead. In some instances, the linker (e.g., L or L’) is a bond. In some instances, G-L- is a protein-binding ligand.
[0384] In some embodiments, the protein-binding ligand (e.g., G or G’) has or comprises a structure shown in Table 1 A:
[0385] In some embodiments, the protein (e.g., KRAS)-binding ligand (e.g., G or G’) has or comprises a structure shown in Table IB:Table IB
[0386] In some embodiments, the protein-binding ligand (e.g., G or G’) has or comprises a structure shown in Table 1C:
[0387] In some embodiments, Y2is a blocking group. In some embodiments, Y2is a group that directs binding of a protein (e.g., a protein described herein) or a mutant thereof to a position other than Y2. In some embodiments, Y2is a group that directs covalent and / or irreversible binding of a cysteine residue of a protein (e.g., a protein described herein) or a mutant thereof to a position other than Y2. In some embodiments, Y2is a group that directs covalent and / or irreversible binding of a cysteine residue of a protein (e.g., a protein described herein) or a mutant thereof to a position ortho or meta to Y2. In some embodiments, Y2is a group that directs covalent and / or irreversible binding of a cysteine residue of a protein (e.g., a protein described herein) or a mutant thereof to a position ortho to Y2. In some embodiments, Y2is a group that directs covalent and / or irreversible binding of a cysteine residue of a protein (e.g., a protein described herein) or a mutant thereof to a position meta to Y2.
[0388] In some embodiments, Y2is not a leaving group, such as halo (e.g., fluoro).
[0389] In some embodiments, Y2is not halo. In some embodiments, Y2is not fluoro.
[0390] In some embodiments, Y2is hydrogen, CN, NO2, hydroxy, substituted or unsubstituted amino (e.g., -NRxaRya-, where Rxais hydroxy and Ryais hydrogen), substituted or unsubstitutedamido (e.g., -CONRxaRya-, where Rxais hydroxy or substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo) and Ryais hydrogen or substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo)), substituted or unsubstituted alkyl (e.g., fluoroalkyl), substituted or unsubstituted alkoxy (e.g., fluoroalkoxy), or substituted or unsubstituted heteroalkyl (e.g., alkylamine substituted with oxo and / or hydroxy)).
[0391] In some embodiments, Y2is hydrogen, CN, NO2, hydroxy, substituted amino (e.g., - NRxaRya-, where Rxais hydroxy or substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo) and Ryais hydrogen or substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo)), unsubstituted alkyl (e.g., methyl), substituted alkyl (e.g., alkyl substituted with halo (e.g., fluoroalkyl (e.g., methyl substituted with one, two, or three fluoro))), unsubstituted alkoxy (e.g., methoxy), substituted alkoxy (e.g., alkoxy substituted with halo (e.g., fluoroalkoxy (e.g., methoxy substituted with one, two, or three fluoro))), or substituted heteroalkyl (e.g., alkylamine substituted with oxo and / or hydroxy).
[0392] In some embodiments, Y2is CN, NO2, hydroxy, substituted or unsubstituted amino (e.g., -NRxaRya-, where Rxais hydroxy and Ryis hydrogen), substituted or unsubstituted amido (e.g., -CONRxaRya-, where Rxais hydroxy or substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo) and Ryais hydrogen or substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo)), substituted or unsubstituted alkyl (e.g., fluoroalkyl), substituted or unsubstituted alkoxy (e.g., fluoroalkoxy), or substituted or unsubstituted heteroalkyl (e.g., alkylamine substituted with oxo and / or hydroxy)).
[0393] In some embodiments, Y2is CN, NO2, hydroxy, substituted or unsubstituted amino (e.g., -NRxaRya-, where Rxais hydroxy or substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo) and Ryais hydrogen or substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo)), substituted or unsubstituted amido (e.g., -CONRxRy-, where Rxais hydroxy or substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo) and Ryais hydrogen or substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo)), substituted or unsubstituted alkyl (e.g., fluoroalkyl), substituted or unsubstituted alkoxy (e.g., fluoroalkoxy), or substituted or unsubstituted heteroalkyl (e.g., alkylamine substituted with oxo and / or hydroxy)).
[0394] In some embodiments, Y2is hydrogen, CN, NO2, hydroxy, substituted or unsubstituted amino (e.g., -NRxaRya-, where Rxais hydroxy and Ryis hydrogen or substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo)), substituted or unsubstituted alkyl (e.g., fluoroalkyl), substituted or unsubstituted alkoxy (e.g., fluoroalkoxy), or substituted or unsubstituted heteroalkyl (e.g., alkylamine substituted with oxo and / or hydroxy)).
[0395] In some embodiments, Y2is hydrogen, CN, NO2, hydroxy, substituted or unsubstituted amino (e.g., -NRxaRya-, where Rxais hydroxy or substituted or unsubstituted alkyl (e.g., alkylsubstituted with oxo) and Ryais hydrogen or substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo)), substituted or unsubstituted alkyl (e.g., fluoroalkyl), substituted or unsubstituted alkoxy (e.g., fluoroalkoxy), or substituted or unsubstituted heteroalkyl (e.g., alkylamine substituted with oxo and / or hydroxy)).
[0396] In some embodiments, Y2is hydrogen, CN, NO2, hydroxy, substituted amino (e.g., - NRxaRya-, where Rxais hydroxy and Ryis hydrogen or substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo)), unsubstituted alkyl (e.g., methyl), substituted alkyl (e.g., alkyl substituted with halo (e.g., fluoroalkyl (e.g., methyl substituted with one, two, or three fluoro))), unsubstituted alkoxy (e.g., methoxy), substituted alkoxy (e.g., alkoxy substituted with halo (e.g., fluoroalkoxy (e.g., methoxy substituted with one, two, or three fluoro))), or substituted heteroalkyl (e.g., alkylamine substituted with oxo and / or hydroxy).
[0397] In some embodiments, Y2is hydrogen, CN, NO2, substituted alkoxy (e.g., alkoxy substituted with halo (e.g., fluoroalkoxy (e.g., methoxy substituted with one, two, or three fluoro), or substituted alkyl (e.g., alkyl substituted with halo (e.g., fluoroalkyl (e.g., methyl substituted with one, two, or three fluoro))).
[0398] In some embodiments, Y2is hydrogen, CN, NO2, amino (e.g., -NH2), hydroxy, substituted or unsubstituted alkoxy (e.g., methoxy), unsubstituted or substituted heteroalkyl (e.g., alkylamine or heteroalkyl substituted with oxo, such as Me2N(CO)O, MeNHCO-, Me2NCO-, and MeCONH-), unsubstituted alkyl (e.g., methyl), or substituted alkyl (e.g., alkyl substituted with hydroxy or amino (e.g., -NH2), alkyl substituted with oxo and amino (e.g., -C(O)NH2), alkyl substituted with hydroxy and oxo (e.g., -COOH), alkyl substituted with oxo and heterocyclyl (e.g., azetidinyl), alkyl substituted with halo (e.g., fluoroalkyl (e.g., methyl substituted with one, two, or three fluoro))). In some embodiments, Y2is unsubstituted alkylamine (e.g., diaminoalkyl), such as -CH2NHMe, -CH2NMe2, and -NHCH2CH2Nme2. In some embodiments, Y2is heteroalkyl substituted with oxo, such as Me2N(CO)O, MeNHCO-, Me2NCO-, and MeCONH-. In some embodiments, Y2is substituted alkyl. In some embodiments, Y2is alkyl substituted with hydroxy or amino (e.g., -NH2). In some embodiments, Y2is alkyl substituted with oxo and amino (e.g., - C(O)NH2). In some embodiments, Y2is alkyl substituted with hydroxy and oxo (e.g., -COOH). In some embodiments, Y2is alkyl substituted with oxo and heterocyclyl (e.g., -O-C(O)- (azetidinyl)). In some embodiments, Y2is alkyl substituted with halo (e.g., fluoroalkyl (e.g., methyl substituted with one, two, or three fluoro))).
[0399] In some embodiments, Y2is hydrogen, CN, NO2, or substituted alkyl (e.g., alkyl substituted with halo (e.g., fluoroalkyl (e.g., methyl substituted with one, two, or three fluoro))).
[0400] In some embodiments, Y2is CN, NO2, substituted alkoxy (e.g., alkoxy substituted with halo (e.g., fluoroalkoxy (e.g., methoxy substituted with one, two, or three fluoro), or substitutedalkyl (e.g., alkyl substituted with halo (e.g., fluoroalkyl (e.g., methyl substituted with one, two, or three fluoro))).
[0401] In some embodiments, Y2is hydrogen, CN, NO2, -OH, OCHF2, OCH2F, OCF3, OCH3, CH3, CHF2, CH2F, CF3, NHCOCH3, CONHCH3, CONHOH, N(OH)C(=O)H, or C(=O)OH.
[0402] In some embodiments, Y2is CN, NO2, -OH, OCHF2, OCH2F, OCF3, OCH3, CH3, CHF2, CH2F, CF3, NHCOCH3, CONHCH3, CONHOH, N(OH)C(=O)H, or C(=O)OH.
[0403] In some embodiments, Y2is hydrogen, CN, NO2, or CF3.
[0404] In some embodiments, Y2is CN, NO2, or CF3.
[0405] In some embodiments, Y2is CN or NO2.
[0406] In some embodiments, Y2is hydrogen.
[0407] In some embodiments, Y2is CN.
[0408] In some embodiments, Y2is NO2.
[0409] In some embodiments, Y2is CF3.
[0410] In some embodiments, Y2is OCH3.
[0411] In some embodiments, Y2is unsubstituted amino.
[0412] In some embodiments, Y2is substituted alkoxy. In some embodiments, Y2is substituted C1-C3 alkoxy. In some embodiments, Y2is -O(CH2)2N(CH3)2.
[0413] In some embodiments, Y2is heterocyclyl. In some embodiments, Y2is N-heterocyclyl. In some embodiments, Y2is pyrrolidine.
[0414] In some embodiments, Y2is heteroalkyl. In some embodiments, Y2is C1-C3 heteroalkyl. In some embodiments, Y2is SCH3.
[0415] In some embodiments, such as when Y2is hydrogen, thiol, substituted thioether, substituted alkoxy (e.g., fluoroalkoxy), substituted amino, or NO2, the compound interacts with a protein or a mutant thereof at a position other than Y2. In some embodiments, such as when Y2is H, thiol, substituted thioether, substituted alkoxy (e.g., fluoroalkoxy), substituted amino, or NCh, the compound covalently and / or irreversibly interacts with a cysteine residue of the protein or the mutant thereof at a position other than Y2. In some embodiments, such as when Y2is H, thiol, substituted thioether, substituted alkoxy (e.g., fluoroalkoxy), substituted amino, or NO2, the compound covalently and / or irreversibly interacts with a cysteine residue of the protein or the mutant thereof at a position ortho or meta to Y2.
[0416] In some embodiments,Kdirects binding of a protein (e.g., BTK, EGFR, FGFR, BMX, TEAD, JAK3, KRAS) or a mutant thereof to a position ortho or meta to L or L’ . In someX1sz=x2embodiments,Kdirects binding of a protein (e.g., BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS) or a mutant thereof to a position ortho to L or L’. In someembodiments,Kdirects binding of a protein (e.g., BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS) or a mutant thereof to a position meta to L or L’ .
[0417] In some embodiments,covalently and / or irreversibly directs binding of a cysteine residue of a protein (e.g., BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS) or a mutant thereof to a position ortho or meta to L or L’. In some embodiments, / X1^S^X2Kcovalently and / or irreversibly directs binding of a cysteine residue of a protein (e.g., BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS) or a mutant thereof to a positionp ortho to L or L’ . In some embodiments,Rxcovalently and / or irreversibly directs binding of a cysteine residue of a protein (e g., BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS) or a mutant thereof to a position meta to L or L’ .
[0418] In some embodiments, a warhead group described herein has or comprises a structure shown in Table A:
[0419] In some embodiments, L or L’ is a linker. In some embodiments, L or L’ is a bond, -O- , amino (e.g., -NR2-, where R2is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted carbocyclyl), substituted or unsubstituted alkyl(ene), substituted or unsubstituted alkoxy, substituted or unsubstituted heteroalkyl(ene) (e.g., alkylamine (e.g., -NR3R4-, where R3is substituted or unsubstituted alkyl(ene), substituted or unsubstituted heteroalkyl(ene), substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocycyl and R4is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted carbocyclyl)), substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl (e.g., -NR5R6-, where R5and R6are taken together to form a substituted or unsubstituted heterocyclyl). In some embodiments, L or L’ is a bond, amino (e.g., -NR2-, where R2is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted carbocyclyl), substituted or unsubstituted alkyl(ene), substituted or unsubstituted alkoxy, substituted or unsubstituted heteroalkyl(ene) (e.g., alkylamine (e.g., -NR3R4-, where R3is substituted or unsubstituted alkyl(ene), substituted or unsubstituted heteroalkyl(ene), substituted or unsubstituted carbocyclyl, or substituted orunsubstituted heterocycyl and R4is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted carbocyclyl)), substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl (e.g., -NR5R6-, where R5and R6are taken together to form a substituted or unsubstituted heterocyclyl).
[0420] In some embodiments, L or L’ is a bond, -O-, amino, substituted or unsubstituted alkyl(ene), substituted or unsubstituted alkoxy, substituted or unsubstituted heteroalkyl(ene), substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl. In some embodiments, L or L’ is amino, substituted or unsubstituted heteroalkyl(ene), or substituted or unsubstituted heterocyclyl. In some embodiments, L or L’ is amino, -O-, substituted or unsubstituted heteroalkyl(ene), or substituted or unsubstituted heterocyclyl.
[0421] In some embodiments, L orL’ is a bond, amino, substituted or unsubstituted alkyl(ene), substituted or unsubstituted alkoxy, substituted or unsubstituted heteroalkyl(ene), substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl. In some embodiments, L or L’ is amino, substituted or unsubstituted heteroalkyl(ene), or substituted or unsubstituted heterocyclyl.
[0422] In some embodiments, L or L’ is amino (e.g., -NR2-, where R2is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted carbocyclyl), substituted or unsubstituted heteroalkyl(ene) (e.g., alkylamine (e.g., -NR3R4-, where R3is substituted or unsubstituted alkyl(ene), substituted or unsubstituted heteroalkyl(ene), substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocycyl and R4is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted carbocyclyl)), or substituted or unsubstituted heterocyclyl (e.g., - NR5R6-, where R5and R6are taken together to form a substituted or unsubstituted heterocyclyl).
[0423] In some embodiments, L or L’ comprises one or more N atom(s).
[0424] In some embodiments, L or L’ is amino. In some embodiments, L or L’ is -NR2-, where R2is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted carbocyclyl. In some embodiments, L or L’ is -NH- or -NCH3-. In some embodiments, L or L’ is -NH-.
[0425] In some embodiments, L or L’ is substituted or unsubstituted alkylamine. In some embodiments, L or L’ is substituted alkylamine (e.g., alkylamine substituted with oxo, such as - NHC(O)-). In some embodiments, L or L’ is unsubstituted alkylamine. In some embodiments, L or L’ is methylamine, ethylamine, propylamine, or butylamine. In some embodiments, L or L’ is methylamine, ethylamine, or propylamine.
[0426] In some embodiments, the linker (e.g., L or L’) is -NR4-R3-, -NR4-R3-NR7a-, -NR4-R3- O-, or -C(O)NR4-R3-, where R3is substituted or unsubstituted alkyl(ene), substituted or unsubstituted heteroalkyl(ene), substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocycyl, R4is hydrogen, substituted or unsubstituted alkyl, or substituted orunsubstituted carbocyclyl, and R7ais H or substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo). In some embodiments, L or L’ is -C(O)NH(unsubstituted alkyl)-. In some embodiments, L or L’ is -C(O)NH(methyl)-, -C(O)NH(ethyl)-, or -C(O)NH(propyl)-. In some embodiments, L or L’ is -NR3R4-, where R3is substituted or unsubstituted alkyl(ene), substituted or unsubstituted heteroalkyl(ene), substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocycyl and R4is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted carbocyclyl.
[0427] In some embodiments, L or L’ is -NH(heterocyclyl)-. In some embodiments, L is - NH(azetidinyl)-.
[0428] In some embodiments, L or L’ is substituted or unsubstituted heterocyclyl. In some embodiments, the linker (e.g., L or L’) is -NR5R6-, -NR5R6-NR7-, -NR5R6-C(O)-, -NR5R6- CH2NR7-, -NR5R6-CH2NR7C(O)-, -C(O)NR5R6-NR7-, -C(O)NR5R6-O-, -NR5R6-O-, or - C(O)NR5R6CH2-NR7-, where R5and R6are taken together to form a substituted or unsubstituted heterocyclyl, and R7is H, substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo), or alkoxy. In some embodiments, NR5R6-, -NR5R6-NR7-, -NR5R6-C(O)-, -NR5R6-CH2NR7-, - NR5R6-CH2NR7C(O)-, -C(O)NR5R6-NR7-, or -C(O)NR5R6CH2-NR7-, where R5and R6are taken together to form a substituted or unsubstituted heterocyclyl, and R7is H, substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo), or alkoxy. In some embodiments, L or L’ is -NR5R6-, where R5and R6are taken together to form a substituted or unsubstituted heterocyclyl. In some embodiments, L or L’ (or -NR5R6-) is substituted or unsubstituted piperazinyl or substituted or unsubstituted piperidinyl. In some embodiments, L or L’ (or -NR5R6-) is substituted or unsubstituted piperidinyl. In some embodiments, L or L’ (or -NR5R6-) is substituted or unsubstituted piperazinyl. In some embodiments, L or L’ (or -NR5R6-) is piperazinyl substituted with methyl.
[0429] In some embodiments, -NR5R6- is substituted or unsubstituted piperazinyl (e.g., piperazinyl substituted with methyl), substituted or unsubstituted piperidinyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted azepanyl, or diazepanyl (e.g., 1,4-diazepanyl).
[0430] In some embodiments, -NR5R6- is substituted or unsubstituted piperidinyl or substituted or unsubstituted azetidinyl and -NR7- is -NH-, -NCH3-, -NC(O)CH3-, or -NCH2CH2OCH3-.
[0431] In some embodiments, L or L’ is -NR5R6-C(O)- and -NR5R6- is unsubstituted 1,4- diazepanyl.
[0432] In some embodiments, L or L’ is -C(O)NR5R6-NR7-, -NR5R6- is unsubstituted piperidinyl or unsubstituted pyrrolidinyl, and -NR7- is -NH-.
[0433] In some embodiments, L or L’ is -NR5R6-CH2NR7C(O)-, -NR5R6- is unsubstituted pyrrolidinyl, and -NR7- is -NH-.
[0434] In some embodiments, L or L’ is -NR5R6-CH2NR7-, -NR5R6- is unsubstituted azetidinyl or azepanyl, and -NR7- is -NH-.
[0435] In some embodiments, L or L’ is -NR5R6-CH2NR7C(O)-, -NR5R6- is unsubstituted azetidinyl, and -NR7- is -NH-.
[0436] In some embodiments, L or L’ comprises two N atom(s). In some embodiments, L or L’ comprises or is (substituted or unsubstituted) diaminoalkyl, (substituted or unsubstituted) diamino-cycloalkyl, (substituted or unsubstituted) amino-heterocyclyl (e.g., the heterocyclyl being nitrogen containing), (substituted or unsubstituted) heterocyclyl (e.g., containing 2 nitrogen atoms). In some embodiments, the heterocyclyl is optionally fused or spirocyclic.
[0437] In some embodiments, L or L’ is or comprises -C(O)-diaminoalkyl-. In some embodiments, each amino group of the diaminoalkyl is independently unsubstituted or substituted. In some embodiments, each amino group of the diaminoalkyl is independently unsubstituted or substituted with methyl.
[0438] In some embodiments, L or L’ comprises one or more rings. In some embodiments, L or L’ comprises one or more fused or spirocyclic rings.
[0439] In some embodiments, L or L’ is or comprises a spirocyclic ring. In some embodiments, L or L’ is or comprises l,7-diazaspiro[4.5]decane.
[0440] In some embodiments, L or L’ is or comprises substituted or unsubstituted phenyl. In some embodiments, L or L’ is or comprises substituted phenyl. In some embodiments, the phenyl is substituted with substitued with one or more substituent selected from the group consisting of halo, cyano, amino, alkylamino, heteroalkyl (e.g., substituted alkanolamine or substituted diaminoalkyl), -N-(substituted heterocyclyl), and substituted heterocyclyl. In some embodiments, the phenyl is substituted with substitued halo, cyano, amino, alkylamino, heteroalkyl (e.g., substituted alkanolamine or substituted diaminoalkyl), -N-(substituted heterocyclyl), or substituted heterocyclyl, such as wherein the substituted heterocyclyl is piperidinyl or pyrrolidinyl substituted with amino or alkylamine. In some embodiments, L or L’ is -NH-(unsubstituted phenyl)-, -NH-(unsubstituted phenyl)-NH-, -NH-(unsubstituted phenyl)-C(O)-, -CH2NH- (unsubstituted phenyl)-C(O)-, -CH2-(unsubstituted phenyl)-NH-, -NHCH2-(unsubstituted phenyl)-C(O)-, -NHC(O)-(unsubstituted phenyl)-C(O)-, -NH-(substituted phenyl)-C(O)-, - C(O)NH-(substituted phenyl)-C(O)-, -C(O)NH-(substituted phenyl)-C(O)NH-, -NH- (unsubstituted phenyl)-C(O)NH-, -O-(unsubstituted phenyl)-C(O)NH-, or-NH-(substituted phenyl)-C(O)NH-. In some embodiments, L or L’ is -NH-(unsubstituted phenyl)-, -NH-(unsubstituted phenyl)-C(O)-, -NH-(substituted phenyl)-C(O)-, -NH-(unsubstituted phenyl)- C(O)NH-, or-NH-(substituted phenyl)-C(O)NH-.
[0441] In some embodiments, L or L’ is:
[0442] In some embodiments, L or L’ is a bond.
[0443] In some embodiments, provided herein is a compound (e.g., of Formula (I-A) or Formula (I-B)), wherein the compound (e.g., of Formula (I-A) or Formula (I-B)) comprises a linker (e.g., L) of any one of the compounds of Table 2C or Table 2D, such as wherein the linker (e.g., L) is the part of the compound identified with a box around it in FIG. IB or FIG. 1C.
[0444] In some instances, such as when L is substituted or unsubstituted heterocyclyl, L is part of G and / or the warhead.
[0445] In some embodiments, provided herein is a compound (e.g., of Formula (I-A) or Formula (I-B)), wherein the compound (e.g., of Formula (I-A) or Formula (I-B)) comprises aprotein-binding ligand provided in Table 1A, Table IB, or Table 1C, a linker described herein, and a warhead group provided in Table A.
[0446] In some embodiments, a compound provided herein has a structure shown in Table 2A, Table 2B, Table 2C, or Table 2D.
[0447] In some embodiments, a compound provided herein, such a compound of Formula (A), Formula (I), Formula (I-A), or Formula (I-B) or provided in Table 1A, Table IB, or Table 1C, forms a bond, such as a covalent bond with a polypeptide provided herein. In some embodiments, the polypeptide covalently binds to the compound. In some embodiments, the polypeptide covalently binds to the compound, wherein the polypeptide comprises a thiol that covalently binds to the compound. In some embodiments, the polypeptide covalently binds to the compound, wherein the polypeptide comprises a thiol, such a thiol of a cysteine residue of the polypeptide, that covalently binds to the compound.
[0448] In some embodiments, a compound provided herein has reduced reactivity with GSH. In some embodiments, a compound provided herein has reduced reactivity with GSH (and GSH / GST catalyzed reactions) while still retaining the ability to bind to a (target) polypeptide. In some embodiments, a compound provided herein has increased stability to GSH, such as GSH metabolism in vitro and / or in vivo, such as in liver cells and whole blood. In some embodiments, a compound provided herein has a higher affinity to (e.g., and covalently modifying) the polypeptide (e.g., a target protein described herein) than GSH. In some embodiments, GSH has a binding affinity for a compound provided herein (e.g., Kd) of more than 0.1 μM (e.g., 1 pM, 10 pM, 100 pM, or 1000 μM or more). In some instances, GSH has a binding affinity for a compound provided herein (e.g., Kd) of more than 10 pM. In some instances, GSH has a binding affinity (e.g., Kd) for a compound provided herein of no less than 10 pM.
[0449] In some embodiments, a compound provided herein has reduced reactivity with glutathione (GSH). In some embodiments, a compound provided herein has a reduced reactivity with the sulfur (e.g., thiol) of glutathione (GSH), such as relative to that of a (e.g., sulfur- containing) polypeptide. In some embodiments, a compound provided herein is inert glutathione (GSH) metabolism. In some embodiments, a compound provided herein does not substantially covalently bind to glutathione (GSH). In some embodiments, the lack of substantial covalent binding of the compound to glutathione is demonstrated by the lack of binding of glutathione to the compound, such as measured by glutathione S-trasferase (GST) assay described herein, such as at Example IV.
[0450] Tables 10A-10F of the Examples demonstrate reactivity (expressed as ICso and WRso values) and selectivity of compounds described herein. For example, Tables 10A-10F show, in some instances, that compounds described herein have reduced reactivity with glutathione (GSH),such as in comparison to a target protein, such as a target protein described herein (e.g., BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof). Additionally, Tables 10A-10F, in some instances, demonstrate that compounds described herein lack covalent binding to GSH. Moreover, Tables 10A-10F demonstrate, in some instances, that compounds described herein bind to and / or (e.g., covalently) modify a target protein, such as a target protein described herein (e.g, BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof), without the compound substantially covalently binding to GSH. Furthermore, Tables 10A-10F demonstrate, in some instances, compounds that are selective for a target protein, such as a target protein described herein (e.g, BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof), relative to GSH. In some cases, the compounds provided herein contact, bind to, and / or modify a target protein, such as a target protein described herein (e g., BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof), in the absence of any binding, including covalent binding, of GSH to the compounds. In some cases, compounds described herein are 10-fold or more selective for a target protein, such as a target protein described herein (e.g, BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof), relative to GSH. In some cases, compounds described herein are 100-fold or more selective for a target protein, such as a target protein described herein (e.g., BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof), relative to GSH. In some cases, compounds described herein are 1000-fold or more selective for a target protein, such as a target protein described herein (e.g, BTK, EGFR, FGFR, AURKA, KIT, BMX, TEAD, JAK3, KRAS, or a mutant thereof), relative to GSH.
[0451] In some embodiments, a compound provided herein is selective for the polypeptide (e.g., a target protein described herein) relative to glutathione (GSH). In some embodiments, a compound provided herein is selective for binding to the polypeptide (e.g., a target protein described herein) relative to GSH. In some embodiments, a compound provided herein is selective for covalent binding to the polypeptide (e.g, a target protein described herein) relative to GSH. In some embodiments, compound provided herein is selective for the polypeptide (e.g, a target protein described herein) relative to GSH at a ratio of at least 10: 1 (e.g, 10: 1 or more, 20: 1 or more, 50: 1 or more, 100: 1 or more, 500: 1 or more, 1000: 1 or more). In some embodiments, the compound is selective for the polypeptide (e.g, a target protein described herein) relative to GSH at a ratio of about 2: 1 to about 1000: 1. In some embodiments, the compound is selective for the polypeptide (e.g, a target protein described herein) relative to GSH at a ratio of about 10: 1 to about 100: 1. In some embodiments, a compound provided herein is at least 2-fold more (e.g, 2- fold or more, 5-fold or more, 10-fold or more, 25-fold or more) selective for the polypeptide (e.g, a target protein described herein) relative to GSH. In some embodiments, a compound providedherein is 2-fold to about 100-fold more selective for the polypeptide (e.g., a target protein described herein) relative to GSH. In some embodiments, a compound provided herein is 2-fold to about 50-fold more selective for the polypeptide (e.g., a target protein described herein) relative to GSH.
[0452] In some embodiments, a compound provided herein has a structure represented in Table 2A, Table 2B, Table 2C, or Table 2D.Table 2ATable 2BTable 2CTable 2D
[0453] In some embodiments, a compound provided herein is stable to GSH modification, such as described herein. In some embodiments, a compound provided herein is stable to GSH modification and bind (e.g., covalently) to a polypeptide (e.g., a target protein). In some embodiments, a compound provided herein is stable to GSH modification and modifies a polypeptide (e.g., a target protein). In some embodiments, a compound provided herein (e.g., Compounds 53-61) is stable to GSH modification but does not (e.g., necessarily) bind (e.g., covalently) to a polypeptide (e.g., a target protein). In some embodiments, a compound provided herein (e.g., Compounds 53-61) is stable to GSH modification but does not (e.g., necessarily) modify a polypeptide (e.g., a target protein). In some embodiments, GSH stability is demonstrated in Table 7.Preparation of Compounds
[0454] The compounds used in the reactions described herein are made according to organic synthesis techniques known to those skilled in this art, starting from commercially available chemicals and / or from compounds described in the chemical literature. "Commercially available chemicals" are obtained from standard commercial sources including Acros Organics (Pittsburgh, PA), Aldrich Chemical (Milwaukee, WI, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park, UK), Avocado Research (Lancashire, U.K.), BDH Inc. (Toronto, Canada), Bionet (Cornwall, U.K.), Chemservice Inc. (West Chester, PA), Crescent Chemical Co. (Hauppauge, NY), Eastman Organic Chemicals, Eastman Kodak Company (Rochester, NY), Fisher Scientific Co. (Pittsburgh, PA), Fisons Chemicals (Leicestershire, UK), Frontier Scientific (Logan, UT), ICN Biomedicals, Inc. (Costa Mesa, CA), Key Organics (Cornwall, U.K.), Lancaster Synthesis (Windham, NH), Maybridge Chemical Co. Ltd. (Cornwall, U.K.), Parish Chemical Co. (Orem, UT), Pfaltz & Bauer, Inc. (Waterbury, CN), Polyorganix (Houston, TX), Pierce Chemical Co. (Rockford, IL), Riedel de Haen AG (Hanover, Germany), Spectrum Quality Product, Inc. (New Brunswick,NJ), TCI America (Portland, OR), Trans World Chemicals, Inc. (Rockville, MD), and Wako Chemicals USA, Inc. (Richmond, VA).
[0455] Suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, "Synthetic Organic Chemistry", John Wiley & Sons, Inc., New York; S. R. Sandler et al., "Organic Functional Group Preparations," 2nd Ed., Academic Press, New York, 1983; H. O. House, "Modern Synthetic Reactions", 2nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif. 1972; T. L. Gilchrist, "Heterocyclic Chemistry", 2nd Ed., John Wiley & Sons, New York, 1992; J. March, "Advanced Organic Chemistry: Reactions, Mechanisms and Structure", 4th Ed., Wiley-Interscience, New York, 1992. Additional suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, Fuhrhop, J. and Penzlin G. "Organic Synthesis: Concepts, Methods, Starting Materials", Second, Revised and Enlarged Edition (1994) John Wiley & Sons ISBN: 3-527-29074-5; Hoffman, R.V. "Organic Chemistry, An Intermediate Text" (1996) Oxford University Press, ISBN 0-19-509618- 5; Larock, R. C. "Comprehensive Organic Transformations: A Guide to Functional Group Preparations" 2nd Edition (1999) Wiley-VCH, ISBN: 0-471-19031-4; March, J. "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure" 4th Edition (1992) John Wiley & Sons, ISBN: 0-471-60180-2; Otera, J. (editor) "Modern Carbonyl Chemistry" (2000) Wiley-VCH, ISBN: 3-527-29871-1; Patai, S. "Patai's 1992 Guide to the Chemistry of Functional Groups" (1992) Interscience ISBN: 0-471-93022-9; Solomons, T. W. G. "Organic Chemistry" 7th Edition (2000) John Wiley & Sons, ISBN: 0-471-19095-0; Stowell, J.C., "Intermediate Organic Chemistry" 2nd Edition (1993) Wiley-Interscience, ISBN: 0-471-57456-2; "Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia" (1999) John Wiley & Sons, ISBN: 3-527-29645-X, in 8 volumes; "Organic Reactions" (1942-2000) John Wiley & Sons, in over 55 volumes; and "Chemistry of Functional Groups" John Wiley & Sons, in 73 volumes.
[0456] Specific and analogous reactants are optionally identified through the indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which are available in most public and university libraries, as well as through on-line databases (contact the American Chemical Society, Washington, D.C. for more details). Chemicals that are known but not commercially available in catalogs are optionally prepared by custom chemical synthesis houses, where many of the standard chemical supply houses (e.g., those listed above) provide custom synthesis services. A reference useful for the preparation and selection of pharmaceuticalsalts of the benzenesulfonamide derivative compounds described herein is P. H. Stahl & C. G. Wermuth "Handbook of Pharmaceutical Salts", Verlag Helvetica Chimica Acta, Zurich, 2002.Pharmaceutical Compositions
[0457] In certain embodiments, the benzenesulfonamide derivative compound described herein is administered as a pure chemical. In other embodiments, the benzenesulfonamide derivative compound described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21stEd. Mack Pub. Co., Easton, PA (2005)).
[0458] Provided herein is a pharmaceutical composition comprising at least one benzenesulfonamide derivative compound as described herein, or a salt, solvate, tautomer, or regioisomer thereof, and one or more pharmaceutically acceptable carriers. The carrier(s) (or excipient(s)) is acceptable or suitable if the carrier is compatible with the other ingredients of the composition and not deleterious to the recipient (i.e., the subject or the patient) of the composition.
[0459] In some embodiments, provided herein is a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula (A), Formula (I), Formula (I- A), or Formula (I-B), or a compound disclosed in Table 2A, Table 2B, Table 2C, or Table 2D, or a pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof.
[0460] In some embodiments, provided herein is a pharmaceutical composition comprising a compound provided herein, such as a compound of Formula (A), Formula (I), Formula (I- A), or Formula (I-B), or a compound disclosed in Table 2A, Table 2B, Table 2C, or Table 2D, or a pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof.
[0461] In some embodiments, provided herein is a pharmaceutical composition comprising a compound provided herein, such as a compound of Formula (A), Formula (I), Formula (I- A), or Formula (I-B), or a compound disclosed in Table 2A Table 2B, Table 2C, Table 2D, or a pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof. In some embodiments, the compound has reduced reactivity with glutathione. In some embodiments, reduced reactivity is described elsewhere herein.
[0462] In some embodiments, provided herein is a pharmaceutical composition comprising a compound provided herein, such as a compound of Formula (A), Formula (I), Formula (I- A), or Formula (I-B), or a compound disclosed in Table 2A, Table 2B, Table 2C, Table 2D, or a pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof. In some embodiments, the compound is selective for a polypeptide relative to glutathione. In someembodiments, the compound is selective for a protein relative to glutathione. In some embodiments, selectivity for a polypeptide relative to glutathione is described elsewhere herein.
[0463] In some embodiments, provided herein is a pharmaceutical composition that is (e.g., at least partially) stable to glutathione. In some embodiments, the pharmaceutical composition comprises a compound provided herein, such as a compound of Formula (A), Formula (I), Formula (I-A), or Formula (I-B), or a compound disclosed in Table 2A, Table 2B, Table 2C, Table 2D, or a pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof.
[0464] In some embodiments, the pharmaceutical compositions provided herein are stable to glutathione (GSH) in the presence of a polypeptide. In some embodiments, the pharmaceutical compositions are at least partially stable to glutathione (GSH) in the presence of a polypeptide.
[0465] In some embodiments, provided herein is a method of preparing a pharmaceutical composition comprising mixing a compound of Formula (A), Formula (I), Formula (I-A), or Formula (I-B), or a compound disclosed in Table 2A, Table 2B, or Table 2C, Table 2D, or a pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof, and a pharmaceutically acceptable carrier.
[0466] In certain embodiments, the benzenesulfonamide derivative compound as described by Formula (A), Formula (I), Formula (I-A), or Formula (I-B), or a compound disclosed in Table 2A, Table 2B, Table 2C, or Table 2D is substantially pure, in that it contains less than about 5%, or less than about 1%, or less than about 0.1%, of other organic small molecules, such as unreacted intermediates or synthesis by-products that are created, for example, in one or more of the steps of a synthesis method.
[0467] Suitable oral dosage forms include, for example, tablets, pills, sachets, or capsules of hard or soft gelatin, methylcellulose or of another suitable material easily dissolved in the digestive tract. In some embodiments, suitable nontoxic solid carriers are used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. (See, e.g., Remington: The Science and Practice of Pharmacy (Gennaro, 21stEd. Mack Pub. Co., Easton, PA (2005)).
[0468] In some embodiments, the compound as described by Formula (A), Formula (I), Formula (I-A), or Formula (I-B), or a compound disclosed in Table 1A, Table IB, or Table 1C, or pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof, is formulated for administration by injection. In some instances, the injection formulation is an aqueous formulation. In some instances, the injection formulation is a non-aqueous formulation. In some instances, the injection formulation is an oil-based formulation, such as sesame oil, or the like.
[0469] The dose of the composition comprising at least one compound as described herein differs depending upon the subject or patient's (e.g., human) condition. In some embodiments, such factors include general health status, age, and other factors.
[0470] Pharmaceutical compositions are administered in a manner appropriate to the disease to be treated (or prevented). An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration. In general, an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and / or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and / or overall survival, or a lessening of symptom severity. Optimal doses are generally determined using experimental models and / or clinical trials. The optimal dose depends upon the body mass, weight, or blood volume of the patient.
[0471] Oral doses typically range from about 1.0 mg to about 1000 mg, one to four times, or more, per day.Methods of Polypeptide Modification
[0472] Provided herein are methods of modifying a polypeptide (e.g., a target protein described herein) in the presence of glutathione with a compound provided herein, such as in the absence of the compound reacting with glutathione or being metabolized by glutathione. In some embodiments, a polypeptide (e.g., a target protein described herein) is modified without reacting with or being metabolized in the presence of glutathione as demonstrated by a glutathione S- transferase (GST) assay described elsewhere herein (e.g., Example IV).
[0473] In some embodiments, the method comprises contacting the polypeptide (e.g., a protein) with a compound provided herein, such as a compound of Formula (A), Formula (I), Formula (I- A), or Formula (I-B), or represented in Table 2A, Table 2B, Table 2C, or Table 2D or a pharmaceutically acceptable salt thereof. In some embodiments, the method comprises contacting the polypeptide with the compound to form a covalent bond with the polypeptide. In some embodiments, the compounds provided herein have reduced reactivity to GSH. In some embodiments, the compounds provided herein are selective for the polypeptide over GSH.
[0474] In some embodiments, provided herein are methods of modifying a polypeptide (e.g., a target protein described herein) with a compound provided herein, such as a compound of Formula (A), Formula (I), Formula (I-A), or Formula (I-B), or represented in Table 2A, Table 2B, Table 2C, or Table 2D or a pharmaceutically acceptable salt thereof. In some embodiments, provided herein are methods of selectively modifying a polypeptide with a compound provided herein. In some embodiments, the method comprises contacting the polypeptide with any of the compoundsprovided herein. In some embodiments, the compound has reduced reactivity with glutathione (GSH).
[0475] In some embodiments, provided herein are methods of modifying a polypeptide (e.g., a target protein described herein) with a compound provided herein in the presence of glutathione (GSH). In some embodiments, the method comprises contacting the polypeptide with a compound provided herein, such as a compound of Formula (A), Formula (I), Formula (I- A), or Formula (I- B), or represented in Table 2A, Table 2B, Table 2C, or Table 2D, or a pharmaceutically acceptable salt thereof. In some embodiments, the method comprises contacting the polypeptide with the compound (or a warhead group thereof) to form a covalent bond with the polypeptide. In some embodiments, the method comprises contacting the polypeptide with the compound (or a warhead group thereof) to form a covalent bond with a sulfur atom of a cysteine residue of the polypeptide. In some embodiments, the method comprises contacting the polypeptide with the compound (or a warhead group thereof) without the compound substantially covalently binding to GSH. In some embodiments, the method comprises contacting the polypeptide with the compound (or a warhead group thereof) to form a covalent bond polypeptide without the compound substantially covalently binding to GSH. In some embodiments, the method comprises contacting the polypeptide with the compound (or a warhead group thereof) to form a covalent bond with a sulfur atom of a cysteine residue of the polypeptide, without substantially covalently binding to GSH.
[0476] In some embodiments, provided herein is a method of modifying a polypeptide in the presence of glutathione (GSH) with a compound provided herein, such as a compound of Formula (A), Formula (I), Formula (I-A), or Formula (I-B), or represented in Table 2A, Table 2B, Table 2C, or Table 2D, or a pharmaceutically acceptable salt thereof. In some embodiments, provided herein is a method of selectively modifying a polypeptide in the presence of glutathione (GSH) with a compound provided herein, such as a compound of Formula (A), Formula (I), Formula (I- A), or Formula (I-B), or represented in Table 2A, Table 2B, Table 2C, or Table 2D, or a pharmaceutically acceptable salt thereof. In some embodiments, the method comprises contacting the polypeptide with any of the compounds provided herein. In some embodiments, the compound is selective for the polypeptide relative to GSH. In some embodiments, the selectivity for the polypeptide relative to GSH is described elsewhere herein.
[0477] In some embodiments, modifying herein comprises forming a bond. In some embodiments, modifying comprises forming a bond between the polypeptide and the compound. In some embodiments, modifying comprises forming a covalent bond. In some embodiments, modifying comprises forming a covalent bond between the polypeptide and the compound. In some embodiments, forming a bond comprises forming a non-covalent bond. In some embodiments, non-covalent bonding comprises electrostatic interactions, hydrogen bonding, Vander Waals interactions, or depletion interactions. In some embodiments, forming a bond comprises an electrostatic interaction. In some embodiments, forming a bond comprises forming a non- covalent bond between the compound and polypeptide and the compound.
[0478] In some embodiments, the method comprises contacting the compound (or a warhead group thereof) with the polypeptide to form a covalent bond with the polypeptide. In some embodiments, the method comprises forming a covalent bond with a heteroatom (e.g., a sulfur atom, a nitrogen atom, or an oxygen atom) of the polypeptide. In some embodiments, the method comprises forming a covalent bond with a sulfur atom of the polypeptide. In other embodiments, the method comprises forming a covalent bond with an oxygen or nitrogen atom of the polypeptide. In some embodiments, the method comprises forming a covalent bond with a sulfur atom of a cysteine residue of the polypeptide. In some embodiments, the polypeptide covalently binds to the compound (or a warhead group thereof).
[0479] In some embodiments, the method comprises contacting the polypeptide with a compound (or a warhead group thereof) provided herein without the compound substantially covalently binding to glutathione (GSH). In some embodiment, the lack of substantial binding to GSH is demonstrated by the lack of covalent binding of GSH to the compound (as measured using a GST assay described elsewhere herein). In some embodiments, the polypeptide contacts the compound (or a warhead group thereof) in the absence of covalent binding of GSH to the compound. In some embodiments, the polypeptide covalently binds to the compound (or a warhead group thereof) in the absence of covalent binding of GSH to the compound.
[0480] In some embodiments, glutathione (GSH) has a half life of at least 1 minute (e.g., 10 minutes or more, 30 minutes or more, 60 minutes or more, 100 minutes or more, or 200 minutes or more), such as in the presence of a compound provided herein. In some embodiments, GSH has a half life of at least 10 minutes in the presence of a compound provided herein. In some embodiments, GSH has a half life of at least 30 minutes in the presence of a compound provided herein. In some embodiments, GSH has a half life of at least 60 minutes in the presence of a compound provided herein. In some embodiments, GSH has a half life at least 100 minutes in the presence of a compound provided herein. In some embodiments, GSH has a half life of at least 200 minutes in the presence of a compound provided herein. In some embodiments, GSH has a half life of 1 minutes to 200 minutes, such as in the presence of a compound provided herein. In some embodiments, GSH has a half life of about 10 minutes to about 100 minutes, such as in the presence of a compound provided herein. In some embodiments, GSH half-life is measured using a glutathione S-transferase (GST) assay described herein, such as in Example IV.
[0481] In some embodiments, a compound provided herein, such as a compound of Formula (A), Formula (I), Formula (I-A), or Formula (I-B), or represented in Table 2A, Table 2B, Table2C, or Table 2D or a pharmaceutically acceptable salt thereof, has an IC50 for a polypeptide (e.g., a target protein described herein) of at least 10 μM (e.g., 10 μM or less, 1 μM or less, 0.1 μM or less). In some embodiments, a compound provided herein has an IC50 for a polypeptide (e.g., a target protein described herein) of at least 10 μM (e.g., 10 μM or less, 1 μM or less, 0.1 μM or less, or 0.01 μM or less). In some embodiments, a compound provided herein has an IC50 for a polypeptide (e.g., a target protein described herein) of 1 μM or less. In some embodiments, a compound provided herein has an IC50 for a polypeptide (e.g., a target protein described herein) of 0.1 μM or less. In some embodiments, a compound provided herein has an IC50 for a polypeptide (e.g., a target protein described herein) of 0.01 μM or less. In some embodiments, a compound provided herein has an IC50 for a polypeptide (e.g., a target protein described herein) of about 0.01 μM to about 10 pM.
[0482] In some embodiments, a compound provided herein, such as a compound of Formula (A), Formula (I), Formula (I-A), or Formula (I-B), or represented in Table 2A, Table 2B, Table 2C, or Table 2D or a pharmaceutically acceptable salt thereof has an IC50 for a polypeptide (e.g., a target protein described herein) of at least 10 μM and a GSH half life of greater than about 10 minutes (e.g., IC50 of at least 1 μM and a GSH half life of greater than about 10 minutes (e.g., IC50 of at least 0.1 μM and a GSH half life of greater than about 100 minutes)). In some embodiments, a compound provided herein has a an IC50 for a polypeptide (e.g., a target protein described herein) of 1 μM or less and a GSH half life of about 10 minutes or more. In some embodiments, a compound provided herein has a IC50 for a polypeptide (e.g., a target protein described herein) of 0.1 μM or less and a GSH half life of about 100 minutes or more. In some embodiments, a compound provided herein has a IC50 for a polypeptide (e.g., a target protein described herein) of 0.01 μM or less and a GSH half life of about 200 minutes or more. In some embodiments, a compound provided herein has an IC50 for a polypeptide (e.g., a target protein described herein) of about 0.01 μM to about 10 μM (e.g., about 0.1 μM to about 10 pM, about 0.1 μM to about 1 pM) and a GSH half life of about 10 minutes to about 200 minutes (e.g., about 30 minutes to about 100 minutes, e.g., about 50 minutes to about 100 minutes).
[0483] In some embodiments, the polypeptides described herein is a protein. In some embodiments, the polypeptide comprises natural and / or non-natural amino acid residues. In some embodiments, the polypeptide comprises natural amino acid residues. In some embodiments, the polypeptide comprises cysteine (e.g., a cysteine residue), such as a nucleophilic cysteine. In some embodiments, the polypeptide comprises methionine (e.g., a methionine residue). In some embodiments, the polypeptide comprises non-natural amino acids. In some embodiments, the polypeptide comprises non-natural amino acid residues. In some embodiments, the polypeptidecomprises homocysteine. In some embodiments, the polypeptide comprises sulfur containing amino acids. In some embodiments, the polypeptide comprises a thiol, such as a nucleophilic thiol.
[0484] In some embodiments, the polypeptides described herein comprise a nucleophile. In some embodiments, the polypeptide (e.g., target protein provided herein) comprises a sulfur, oxygen, or nitrogen containing nucleophile. In some embodiments, the polypeptide (e.g., target protein provided herein) comprises a sulfur containing nucleophile. In some embodiments, the polypeptide (e.g., target protein provided herein) comprises a cysteine nucleophile. In some embodiments, the polypeptide comprises a cysteine residue, such as cysteine nucleophile. In some embodiments, the polypeptide (e.g., target protein provided herein) comprises a methionine nucleophile. In some embodiments, the polypeptide (e.g., target protein provided herein) comprises an oxygen containing nucleophile. In some embodiments, the polypeptide (e.g., target protein provided herein) comprises a hydroxyl containing nucleophile, such as a hydroxyl of a serine or a tyrosine residue. In some embodiments, the polypeptide (e.g., target protein provided herein) comprises a serine nucleophile. In some embodiments, the polypeptide (e.g., target protein provided herein) comprises a tyrosine nucleophile. In some embodiments, the polypeptide (e.g., target protein provided herein) comprises a nitrogen containing nucleophile. In some embodiments, the polypeptide (e.g., target protein provided herein) comprises an amino containing nucleophile, such as an amino of a lysine residue. In some embodiments, the polypeptide (e.g., target protein provided herein) comprises a lysine nucleophile.
[0485] In some embodiments, a polypeptide provided herein is Bruton’s tyrosine kinase (BTK), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), aurora kinase A (AURKA), proto-oncogene c-KIT (KIT), or BMX non-receptor tyrosine kinase (BMX). In some embodiments, the polypeptide is Bruton’s tyrosine kinase (BTK). In some embodiments, the polypeptide is epidermal growth factor receptor (EGFR). In some embodiments, the polypeptide is fibroblast growth factor receptor (FGFR). In some embodiments, the polypeptide is aurora kinase A (AURKA). In some embodiments, the polypeptide is proto- oncogene c-KIT (KIT). In some embodiments, the polypeptide is BMX non-receptor tyrosine kinase (BMX). In some embodiments, the polypeptide is transcriptional enhancer factor TEF (TEAD). In some embodiments, the polypeptide is Janus kinase 3 (JAK3).
[0486] In some embodiments, the polypeptide reacts (e.g., forms a bond with) with a compound provided herein. In some embodiments, the polypeptide reacts (e.g., forms a bond with) with a compound of Formula (A), or Formula (I), Formula (I-A), or Formula (I-B), or represented in Table 2A, Table 2B, Table 2C, or Table 2D.
[0487] In some embodiments, the thiol of the polypeptide reacts (e.g., forms a bond with) with a compound provided herein. In some embodiments, the thiol of the polypeptide reacts (e.g., formsa bond) with a compound of Formula (A), or Formula (I), Formula (I-A), or Formula (I-B), or represented in Table 2A, Table 2B, Table 2C, or Table 2D.
[0488] In some embodiments, the methods provided herein further comprise inhibiting, deactivating, or degrading the polypeptide. In some embodiments, the method further comprises inhibiting the polypeptide. In some embodiments, the method further comprises deactivating the polypeptide. In some embodiments, the method further comprises degrading the polypeptide. In some instances, contacting of the polypeptide with any of the compounds provided herein inhibits, deactivates, or degrades the polypeptide. In some embodiments, binding of the polypeptide inhibits, deactivates, or degrades the polypeptide. In some embodiments, covalent binding of the polypeptide, such as a covalent binding with a thiol of the polypeptide, inhibits, deactivates, or degrades the polypeptide. In some embodiments, the polypeptide is inhibited or deactivated by a factor of at least 2 (e.g., 2 or more, 3 or more, 4 or more, 5 or more).
[0489] In some embodiments, provided herein is a method of modifying (e.g., attaching to and / or degrading) a polypeptide with a benzenesulfonamide derivative compound as described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof, comprising contacting the polypeptide with the compound to form a covalent bond with a sulfur atom of a cysteine residue of the polypeptide.
[0490] In some embodiments, the method provides for selectively modifying a polypeptide with a compound. In some embodiments, the selectivity is for a sulfur-containing nucleophile of the protein over other (e.g., intracellular) sulfur-containing nucleophiles (e.g., in a biological system). In some embodiments, modifying comprises covalent modification of the polypeptide, such as a protein. In some embodiments, modifying a polypeptide occurs intracellularly.
[0491] In some embodiments, provided herein is a method of binding a compound to a polypeptide, comprising contacting the polypeptide with a benzenesulfonamide derivative compound as described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof. In some embodiments, the protein is BTK. In some embodiments, the protein is EGFR. In some embodiments, the protein is FGFR. In some embodiments, the protein is AUKRA. In some embodiments, the protein is KIT. In some embodiments, the protein is BMX. In some embodiments, the protein is TEAD. In some embodiments, the protein is JAK3. In some embodiments, the protein is KRAS.
[0492] In some embodiments, provided herein is a method of disrupting a protein, or an active fragment thereof (e.g. a function thereof), comprising contacting the protein or an active fragment thereof (e.g., polypeptide thereof) with a compound described herein, or a salt, solvate, tautomer, or regioisomer thereof.Methods of Treatment
[0493] In some embodiments, provided herein is a compound of Formula (A), Formula (I), Formula (I-A), or Formula (I-B), or a compound disclosed in Table 2A, Table 2B, Table 2C, or Table 2D or a pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof, for use in a method of treatment of the human or animal body.
[0494] In some embodiments, provided herein is a compound of Formula (A), Formula (I), Formula (I-A), or Formula (I-B), or a compound disclosed in Table 2A, Table 2B, Table 2C, or Table 2D or a pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof, for use in a method of treatment of cancer or neoplastic disease.
[0495] In some embodiments, provided herein is a use of a compound of Formula (A), Formula (I), Formula (I-A), or Formula (I-B), or a compound disclosed in Table 2A, Table 2B, Table 2C, or Table 2D, or a pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof, in the manufacture of a medicament for the treatment of cancer or neoplastic disease.
[0496] In some embodiments, described herein is a method of treating cancer in a patient in need thereof comprising administering to the patient a compound of Formula (A), Formula (I), Formula (I-A), or Formula (I-B), or a pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof.
[0497] In some embodiments, described herein is a method of treating cancer in a patient in need thereof comprising administering to the patient a compound disclosed in Table 2A, Table 2B, Table 2C, or Table 2D, or a pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof.
[0498] In some embodiments, also described herein is a method of treating cancer in a patient in need thereof comprising administering to the patient a pharmaceutical composition comprising a compound of Formula (A), Formula (I), Formula (I-A), or Formula (I-B), or provided in Table 2A, Table 2B, Table 2C, or Table 2D, or a pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof, and a pharmaceutically acceptable excipient.
[0499] In some embodiments, also described herein is a method of treating cancer in a patient in need thereof comprising administering to the patient a pharmaceutical composition comprising a compound disclosed in Table 2A, Table 2B, Table 2C, or Table 2D, or a pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof, and a pharmaceutically acceptable excipient. In some embodiments, the cancer is selected from chronic and acute myeloid leukemia. In some embodiments, the cancer is selected from chronic lymphocytic leukemia and small lymphocytic lymphoma.
[0500] Provided herein is the method wherein the pharmaceutical composition is administered orally. Provided herein is the method wherein the pharmaceutical composition is administered by injection.
[0501] In some embodiments, provided herein is a protein, or an active fragment thereof, modified with a benzenesulfonamide derivative compound as described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or regioisomer thereof, wherein the compound forms a covalent bond with a sulfur atom of a cysteine residue of the protein. In some embodiments, the protein is BTK. In some embodiments, the protein is EGFR. In some embodiments, the protein is FGFR. In some embodiments, the protein is AURKA. In some embodiments, the protein is KIT. In some embodiments, the protein is BMX. In some embodiments, the protein is TEAD. In some embodiments, the protein is JAK3. In some embodiments, the protein is KRAS.
[0502] In some embodiments, provided herein is a method of modifying (e.g., attaching to and / or degrading) a polypeptide with a benzenesulfonamide derivative compound as described herein, comprising contacting the polypeptide with the compound to form a covalent bond with a sulfur atom of a cysteine residue of the polypeptide.
[0503] In some embodiments, provided herein is a method of binding a compound to KRAS or an active fragment thereof (e.g., a polypeptide), comprising contacting the polypeptide with a benzenesulfonamide derivative compound as described herein.
[0504] Other embodiments and uses will be apparent to one skilled in the art in light of the present disclosures. The following examples are provided merely as illustrative of various embodiments and shall not be construed to limit the present disclosure in any way.EXAMPLESI. Chemical Synthesis
[0505] In some embodiments, the benzenesulfonamide derivative compounds disclosed herein are synthesized according to the following examples. As used below, and throughout the specification, the following abbreviations, unless otherwise indicated, shall be understood to have the following meanings:°C degrees Celsius5 chemical shift in parts per million downfield from tetramethyl silaneACN acetonitrile bs or brs broad singletDCM dichloromethane (CH2CI2) dd doublet of doubletsDMF dimethylformamideDMSO dimethylsulfoxideEA or EtO Ac ethyl acetateESI electrospray ionizationEt ethylFA formic acid g gram(s) h / hr / hrs hour(s)HPLC high performance liquid chromatographyHz hertzJ coupling constant (in NMR spectrometry)LCMS liquid chromatography mass spectrometry u micro m multiplet (spectral); meter(s); milliM molarM+parent molecular ionMe methylMHz megahertz min minute(s) mol mole(s); molecular (as in mol wt) mL milliliterMS mass spectrometry nm nanometer(s)NMR nuclear magnetic resonance pH potential of hydrogen; a measure of the acidity or basicity of an aqueous solutionPE petroleum etherRbf round bottom flaskPMB para-methoxybenzyl r.t room temperatureRT retention time s singlet (spectral) t triplet (spectral)T temperatureTFA trifluoroacetic acidTHF tetrahydrofuran
[0506] Exemplary compounds of the application are synthesized using the methods described herein, or other methods, which are known in the art. Unless otherwise noted, reagents and solvents are obtained from commercial suppliers.
[0507] Anhydrous solvents, methanol, acetonitrile, dichloromethane, tetrahydrofuran and dimethylformamide, are purchased from Sigma Aldrich and used directly from Sure-Seal bottles. Reactions are performed under an atmosphere of dry nitrogen in oven-dried glassware and are monitored for completeness by thin-layer chromatography (TLC) using silica gel (visualized by UV light, or developed by treatment with KMnCh stain and ninhydrin stain) or by LC / MS. NMR spectra are recorded in Bruker Avance III spectrometer at 23°C, unless otherwise stated, operating at 400 MHz for1H NMR and 376 MHz19F NMR spectroscopy either in CDCh, CD3OD, CD3CN or DMSO-dk Chemical shifts (d) are reported in parts per million (ppm) after calibration to residual isotopic solvent. Coupling constants (J) are reported in Hz. Mass spectrometry was performed with an Agilent G6110A single quad mass spectrometer with an ESI source associated with an Agilent 1100 HPLC system or a Shimadzu LCMS 2020 N-Series single quad mass spectrometer with an ESI source associated with an Agilent 1290 Infinity II HPLC system. The following conditions were employed for LCMS analysis:
[0508] LCMS Method I: Mobile phase is a linear gradient consisting of a changing solvent composition of 5 % to 98% ACN in H2O with 10 mM NH4HCO3 over 2.5 minutes. Method was run on a Phenomenex Kinetex EVO C18 (50 x 3.0 mm), 2.6 pm column; column maintained at a temperature of 30°C; flow rate of 0.8 mL / min.
[0509] LCMS Method II: Mobile phase is a linear gradient consisting of a changing solvent composition of 5 % to 95% ACN in H2O with 0.1 % Formic acid (v / v) over 2.5 minutes. Method was run on an Agilent ZORBAX ECLIPSE PLUS C18 (50 x 2.1 mm), 1.8 pm column; column maintained at a temperature of 30°C; flow rate of 0.7 mL / min.
[0510] Before biological testing, inhibitor purity was evaluated by reversed-phase HPLC (rpHPLC). HPLC was performed with a Shimadzu LC Prominence-I series with PDA (210 - 400 nm) and ELSD detectors or Agilent 6120 Mass detector and Diode array Detector. The following conditions were employed for analysis by rpHPLC, UPLC, HPLC, and LCMS:
[0511] Method I: Mobile phase is a linear gradient consisting of a changing solvent composition of 10 % to 90% ACN in H2O with 0.1 % TFA (v / v) over 9 minutes, followed by 5 minutes of 100% ACN. Method was run on a Welch Xtimate 5 pm C18, 150 mm x 4.6 mm column; maintained at a temperature of 30°C; flow rate of 1.0 mL / min.
[0512] Method II: Mobile phase is a linear gradient consisting of a changing solvent composition of 10 % to 90% ACN in H2O with 0.1 % Ammonia (v / v) over 7 minutes, followedby 5 minutes of 100% ACN. Method was run on a Waters Atlantis 5 pm C18, 150 mm x 4.6 mm column; maintained at a temperature of 30°C; flow rate of 1.0 mL / min.
[0513] Method III: Mobile phase is a linear gradient consisting of a changing solvent composition of 15 % to 100% ACN in H2O with 0.1 % TFA (v / v) over 15 minutes. Method was run on a Phenom enex Luna §μm C18 150 mm x 4.6 mm column; column maintained at a temperature of 25°C; flow rate of 1.0 mL / min.
[0514] Method IV: Mobile phase is a linear gradient consisting of a changing solvent composition of 5 % to 100% ACN in FLO with 0.1 % Formic acid (v / v) over 10 minutes. Method was run on a X-Select C18 (4.6 * 150mm), 5μm column; column maintained at a temperature of 25°C; flow rate of 2.0 mL / min.
[0515] Additional analytical protcols referred to herein are provided in the table below:
[0516] For reporting HPLC data, percentage purity is given after the retention time for each condition. All biologically evaluated compounds are >95 % chemical purity as measured by HPLC.Sulfonyl chloride 1: Synthesis of 4-cyano-2,3,5,6-tetrafluorobenzenesulfonyl chloride. Benzyl mercaptan Trichloraisocyanuric DtPEA. Dioxane add. ACN, ACOH 100 X*, 2h Water, RT, 2hsw5 *Step-1: Synthesis of 4-(benzylthio)-2,3,5,6-tetrafluorobenzonitrile
[0517] In a sealed tube vial 2,3,4,5,6-pentafluorobenzonitrile (25.0 g, 0.098 mol) was dissolved in 1,4 Dioxane (250 mL) at room temperature. Benzyl mercaptan (14.646 g, 118.11 mmol) was added to the above solution and stirred for another 5 minutes. DIPEA (50 mL, 0.295 mol) was added and the reaction vial was sealed and heated at 100 °C for 2 hours. After completion (as monitored by TLC), the reaction mixture was concentrated under reduced pressure to yield a brown solid residue. Product was eluted at 2% Ethyl acetate in Hexanes. Combined pure fraction was concentrated under reduced pressure to obtain title compound as off white solid (26.0 g, 87.465 mmol, 88%).1H NMR (400 MHz, CDC13): δ 4.22-4.29 (m, 2H), 7.26-7.33 (m, 5H).Step-2: Synthesis of 4-cyano-2,3,5,6-tetrafluorobenzenesulfonyl chloride
[0518] To a stirred solution of 4-(benzylthio)-2,3,5,6-tetrafluorobenzonitrile (2.0 g, 6.728 mmol) in Acetonitrile (10 mL), was added Acetic acid (0.5 mL) and Water (0.3 mL) at 0 °C under Nitrogen atmosphere. The reaction mixture was stirred at 0 °C for 10 minutes. Trichloroisocyanuric acid (3.127 g, 13.456 mmol) was then added portionwise at 0 °C. The reaction mixture was stirred at room temperature for 2 hours or until complete consumption of starting material. After completion (as monitored by TLC), the reaction mixture was quenched with Water (30 mL). The aqueous layer was extracted with Dichloromethane (2 x 50 mL). The combined organic layer was evaporated under reduced pressure to afford crude product as yellow solid (1.200 g, crude) The crude was used in the next step without column purification.Sulfonyl chloride 2: Synthesis of 2,3,5,6-tetrafluoro-4-(methylcarbamoyl)benzenesulfonyl chlorideStep-1: Synthesis of 4-(benzylthio)-2,3,5,6-tetrafluoro-N-methylbenzamide
[0519] TEA (0.8 mL, 5.739 mmol) was added to a stirred solution of 2,3,4,5,6-pentafluoro-N- methylbenzamide (1.100 g, 4.886 mmol) in Methanol (10 mL) at room temperature under Nitrogen atmosphere. To the reaction mixture, Benzyl Mercaptan (0.620 g, 4.992 mmol) was added and reaction mixture was stirred for 6 hours at 60 °C. After completion, the reaction mixture was concentrated under reduced pressure to obtain off white solid. The crude was further triturated with 10% Diethyl ether in Pentane to obtain title compound as off-white solid (1.0 g, 3.037 mmol, 62%). LCMS (Method-C): Retention Time 1.717 min, 95.36%, 254nm, ES(+ve): 330.1 [M+H]+.Step-2: Synthesis of 2,3,5,6-tetrafluoro-4-(methylcarbamoyl)benzenesulfonyl chloride
[0520] Prepared by a method analogous to Sulfonyl chloride 1, Step-2 using 4-(benzylthio)- 2,3,5,6-tetrafluoro-N-methylbenzamide (200 mg, 0.607 mmol). After completion, the reaction mixture was diluted with Water (20 mL) and aqueous layer was extracted with Ethyl acetate (3 x 20 mL). The combined organic layer was dried over anhydrous Sodium sulphate, filtered and the solvent was removed in vacuo to obtain crude title compound (170 mg, crude). The crude title compound was used in next step without column purification.Sulfonyl chloride 3: Synthesis of 4-(dimethylcarbamoyl)-2,3,5,6-tetrafluorobenzenesulfonyl chloride
[0521] Prepared by a method analogous to Sulfonyl chloride 2 using 2,3,4,5,6-pentafluoro- N,N-dimethylbenzamide (1.200 g, 5.020 mmol). Yield (200 mg, crude).Sulfonyl chloride 4: Synthesis of 4-(difluoromethoxy)-2,3,5,6-tetrafluorobenzenesulfonyl chlorideStep-1: Synthesis of 4-(benzylthio)-2,3,5,6-tetrafluorophenol
[0522] To a stirred solution of 2,3,5,6-tetrafluorophenol (5 g, 30.1 lOmmol) in dry THF (50mL) was dropwise added a solution of n-BuLi (2.5M in Hexanes, 24.080 mL, 60.220mmol) at -78°C and was stirred at -78°C for Ih. The resulting reaction mixture was added a solution of 1,2- dibenzyldisulfane (7.42g, 30.1 lOmmol) in THF (70mL) and reaction mixture was allowed to stir at -78 °C for Ih. After the completion of reaction, the reaction mixture was diluted with solution of IN HC1 (50mL) and was extracted with Ethyl acetate (200mL X 2). The combined organic phases were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The obtained crude was purified by flash column chromatography using 5% DCM in hexane to afford title compound as a white solid (6g, 20.8 lOmmol, 62% yield). LCMS (Method- H): Retention Time: 2.389 min, 90%, 220 nm, ES (+ve): 287.1 [M-H]-Step-2: Synthesis of benzyl(4-(difluoromethoxy)-2,3,5,6-tetrafluorophenyl)sulfane
[0523] To a stirred solution 4-(benzylthio)-2,3,5,6-tetrafluorophenol (2.5g, 8.670mmol) in acetone (30mL) were added cesium carbonate (3.590 g, 26.020mmol) and Ethyl 2-bromo-2,2- difluoroacetate (5.280 g, 26.020mmol) at room temperature and reaction mixture was stirred at 75 °C for 4h. After the completion of reaction, the reaction mixture was cooled to room temperature and concentrated under reduced pressure. Residue obtained was suspended into water (100 mL) and was extracted with Ethyl acetate (200 mL X 2). The combined organic phases were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The obtained crude was purified by flash column chromatography, product eluted with 2% Ethyl acetate in Hexanes to afford title compound as a colorless oil (1.2g, 3.550mmol, 41% yield). IH NMR (400 MHz, DMSO-d6) 4.18 (s, 2H), 7.19 - 7.54 (t, J = 70 Hz, IH), 7.21 - 7.30 (m, 5H).Step-3: Synthesis of 4-(difluoromethoxy)-2,3,5,6-tetrafluorobenzenesulfonyl chloride
[0524] To a stirred solution benzyl(4-(difluoromethoxy)-2,3,5,6-tetrafluorophenyl)sulfane (1 ,0g, 2.960mmol) in Acetic acid (8 mL) was added water (2 ml) and acetonitrile (5 mL) followed by portion wise addition of l,3-Dichloro-5,5-dimethylhydantoin (583 mg, 5.920mmol) (portion wise) at 0°C. The resulting reaction mixture was stirred at room temperature for Ih. After the completion of reaction, the reaction mixture was diluted with IN aqueous solution of HC1 (100mL) and was extracted with n-hexanes (100 mL X 2). The combined organic phases were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The obtained crude was purified by flash column chromatography, product eluted with 6% ethyl acetate in hexane to afford title compound as a colorless oil (700 mg, 2.230mmol, 75% yield). The obtained product was used directly in the next step.Sulfonyl chloride 5: Synthesis of 2,3,5,6-tetrafluoro-4-methylbenzenesulfonyl chlorideStep-1: Synthesis of benzyl(2,3,5,6-tetrafluorophenyl)sulfane
[0525] 3 -bromo-l,2,4,5-tetrafluorobenzene (8.0 g, 34.939 mmol) and phenylmethanethiol (4.34 g, 34.939 mmol) were dissolved in 1,4-dioxane (80.0 mL), added DIPEA (9.03 g, 69.878 mmol) into Reaction mixture and purged with nitrogen gas for 5 min. Xantphos (1.01 g, 1.746 mmol) and Pd2(dba)3 (0.639 g, 1.746 mmol) was added into the reaction maixture and purged again with nitrogen gas for 5 min. Reaction mixture was heated at 110 °C for 16 hours. The reaction mixture was partitioned between Water (120 mL) and Ethyl acetate (50.0 mL), aqueous layer was further extracted with Ethyl acetate (2 x 30.0 mL), dried over anhydrous Na2SO4, filtered and the solvent was removed in vacuo to give crude product. The resulting crude was purified by column chromatography (normal phase, 40-60 mesh silica gel, gradient 0-80% EtOAc in hexanes, Residue dry loaded) to afford pure title compound (7.0 g, 25.710 mmol 73% yield). 'HNMR (400 MHz, CDC13): δ 4.15 (s, 2H), 7.00-7.04 (m, 1H), 7.27-7.29 (m, 5H).Step-2: Synthesis of benzyl(2,3,5,6-tetrafluoro-4-methylphenyl)sulfane
[0526] To a stirred solution of benzyl(2,3,5,6-tetrafluorophenyl)sulfane (8.0 g, 29.383 mmol) in THF (80 mL) at -78 °C under nitrogen. / / -BuLi (2.5 M in Hexane) (16.45 mL, 41.137 mmol) was added drop-wised over a period of 10 minutes and kept at -78 °C for 1 hour. The solution of Methyl iodide (20.85 g, 146.91 mmol) in THF (10 mL) was added drop-wise to the above reaction mixture over a period of 15 minutes and kept at -78 °C for 0.5 hours. After completion (as monitored by TLC), the reaction mixture was quenched with 10% HC1 solution (70 mL) and gradually brought to RT. The THF layer was separated and the aqueous layer was extracted with Ethyl acetate (3 x 200 mL). The combined organic phases were dried over anhydrous Na2SO4 and filtered off. The solvent was removed in vacuo. The resulting crude was purified by flash column chromatography. The desired product was eluted at 2% EtOAc / Hexanes and obtained as a clear oil (7.5 g, 26.19 mmol, 89%).1H NMR (400 MHz D, MSO) δ 2.27 (s, 3H), 4.10 (s, 2H), 7.27- 7.29 (m, 5H).Step-3: Synthesis of 2,3,5,6-tetrafluoro-4-methylbenzenesulfonyl chloride
[0527] Prepared by a method analogous to Sulfonyl chloride 2, Step-2 using benzyl(2, 3,5,6- tetrafluoro-4-methylphenyl)sulfane (0.500 g, 1.736 mmol). Yield (223 mg, crude).Sulfonyl chloride 6: Synthesis of methyl 4-(chlorosulfonyl)-2,3,5,6-tetrafluorobenzoateStep-1: Synthesis of 4-(benzylthio)-2,3,5,6-tetrafluorobenzoic acid
[0528] To a stirred solution of 2,3,5, 6-tetrafluorobenzoic acid (2.0 g, 10.309 mmol) in dry THF (20 mL) was dropwise added a solution of n-BuLi (2.5 M in Hexanes) (8.2 mL, 20.618 mmol) at -78 °C under Nitrogen atmosphere. The above solution was stirred at -78 °C for 1 hour. A solution of 1,2-dibenzyldisulfane (3.0 g, 12.371 mmol) in THF (30 mL) was added drop wise to the above reaction mixture and the reaction mixture was allowed to stir at -78 °C for 1 hour. After completion (as monitored by TLC), the reaction mixture was diluted with solution of IN HC1 (50 mL) and the aqueous layer was extracted with DCM (2 x 100 mL). The combined organic phases were dried over anhydrous Sodium sulphate, filtered and concentrated under reduced pressure. The crude compound was used in next step without further purification (0.700 mg, 2.213 mmol). 'HNMR (400 MHz, DMSO-d6): δ 4.25 (s, 2H), 7.25-7.27 (m, 5H), 14.41 (bs, 1H).Step-2: Synthesis of methyl 4-(benzylthio)-2,3,5,6-tetrafluorobenzoate
[0529] 4-(benzylthio)-2,3,5,6-tetrafluorobenzoic acid (0.400 g, 1.265 mmol) was dissolved in Methanol (20 mL) under Nitrogen atmosphere and the solution was cooled to 0 °C. SOCI2 (2 mL) was added drop wise to the above reaction mixture. The reaction mixture was gradually brought to room temperature and subsequently heated at 65 °C for 6 hours. After completion, the reaction mixture was concentrated under reduced pressure to get a crude residue. The crude was diluted with Water (10 mL) and aqueous layer was extracted with Ethyl acetate (3 x 10 mL). The combined organic layer was dried over Sodium sulfate and evaporated under reduced pressure to get a crude residue. The crude was purified by silica gel flash column chromatography and the pure compound was eluted at 10% Ethyl acetate in Hexanes to obtain title compound as white solid (0.300 g, 0.909 mmol, 72%). 'HNMR (400 MHz, CDC13): δ 3.97 (s, 3H), 4.16 (s, 2H), 7.24- 7.33 (m, 5H).Step-3: Synthesis of methyl 4-(chlorosulfonyl)-2,3,5,6-tetrafluorobenzoate.
[0530] methyl 4-(benzylthio)-2,3,5,6-tetrafluorobenzoate (0.500 g, 1.515 mmol) was dissolved in a solution of Acetic acid (8 mL) and Water (2 mL) at room temperature. The above solutionwas cooled to 0 °C. l,3-Dichloro-5,5-dimethylhydantoin (0.587 g, 0.303 mmol) was added portion wise to the above solution. The reaction mixture was gradually brought to room temperature and stirred for 1 hour. After completion, the reaction mixture was diluted with IN aqueous HC1 (100 mL) and the aqueous layer was extracted with Ethyl acetate (2 x 100 mL). The combined organic phases were dried over anhydrous Sodium sulphate, filtered and concentrated under reduced pressure to obtain title compound as white solid (400 mg, 1.307 mmol). The crude was used for next step without column purification.19F NMR (400 MHz, DMSO-d6): δ -139.99 - 140.08 (2F), -137.89_-137.98 (2F).Sulfonyl chloride 7: Synthesis of 4-acetamido-2,3,5,6-tetrafluorobenzenesulfonyl chlorideStep-1: Synthesis of benzyl(2,3,5,6-tetrafluoro-4-nitrophenyl)sulfane
[0531] To a stirred solution of l,2,3,4,5-pentafluoro-6-nitrobenzene (5.0 g, 23.470 mmol) in DMF (50 mL), was added DIPEA (8.1 mL, 46.940 mmol) at room temperature under Nitrogen atmosphere. To the reaction mixture, Benzyl Mercaptan (2.910 g, 23.470 mmol) was added and reaction mixture was stirred for 16 hours at 100 °C. After completion, the reaction mixture was diluted with Water (100 mL) and aqueous layer was extracted with Ethyl acetate (3 x 60 mL). The combined organic layer was dried over anhydrous Sodium sulfate, filtered and the solvent was removed in vacuo. The crude was further triturated with 10% Diethyl ether in n-Pentane to obtain title compound as yellow solid (3.0 g, 9.460 mmol, 40%). 'H NMR (400 MHz, DMSO-d6): δ 4.35 (s, 2H), 7.27-7.30 (m, 5H).Step-2: Synthesis of 4-(benzylthio)-2,3,5,6-tetrafluoroaniline
[0532] A solution of benzyl(2,3,5,6-tetrafluoro-4-nitrophenyl)sulfane (2.0 g, 6.300 mmol) in MeOH (20 mL) and Water (10 mL) was stirred at 0 °C for 5 minutes. To the above solution, Zn dust (2.0 g, 31.500 mmol) and Ammonium chloride (1.700 g, 31.500 mmol) was added portion - wise. The reaction mixture was stirred at room temperature for 12 hours. After completion, thereaction mixture was diluted with Water (20 mL) and aqueous layer was extracted with Ethyl acetate (3 x 20 mL). The combined organic layer was dried over anhydrous Sodium sulfate, filtered and the solvent was removed in vacuo. The resulting crude title compound was used in the next step without column purification (2.0 g, crude). 'H NMR (400 MHz, DMSO-d6): δ 3.93 (s, 2H), 6.31 (s, 2H), 7.14-7.24 (m, 5H).Step-3: Synthesis of N-(4-(benzylthio)-2,3,5,6-tetrafluorophenyl)acetamide
[0533] A solution of 4-(benzylthio)-2,3,5,6-tetrafluoroaniline (1.600 g, 5.570 mmol) in DCM (20 mL) was stirred at 0 °C for 5 minutes. To reaction mixture DIPEA (2.9 mL, 16.710 mmol) and Acetyl chloride (1.700 g, 31.500 mmol) was added portion-wise. The reaction mixture was stirred at room temperature for 1 hour. After completion, the reaction mixture was diluted with Water (20 mL) and aqueous layer was extracted with Ethyl acetate (3 x 20 mL). The combined organic layer was dried over anhydrous Sodium sulfate, filtered and the solvent was removed in vacuo. The resulting crude residue was purified by silica gel flash column chromatography. Pure compound was eluted at 15% Ethyl acetate in Hexanes to obtain title compound as colourless semi-solid (360 mg, 0.458 mmol, 74%). LCMS (Method-C): Retention Time: 1.740 min, 100%, 254 nm, ES(-ve): 327.90 [M-H] -Step-4: Synthesis of 4-acetamido-2,3,5,6-tetrafluorobenzenesulfonyl chloride
[0534] Prepared by a method analogous to Sulfonyl chloride 4, Step-3 using N-(4-(benzylthio)- 2,3,5,6-tetrafluorophenyl)acetamide (300 mg, 0.911 mmol). After completion, the reaction mixture was diluted with Water (20 mL) and aqueous layer was extracted with Ethyl acetate (3 x 20 mL). The combined organic layer was dried over anhydrous Sodium sulfate, filtered and the solvent was removed in vacuo to obtain crude title compound (210 mg, crude).Sulfonyl chloride 8: Synthesis of 4-(chlorosulfonyl)-2,3,5,6-tetrafluorophenyl dimethylcarbamateStep-1: Synthesis of perfluorophenyl dimethylcarbamate
[0535] To a stirred solution of pentafluorophenol (2.0 g, 0.010 mol) in THF (20.0 ml) under Nitrogen atmosphere at room temperature was added K2CO3 (4.500 g, 0.032 mol). The reaction mixture was stirred at room temperature for 10 minutes. Dimethylcarbamic chloride (1.280 g, 0.011 mol) was then added and the reaction mixture was stirred for 2 hours at 60 °C. Aftercompletion, the reaction mixture was diluted with Water (100 mL) and the aqueous layer was extracted with Ethyl acetate (3 x 100 mL). The combined organic phase was dried over Sodium sulfate and evaporated under reduced pressure. The resulting crude was used as such for the next step without column purification (2.0 g, crude).1H NMR (400 MHz, DMSO-d6): δ 2.96 (s, 3H), 3.10 (s, 3H).Step-2: Synthesis of 4-(benzylthio)-2,3,5,6-tetrafluorophenyl dimethylcarbamate
[0536] To a stirred solution of perfluorophenyl dimethylcarbamate (2.0 g, 0.008 mol) in MeOH (20 mL), was added TEA (1.3 mL, 0.009 mol) at room temperature under Nitrogen. To the reaction mixture, Benzyl Mercaptan (0.980 g, 0.008 mol) was added and reaction mixture was stirred for 16 hours at 60 °C. After completion, the reaction mixture was concentrated under reduced pressure to obtain light yellow solid. The resulting crude was purified by silica gel flash column chromatography. Pure compound was eluted at 3% Ethyl acetate in Hexanes to obtain title compound as yellow solid. (490 mg, 1.365 mmol, 17%). LCMS (Method-C): Retention Time 2.041 min, 100%, 220 nm, ES(+ve): 360.1 [M+H]+Step-3: Synthesis of 4-(chlorosulfonyl)-2,3,5,6-tetrafluorophenyl dimethylcarbamate
[0537] Prepared by a method analogous to Sulfonyl chloride 7, Step-4 using 4-(benzylthio)- 2,3,5,6-tetrafluorophenyl dimethylcarbamate (490 mg, 1.365 mmol). Yield (570 mg, crude).Sulfonyl chloride 9: Synthesis of 2,3,5,6-tetrafluoro-4-methoxybenzenesulfonyl chlorideStep-1: Synthesis of 4-(benzylthio)-2,3,5,6-tetrafluorophenol
[0538] To a stirred solution of 2,3,5,6-tetrafhiorophenol (1.0 g, 0.006 mol) in dry THF (10 mL) was dropwise added a solution of n-BuLi (2.5 M in Hexanes) (12 mL, 0.015 mol) at -78 °C and was stirred at -78 °C for 1 hour. To the above reaction mixture a solution of 1,2- dibenzyldisulfane (1.630 g, 0.007 mol) in THF (10 mL) was added dropwise and the reaction mixture was allowed to stir at -78 °C for 1 hour. After completion, the reaction mixture was diluted with a solution of IN aqueous HC1 (10 mL) and was extracted with Ethyl acetate (10 mL x 2). The combined organic phases were dried over anhydrous Sodium sulfate, filtered and concentrated under reduced pressure. The obtained crude was purified by flash column chromatography using 5% DCM in Hexanes to obtain title compound as yellow liquid (0.900 g, 3.122 mmol, 52%). LCMS (Method-C): Retention time: 1.836 min, 100%, 265 nm, ES (-ve):287.3 [M-H]’Step-2: Synthesis of benzyl(2,3,5,6-tetrafluoro-4-methoxyphenyl)sulfane
[0539] To a stirred solution of 4-(benzylthio)-2,3,5,6-tetrafluorophenol (0.800 g, 2.775 mmol) in Acetone (8.0 mL) at room temperature under Nitrogen atmosphere was added potassium carbonate (0.958 g, 8.332 mol). Mel (0.2 mL, 3.212mol) was addded to the above reaction mixture and the reaction mixture was stirred at 50 °C for 3 hours. After completion, the reaction mixture was diluted with Water (10 mL) and aqueous layer was extracted with Ethyl acetate (2 x 10 mL). The combined organic layers were dried over anhydrous Sodium sulfate and concentrated under vacuum. The resulting crude was purified by silica gel flash column chromatography. Pure compound was eluted at 12% Ethyl acetate in Hexanes to obtain title compound as off white solid (0.520 g, 1.721 mmol, 62%). 'HNMR (400 MHz, DMSO-d6): δ 4.05 (s, 3H), 4.08 (s, 2H), 7.17- 7.28 (m, 5H).Step-3: Synthesis 2,3,5,6-tetrafluoro-4-methoxybenzenesulfonyl chloride
[0540] Prepared by a method analogous to Sulfonyl chloride 4, Step-3 using benzyl(2, 3,5,6- tetrafluoro-4-methoxyphenyl)sulfane (200 mg, 0.661 mmol). After completion, the reaction mixture was quenched with Water (5 mL). The aqueous layer was extracted with DCM (2 x 10 mL). The combined DCM layers were dried over sodium sulphate and evaporated under reduced pressure to obtain title compound as white solid (170 mg, crude).Sulfonyl chloride 10: Synthesis of 4-(chlorosulfonyl)-2,3,5,6-tetrafluorophenyl azetidine-1- carboxylateStep-1: Synthesis of 4-bromo-2,3,5,6-tetrafluorophenyl azetidine-l-carboxylate
[0541] To a stirred solution of 4-bromo-2,3,5,6-tetrafluorophenol (1.0 g, 4.095 mmol) in DMF (10 mL) was added CS2CO3 (3.988 g, 12.246 mmol) at 0 °C under Nitrogen atmosphere and stirred for 30 minutes. Azetidine- 1 -carbonyl chloride (0.976 g, 8.164 mmol) was added drop-wise to the reaction mixture and stirred at room temperature for 2 hours. After completion, the reaction mixture was diluted with cold Water (100 mL). The aqueous layer was extracted with Ethyl acetate (2 x 50 mL). The combined organic phase was dried over Sodium sulfate and evaporated under reduced pressure to get crude product. The crude residue was purified by silica gel flash chromatography and pure compound was eluted at 10% Ethyl acetate in Hexanes to obtain titlecompound as a white solid (1.2 g, 3.657 mmol, 90%). 'H NMR (400 MHz, CDC13): δ 2.36-2.44 (m, 2H), 4.18 (t, J = 6.8 Hz, 2H), 4.31 (t, J= 6.8 Hz, 2H).Step-2: Synthesis of 4-(benzylthio)-2,3,5,6-tetrafluorophenyl azetidine-l-carboxylate
[0542] To a stirred solution of 4-bromo-2,3,5,6-tetrafluorophenyl azetidine-l-carboxylate (1.2 g, 3.657 mmol) and phenylmethanethiol (0.543 mg, 4.389 mmol) in 1,4 Dioxane (18 mL) was added DIPEA (1.417 g, 10.973 mmol) at room temperature under Nitrogen atmosphere. The reaction mixture was purged with Nitrogen for 10 minutes. Pd2dba3 (0.167 g, 0.182 mmol) and Xantphos (0.211 g, 0.365 mmol) were added and the reaction mixture was again purged with Nitrogen for 5 minutes. The reaction mixture was heated at 110 °C for 2 hours. After completion, the reaction mixture was diluted with Water (40 mL) and the aqueous layer was extracted with Ethyl acetate (3 x 20 mL). The combined organic phase was dried over Sodium sulfate and evaporated under reduced pressure to get crude product. The crude residue was purified by silica gel flash chromatography and pure compound was eluted at 7% Ethyl acetate in Hexanes to obtain title compound as a white solid (0.800 mg, 2.154 mmol, 59%). LCMS (Method-C): Retention Time: 2.043 min, 99.51%, 270 nm, ES(+ve): 371.78 [M+H]+Step-3: Synthesis of 4-(chlorosulfonyl)-2,3,5,6-tetrafluorophenyl azetidine-l-carboxylate
[0543] Prepared by a method analogous to Sulfonyl chloride 1, Step-2 using 4-(benzylthio)- 2,3,5,6-tetrafluorophenyl azetidine-l-carboxylate (0.800g, 2.156 mmol). Yield (0.800 g, crude).Sulfonyl chloride 11: Synthesis of 3-(difluoromethoxy)-2,4,5,6-tetrafluorobenzenesulfonyl chlorideSlop ?OStep-3Step-1: Synthesis of potassium 2,3,4,6-tetrafluorophenolate
[0544] To a solution of 2,3,4,6-tetrafhiorophenol (50.0 g, 333.333 mmol) in THF (900 mL) was added Potassium tert-butoxide (26.900 g, 352.400 mmol) at 0 °C and the resulting reactionmixture was stirred at room temperature for 5 hours. After the completion of the reaction, the reaction mixture was directly concentrated under reduced pressure and was stripped by DCM (2 x 1000 mL). The obtained solid was triturated using n-Pentane to obtain title compound as a white solid (48.0 g, 0.288 mmol) which was used crude as such for next step.Step-2: Synthesis of 3-(Benzylthio)-2,4,5,6-tetrafluorophenol
[0545] To a stirred solution of potassium 2,3,4,6-tetrafluorophenolate (10.0 g, 0.060 mmol) in dry THF (100 mL) was dropwise added a solution of n-BuLi (2.5 M in Hexanes, 68.63 mL, 0.211 mmol) at -78 °C and was stirred at -78 °C for 1 hour. To the resulting reaction mixture was added a solution of 1,2-dibenzyl disulfane (24.150 g, 0.098 mmol) in THF (100 mL) and reaction mixture was allowed to stir at -78 °C for 1 hour. After completion, the reaction mixture was diluted with solution of IN HC1 (250 mL) and was extracted with Ethyl acetate (200mL x 2). The combined organic phases were dried over anhydrous Sodium sulfate filtered and concentrated under reduced pressure. The obtained crude was purified by flash column chromatography using 5% DCM in Hexanes to obtain title compound as yellow liquid (4.500 g, 0.016 mmol, 39%). LCMS (Method- C): Retention time: 1.810 min, 84%, 220 nm, ES (-ve): 287.10 [M-H]'Step-3: Synthesis of benzyl(3-(difluoromethoxy)-2,4,5,6-tetrafluorophenyl)sulfane
[0546] To a stirred solution 3-(benzylthio)-2,4,5,6-tetrafluorophenol (5.0 g, 0.017 mmol) in Acetone (50 mL) were added Cesium carbonate (16.970 g, 0.052 mmol) and Ethyl 2-bromo-2,2- difluoroacetate (7.047 g, 0.035 mmol) at room temperature and reaction mixture was stirred at 75 °C for 4 hours. After the completion, the reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue so obtained was diluted with Water (250 mL) and the aqueous layer was extracted with Ethyl acetate (200 mL x 2). The combined organic phases were dried over anhydrous Sodium sulfate, filtered and concentrated under reduced pressure. The obtained crude was purified by flash column chromatography and pure product was eluted at 2% Ethyl Acetate in Hexanes to obtain title compound as a colorless oil (2.0 g, 5.920 mol, 39 %).1H NMR (400 MHz, DMSO-d6): δ 4.12 (s, 2H), 7.05-7.45 (m, 6H).Step-4: Synthesis of 3-(difluoromethoxy)-2,4,5,6-tetrafluorobenzenesulfonyl chloride
[0547] Prepared by a method analogous to Sulfonyl chloride 4, Step-3 using benzyl(3- (difluoromethoxy)-2,4,5,6-tetrafluorophenyl)sulfane (2.0 g, 5.920 mol). Yield (1.0 g, crude).Sulfonyl chloride 12: Synthesis of 2,3,6-trifluoro-5-(methylcarbamoyl)benzenesulfonyl chlorideStep-1: Synthesis of 3-bromo-2,4,5-trifluoro-N-methylbenzamide
[0548] In a 100 mL RBF previously equipped with a magnetic stirrer and nitrogen balloon was taken 3-bromo-2,4,5-trifhiorobenzoic acid (1.0 g, 3.921 mmol) in DMF (10.0 mL) and cooled to 0 °C. To the reaction mixture, HATU (2.240 g, 5.882 mmol) was added and reaction mixture was stirred for 30 minutes at 0 °C. Then methylamine (2.350 g, 4.706 mmol) and DIPEA (2.01 ml,11.765 mmol) were added successively and reaction mixture was stirred for 30 minutes at room temperature. After completion, the reaction mixture was diluted with Water (100 mL) and aqueous layer was extracted with Ethyl acetate (3 x 50 mL). The combined organic layers were dried over anhydrous Sodium sulfate, filtered and the solvent was removed in vacuo. The resulting crude was purified by flash silica gel column chromatography. Pure compound was eluted at 30% Ethyl acetate to obtain title compound as yellow solid. (500 mg, 1.865 mmol, 47%). LCMS (Method- C): Retention time: 1.519 min, 95.43%, 220 nm, ES (+ve): 268.0 / 270.0 [M+H]+Step-2: Synthesis of 3-(benzylthio)-2,4,5-trifluoro-N-methylbenzamide
[0549] Prepared by a method analogous to Sulfonyl chloride 10, Step 2 using 3-bromo-2,4,5- trifluoro-N-methylbenzamide (500 mg , 1.865 mol). The crude product was purified by silica gel flash chromatography. Pure compound was eluted at 35-40% Ethyl acetate in Hexanes to obtain title compound as yellow solid (400 mg, 1.286 mmol, 69.0 %). LCMS (Method-C): Retention time: 1.778 min, 100%, 280 nm, ES (+ve): 312.28 [M]+.Step-3: Synthesis of 2,3,6-trifluoro-5-(methylcarbamoyl)benzenesulfonyl chloride
[0550] Prepared by a method analogous to Sulfonyl chloride 9, Step 3 using 3-(benzylthio)- 2,4,5-trifluoro-N-methylbenzamide (200 mg, 0.642 mmol). The resulting crude product was purified by silica gel flash chromatography. Pure compound was eluted at 40% Ethyl acetate in Hexanes to obtain title compound as white solid (100 mg , 0.347 mmol, 54%).Sulfonyl chloride 13: Synthesis of 2,3,5,6-tetrafluoro-4-(trifluoroniethyl)benzenesulfonyl chlorideStep-1: Synthesis of benzyl(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)sulfane
[0551] To a stirred solution of benzyl mercaptan (4.45g, 35.87mmol) in THF (125mL) was added n-BuLi (14.3mL, 35.87mmol, 2.5M in hexane) dropwise at -78°C temperature. The resulting reaction mixture was stirred at same temperature for Ih. The resulting lithium thiolate solution was added to a stirred solution of l,2,3,4,5-pentafluoro-6-(trifluoromethyl)benzene (25.4g, 107.63mmol) in THF (75mL) at -78°C temperature. The resulting reaction mixture was stirred at-78°C to room temperature for 16h. After the completion of reaction, the reaction mixture was diluted with diluted HC1 (120mL) and extracted with DCM (3xl20mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford the title compound as a white solid (12.01g, 35.29mmol, 98% yield). 'HNMR (400 MHz, CDC13-t / 6) δ 7.31_7.27 (m, 5H), 4.25 (s, 2H),19F NMR (400 MHz, CDC13-tZ6) 8 - 55.43_-55.55 (3F), -131.74_-131.86 (2F), -141.76_-141.87 (2F).Step-2: Synthesis of 2,3,5,6-tetrafluoro-4-(trifluoromethyl)benzenesulfonyl chloride
[0552] To a stirred solution of benzyl(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)sulfane (1 ,0g, 2.94mmol) in mixture of MeCN (40mL), AcOH (1 ,5mL) and water (ImL) was portion wise added 1,3 -di chi oro-5 5 -dimethylhydantoin (1.15g, 5.88mmol) at 0°C temperature. The reaction mixture was stirred at room temperature for Ih. After completion of the reaction, the reaction mixture was diluted with water (100mL) and extracted with ethyl acetate (2 x 50mL). The combined organic layer was washed with aq. NaHCO3(50mL). The separated organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford the title compound as colorless semi-solid (1.1g, 3.44mmol, quantitative yield). The obtained crude was used in next step without purification.19F NMR (400 MHz, DMSO) δ -55.69 (m, 3F), -137.09 - -137.22 (m, 2F), -141.72 - -141.89 (m, 2F).Sulfonyl chloride 14: 2,3,5,6-tetrafluoro-4-nitrobenzenesulfonyl chlorideSynthesis of l-benzyl(2,3,5,6-tetrafluoro-4-(nitrophenyl)sulfane:
[0553] A 2.5M solution of n-Butyllithium in hexanes (3.54 mL, 1.1 eq.) was added dropwise to a solution of benzyl mercaptan (1 g, 8.1 mmol, 1 eq.) in THF (17.5 mL) at -78°C under a positive pressure of nitrogen. The reaction mixture was left to stir for 30 min. The preparedlithium thiolate was added slowly via cannula to a solution of l,2,3,4,5-pentafluoro-6-nitro- benzene (3.43 g, 16.1 mmol, 2.0 eq.) in THF (17.5 M) at -78 °C and the reaction stirred while gradually warming to rt over 12 hrs. The mixture was quenched with water, and the aqueous phase extracted twice with EtOAc. The organic layer was dried over sodium sulfate, filtered, and evaporated under reduced pressure. The crude material was purified via reverse-phase column chromatography, eluting with 5% ACN in Water (0.1% FA), to yield the product as a brown solid (0.66 g, 2.1 mmol, 26% yield).1H NMR (400 MHz, CDCI3) δ 7.37 - 7.28 (m, 2H), 7.29 (s, 3H), 4.28 (s, 2H).19F NMR (376 MHz, CDCI3) δ -129.73 - -130.32 (m, 2F), -146.22 - -146.77 (m, 2F).Synthesis of 2,3,5, 6-tetrafhioro-4-nitrobenzenesulfonyl chloride
[0554] Neat l,3-dichloro-5,5-dimethyl-imidazolidine-2, 4-dione (830 mg, 4.2 mmol, 2 eq.) was added to an ice cold solution of benzyl(2,3,5,6-tetrafluoro-4-nitrophenyl)sulfane (668 mg, 2.11 mmol, 1 eq.) in CH3CN / ACOH / H2O (12.5 mL / 0.54 mL / 0.37 mL). The resulting pale yellow mixture was stirred at 0 °C for 4 hours, then warmed to r.t. overnight. After the overnight period, the rxn was partitioned between DCM and a saturated aqueous solution of NaHCO3. The organic layer was removed, and the remaining aqueous phase extracted 2x with DCM. The organic extracts were combined, washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum to afford the title compound as a beige semi-solid. The crude material was used without any further purification19F NMR (376 MHz, CDCI3) δ -129.83 (d, J= 11.1 Hz, 2F), -141.52 (dd, J= 15.0, 9.2 Hz, 2F).Synthesis of Sulfonyl Chloride 15: 2,3,5,6-tetrafluoro-4-hydroxybenzenesulfonyl chloride
[0555] Neat 2,3,5,6-tetrafluorophenol (2 g, 12 mmol, 1 eq.) was added slowly to an ice cold solution of chlorosulfonic acid (28 g, 241 mmol, 16 mL, 20 eq.) cooled to 0°C. The reaction vessel was outfitted with a water jacketed reflux condenser and subsequently heated to 120°C using a sand bath for 16 hours. Once the starting material was consumed, the reaction was cooled to room temperature, then poured slowly over crushed ice. The resulting mixture was partitioned between DCM and IM HC1 and the organic phase separated. The remaining aqueous phase was extracted twice more with DCM. The combined organic phases were washed with brine, dried over sodium sulfate, and concentrated in vacuo to afford the desired anticipated product as a brown solid (2.8 g, 10.6 mmol, 89% yield).19F NMR (376 MHz, CDCI3) δ -135.95 - -136.12 (m, 2F), -159.25 - -159.37 (m, 2F).Sulfonamide A: Synthesis of tert-butyl methyl(2,3,5,6-tetrafluoro-4- sulfamoylbenzyl)carbamateStep-1: Synthesis of 2,3,5,6-tetrafluoro-N,N-bis(4-methoxybenzyl)benzenesulfonamide
[0556] To a stirred solution of NH(PMB)2 (7.20g, 28.15mmol) in DCM (70mL) was added 2,3,5,6-tetrafluoro benzene sulfonyl chloride (7.0g, 28.15mmol) at 0°C temperature. The reaction mixture was stirred at room temperature for 20min. After completion of the reaction, the reaction mixture was diluted with water (200mL) and extracted with ethyl acetate (2 x lOOmL). The combined organic layer was dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain crude. The obtained crude was purified by flash column chromatography, product eluted with 24% ethyl acetate in hexane to afford the title compound as an off-white solid (8.0g, 17.04mmol, 60% yield).1H NMR (400 MHz, DMSO-d 6), δ 8.25-8.17 (m, IH), 7.13 (d, J = 8.4Hz, 4H), 6.82 (d, J= 8.8Hz, 4H), 4.44 (s, 4H), 3.71 (s, 6H).Step-2: Synthesis of 4-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2,3,5,6-tetrafluorobenzoic acid
[0557] To a stirred solution of 2,3,5,6-tetrafluoro-N, N-bis (4-methoxybenzyl) benzenesulfonamide (8.0 g, 17.05mmol) in anhydrous THF (80 mL) was added 2.5M n -BuLi in hexane (10ml, 25.58mmol) at -78°C temperature. The reaction mixture was allowed to stir at - 78°C for Ih followed by addition powdered dry ice. The reaction mixture was stirred at room temperature for 30min. After completion of the reaction, the reaction mixture was quenched with IN HC1 (800mL) and extracted with ethyl acetate (2 X 100mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain the title compound as a white solid (7.3g, 14.22mmol, 83% yield). 'H-NMR (400 MHz, DMSO-d 6), δ 7.15 (d, J= 8.4Hz, 4H), 6.81 (d, J= 8.8Hz, 4H), 4.46 (s, 4H), 3.71 (s, 6H). One exchangeable proton not observed.Step-3: Synthesis of 4-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2,3,5,6-tetrafluoro-N- methylbenzamidede
[0558] To a stirred solution of 4-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2,3,5,6- tetrafluorobenzoic acid (1.5g,2.92mmol) in anhydrous DCM (15mL) was added oxalyl chloride (0.37ml, 4.38mmol) at 0°C temperature. The reaction mixture was stirred at room temperature for Ih. After complete formation of acid chloride (Checked on TLC by treating with MeOH), the reaction mixture was concentrated under reduced pressure under N2 atmosphere. The obtained material was dissolved in THF (10ml) and cooled to 0°C temperature. To this reaction mixture methylamine (2M in THF, 4.38ml, 8.77mmol) was added at 0°C temperature under N2 atmosphere. The reaction mixture was allowed to stir at room temperature for 30min. After completion of the reaction, the reaction mixture was diluted water (100mL) and extracted with ethyl acetate (2 X 50mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain the title compound as an off white solid (2.9g, 5.51mmol, Quantitative yield). LCMS: Method-UC08_FAR1, RT 2.454 ESI-MS: measured m / z 527.1[M+1]+.Step-4: Synthesis of 2,3,5,6-tetrafluoro-N,N-bis(4-methoxybenzyl)-4-((methylamino) methyl) benzene sulfonamide
[0559] To a stirred solution of 4-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2,3,5,6-tetrafluoro-N- methylbenzamide (2.9g, 5.51mmol) in anhydrous THF (29mL), was added BH3-THF (0.37ml, 4.38mmol, IM in THF) in dropwise manner at 0°C temperature under N2 atmosphere, the reaction mixture was heated to 70°C for 16h. After completion of reaction, the reaction mixture was cooled to 0°C temperature, quenched with IN HC1 (200mL), extracted with ethyl acetate (2 X 50mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain the title compound as brown sticky solid (1 ,0g, 1.95mmol, Quantitative yield). LCMS: Method-UC08_FAR1, RT 1.976 ESI-MS: measured m / z 513.2 [M+l]+.Step-5: Synthesis of 2,3,5,6-tetrafluoro-4-((methylamino)methyl)benzenesulfonamide
[0560] A mixture of 2,3,5,6-tetrafluoro-N,N-bis(4-methoxybenzyl)-4- ((methylamino)methyl)benzenesulfonamide (1.0g, 19.5mmol) and TFA (10ml) was heated to 70°C for 16h. After completion of reaction, the reaction mixture was concentrated under reduced pressure, dilute with saturated solution of NaHCO3(200ml) and extracted with ethyl acetate (3 X 50mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The obtained material was triturated with n-pentane and diethyl ether(1 : 1) to afford the title compound as a white solid (0.7g, 2.57mmol, Quantitative yield). LCMS: Method-UC08_FAR1, RT 0.191 ESI-MS: measured m / z 273.0 [M+l]+.Step-6: Synthesis of tert-butyl methyl(2,3,5,6-tetrafluoro-4-sulfamoylbenzyl)carbamate
[0561] To a stirred solution of 2,3,5,6-tetrafluoro-4- ((methylamino)methyl)benzenesulfonamide (0.58g, 2.13mmol) in DCM (25mL) were added TEA (0.64g, 6.39mmol) and Boc anhydride (0.23, 1.06mmol) at 0°C temperature. The reaction mixture was stirred at room temperature for 3h. After completion of reaction, the reaction mixture was diluted with water (100mL), extracted with ethyl acetate (2 X 50mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The obtained crude material was purified by column chromatography, product eluted with 10% ethyl acetate in n-hexane to afford the title compound as an off white solid (0.32g, 0.86mmol, 29% yield over four steps). LCMS: Method-UC08_F ARI, RT 2.110 ESI-MS: measured m / z 371.2 [M-Sulfonamide B: Synthesis of 4-((dimethylamino)methyl)-2, 3,5,6- tetrafluorobenzenesulfonamide
[0562] Prepared by the method of Sulfonamide A, Steps 1 to 5 using dimethylamine (2M in THF, 9.73ml, 19.4mmol) in Step 3. Yield (0.7g, 2.62mmol, quantitative). LCMS: (ACQUITY PDA and QDA detector, UC03_ABR2): m / z 287.2 (M+H)+(ESI +ve), RT = 1.94 min, 100%, 200 - 400nm.Sulfonamide C: Synthesis of 2,3,5, 6-tetrafluoro-4-(hydroxymethyl)benzenesulfonamideStep-1: Synthesis of 2,3,5,6-tetrafluoro-4-(hydroxymethyl)-N,N-bis(4-methoxybenzyl) benzene sulfonamide
[0563] To a stirred solution of 4-(N,N-bis(4-methoxybenzyl)sulfamoyl)-2,3,5,6- tetrafluorobenzoic acid (Sulfonamide A, Step 2) (2.0g, 3.89mmol) in THF (20mL) was added IMBH3-THF (19.4mL, 19.49mmol) at 0°C temperature. The resulting reaction mixture was heated at 70°C for 16h. After completion of the reaction, the reaction mixture was diluted with IN HC1 (100mL) and extracted with ethyl acetate (2 x 50mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford the title compound as an off white solid (1.9g, 3.81mmol, quantitative yield). 'H NMR (400 MHz, DMSO) δ 7.10 (d, J = 8.4Hz, 4H), 6.81 (d, J= 8.8Hz, 4H), 5.73 (t, J= 6.0Hz, 1H), 4.57 (d, J= 6.0Hz, 2H), 4.42(s, 4H), 3.71(s, 6H).Step-2: Synthesis of 2,3,5,6-tetrafluoro-4-(hydroxymethyl)benzenesulfonamide:
[0564] 2, 3, 5, 6 -tetrafluoro-4-(hydroxymethyl)-N,N-bis(4-methoxybenzyl) benzene sulfonamide (1.9g, 3.80mmol) was dissolved in trifluoroacetic acid (10ml) and heated at 70°C temperature for 16h. After completion of the reaction, the reaction mixture was cooled to room temperature and concentrated under reduced pressure to obtain the crude. The obtained crude was diluted with saturated solution of NaHCO3(200ml) and extracted with ethyl acetate (2 x lOOmL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford the title compound as a brown gummy solid (1.0g, 3.86mmol, Quantitative yield). *H NMR (400 MHz, DMSO) δ 8.38 (s, 2H), 5.66 (d, J= 6.0Hz, 1H), 4.59 (d, J= 4.4Hz, 2H).Sulfonamide D: Synthesis of tert-butyl (tert-butoxycarbonyl)(2,3,5,6-tetrafluoro-4- sulfamoylbenzyl)carbamateStep-1: Synthesis of 4-(bromomethyl)-2,3,5,6-tetrafluorobenzenesulfonamide
[0565] To a stirred solution of Sulfonamide C (4.0g, 15.43mmol) in DMF (20mL) were added phosphorus tribromide (8.35g, 30.86mmol) at 0°C temperature. The reaction mixture was stirred at room temperature for lOmin. After completion of the reaction, the reaction mixture was diluted with sat. NaHCO3solution (500mL) and extracted with ethyl acetate (2 x lOOmL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain the crude. The obtained crude was purified by flash chromatography, eluted with 20% ethyl acetate in hexane to afford the title compound as a white solid (1.0g, 3.10mmol, 20% yield).1H NMR (400 MHz, DMSO) δ 4.72 (s, 2H). Two exchangeable protons not observed.19F NMR(377 MHz, DMSO) δ -138.81 (dd, J1 = 11.2Hz, .h = 22.7 Hz, 2F), -141.10 (dd, J1 = 11.9Hz, .h = 23.8Hz, 2F).Step-2: Synthesis of tert-butyl (tert-butoxycarbonyl)(2,3,5,6-tetrafluoro-4- sulfamoylbenzyl)carbamate
[0566] To a stirred solution of di-Boc-amine (1.34g, 6.20mmol) in DMF (lOmL) was added potassium carbonate (1.28g, 9.30mmol) at room temperature. The reaction mixture was stirred at room temperature for lOmin. followed by addition of 4-(bromomethyl)-2, 3,5,6- tetrafluorobenzenesulfonamide (1.0g, 3.10mmol). The reaction mixture was heated at 100°C temperature for 5h. After completion of the reaction, the reaction mixture was diluted with cold water (100ml) and extracted with ethyl acetate (2 x 50mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain the crude. The obtained crude was purified by flash column chromatography, eluted with 23% ethyl acetate in hexane to afford the title compound as a white solid (0.8g, 1.74mmol, 56% yield).1H NMR (400 MHz, DMSO) δ 4.90 (s, 2H), 1.41 (s, 18H). Two exchangeable protons not observed.19F NMR (377 MHz, DMSO) δ -140.15 (dd, J1 = 9.7Hz, J2= 22.2 Hz, 2F), -142.16 (dd, J1 = 9.9 Hz, J2= 22.1Hz, 2F).Sulfonamide E: Synthesis of Synthesis of 4-((2-(dimethylamino)ethyl)amino)-2, 3,5,6- tetrafluorobenzenesulfonamide
[0567] To a stirred solution of 2,3,4,5,6-pentafluorobenzenesulfonamide (0.5g, 2.02mmol) in DMF (8mL) were added K2CO3 (0.83g, 6.07mmol) and Nl, N1 -dimethylethane- 1,2-diamine (0.35g, 4.04mmol) at 0°C temperature. The reaction mixture was stirred at room temperature for 2h. After completion of the reaction, the reaction mixture was diluted with water (100mL) and extracted with ethyl acetate (3x50mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford the title compound as an off white solid (0.3g, 1.18mmol, 60% yield). LCMS: (ACQUITY PDA and QDA detector, UC08 FAR1): m / z 316.1 (M+H)+(ESI +ve), RT = 0.65 min, 88.5%, 200 - 400nm.Sulfonyl Fluoride F: Synthesis of 2-(2,3,5,6-tetrafluoro-4-pyrrolidin-l-yl- phenyl)sulfonylpyridine (Compound 24)
[0568] To a stirred solution of l-(4-bromo-2,3,5,6-tetrafluoro-phenyl)pyrrolidine (500 mg, 1.68 mmol) in diethyl ether (10 mL) cooled to 0 °C under argon was added Isopropylmagnesium chloride lithium chloride complex solution (1.3 M, 1.29 mL) slowly. The resulting mixture (clear solution) was stirred at 0 °C for 40 min then treated with pyridine-2-sulfonyl fluoride (270.74 mg, 1.68 mmol) dropwise as a solution in diethyl ether (1 mL); stirred at 0 °C for 5 min then at room temperature for 30 min (mixture turns from colourless to yellow). TLC analysis (DCM / hexanes) shows some SM, small amount of sulfonyl fluoride and a more polar product. Diluted with diethyl ether, washed with brine (lx), brine:water (1: 1, lx) and brine (lx). The organic phase was dried, filtered and concnetrated in vacuo then chromatographed in 0-10% diethyl ether in DCM. The product containing fractions were concentrated in vacuo then triturated with hexanes; filtered to collect the title compound as a white solid (403 mg, 1.12 mmol, 66%).1H NMR (400 MHz, CDC13): δ 8.70 (d, J = 1.8 Hz, 1H), 8.23 (d, J = 8.0 Hz, 1H), 8.05 - 7.95 (m, 1H), 7.59 - 7.50 (m, 1H), 3.64 - 3.79 (m, 4H), 1.99 - 1.89 (m, 4H).19F NMR (376 MHz, CDC13): δ -139.19 - -139.23 (m, 2F), -156.22 - -156.28 (m, 2F).Thiomethyl sulfone G: Synthesis of 4-((2,3,5,6-tetrafluoro-4-(methylthio)phenyl)sulfonyl)aniline (Compound 34)Step-1: Synthesis of l,2,4,5-tetrafluoro-3-((4-nitrophenyl)sulfonyl)benzene
[0569] To a stirred solution of (4-nitrophenyl) (2,3,5,6-tetrafluorophenyl) sulfane (0.95g, 3.13mmol) in THF (lOmL) was added m-CPBA (2.15g, 12.54mmol) at 0°C temperature. The resulting reaction mixture was stirred at room temperature for 16h. After completion of the reaction, the reaction mixture was diluted with saturated solution of NaHCO3(200mL) and extracted with ethyl acetate (3 x 200mL). The combined organic layer was dried over anhydrousNa2SO4, filtered and concentrated under reduced pressure to obtain the crude. The obtained crude was purified by flash column chromatography, product eluted with 40-50% DCM in hexane to afford the title compound as an off-white solid (4.8g, 14.32mmol, 91% yield).1H NMR (400 MHz D, MSO) δ 8.48 (d, J= 92 Hz, 2H), 8.43-8.38 (m, 1H), 8.33 (d, J= 8.8 Hz, 2H).19F NMR (400 MHz, DMSO) δ - 135.74 - 135.86 (m, 2F), -137.37_-137.49 (m, 2F).Step-2: Synthesis of l,2,4,5-tetrafluoro-3-((4-nitrophenyl)sulfonyl)benzene
[0570] To a stirred solution of (4-nitrophenyl) (2,3,5,6-tetrafluorophenyl) sulfane (0.95g, 3.13mmol) in THF (lOmL) was added m-CPBA (2.15g, 12.54mmol) at 0°C temperature. The resulting reaction mixture was stirred at room temperature for 16h. After completion of the reaction, the reaction mixture was diluted with saturated solution of NaHCOs (200mL) and extracted with ethyl acetate (3 x 200mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain the crude. The obtained crude was purified by flash column chromatography, product eluted with 40-50% DCM in hexane to afford the title compound as an off-white solid (4.8g, 14.32mmol, 91% yield).1H NMR (400 MHz D, MSO) δ 8.48 (d, J= 92 Hz, 2H), 8.43-8.38 (m, 1H), 8.33 (d, J= 8.8 Hz, 2H).19F NMR (400 MHz, DMSO) δ - 135.74 - 135.86 (m, 2F), -137.37_-137.49 (m, 2F).Step-3: Synthesis of 4-((2,3,5,6-tetrafluorophenyl)sulfonyl)aniline
[0571] To a stirred solution of l,2,4,5-tetrafluoro-3-((4-nitrophenyl)sulfonyl)benzene (4.8g, 14.32mmol) in MeOH (100mL) was added 10% Pd / C (1.5g, 50% wet) at room temperature. The resulting reaction mixture was purged with H2(g) at room temperature for 5h. After completion of the reaction, the reaction mixture was filtered through celite bed and washed with methanol (100mL). The filtrate was concentrated under reduced pressure to afford the title compound as an off-white solid (2.5g, 8.19mmol, 57% yield). 'HNMR (400 MHz, DMSO) δ 8.27-8.18 (m, 1H), 7.62 (d, J= 8.8 Hz, 2H), 6.66 (d, J= 8.4 Hz, 2H), 6.52 (s, 2H).19F-NMR (400 MHz, DMSO) δ - 136.50_-136.62 (m, 2F), -138.76 -138.87 (m, 2F).Step-4: Synthesis of di-tert-butyl (4-((2,3,5,6-tetrafluorophenyl)sulfonyl)phenyl)carbamate
[0572] To a stirred solution of 4-((2,3,5,6-tetrafluorophenyl)sulfonyl)aniline (3.19g, 10.45mmol) in THF (100mL) were sequentially added TEA (2.11g, 20.91mmol), boc anhydride (4.56g, 20.91mmol) and DMAP (0.127g, 1.05mmol) at 0°C temperature. The resulting reaction mixture was heated at 80°C temperature for 2h. After completion of the reaction, the reaction mixture was cooled to room temperature and diluted with water (100mL). The resulting suspension was extracted with ethyl acetate (2 x 100mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain the crude. Theobtained crude was purified by flash column chromatography, product eluted with 40-50% ethyl acetate in hexane to afford the title compound as a brown solid (1.85g, 3.66mmol, 35% yield). 'H NMR (400 MHz, DMSO) δ 8.41-8.34 (m, 1H), 8.07 (d, J= 8.4 Hz, 2H), 7.57 (d, J= 8.8 Hz, 2H), 1.37 (s, 18H).19F-NMR (400 MHz, DMSO): -136.07_-136.25 (m, 2F), -138.01 -138.13 (m, 2F).Step-5: Synthesis of tert-butyl (4-((2,3,5,6-tetrafluoro-4- (methylthio)phenyl)sulfonyl)phenyl)carbamate
[0573] To a stirred solution of di-tert-butyl (4-((2, 3,5,6- tetrafluorophenyl)sulfonyl)phenyl)carbamate (0.93g, 1.83mmol) in anhydrous THF (lOmL) was added 2.5M w-BuLi solution in / / -hexane (1.47ml, 3.67mmol) at -78°C temperature. The resulting reaction mixture was stirred at -78°C temperature for Ih followed by addition of dimethyl disulfide (0.345g, 3.67mmol). The reaction mixture was allowed to stir at -78°C temperature for 30min. The reaction mixture was gradually allowed to warm up to room temperature and allowed to stir for Ih. After completion of the reaction, the reaction mixture was diluted with aqueous solution of NH4Q (100mL) and extracted with ethyl acetate (3 x lOOmL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain the crude. The obtained crude was purified by Prep. HPLC to afford the title compound as a white solid. (0.37g, 0.82mmol, 23% yield). LCMS: (ACQUITY PDA and QDA detector, UCO4_FAR1): m / z 450.2 (M+H)+(ESI +ve), RT = 2.50 min, 100%, 200 - 400nm. HPLC : (Agilent Technologies. 1260 Series, Infinity-II, HP07 TFAR1) : RT = 7.82 min, 99.0%, 200- 400nm.1H NMR (400 MHz, DMSO) : 5 10.06 (s, IH), 7.92 (d, J = 8.8 Hz, 2H), 7.73 (d, J= 8.8 Hz, 2H), 2.60 (s, 3H), 1.48 (s, 9H).Step-6 : Synthesis of 4-((2,3,5,6-tetrafluoro-4-(methylthio)phenyl)sulfonyl)aniline
[0574] To a stirred solution of tert-butyl (4-((2,3,5,6-tetrafluoro-4- (methylthio)phenyl)sulfonyl)phenyl)carbamate (0.26g, 0.57mmol) in DCM (5mL) was added TFA (5mL) at 0°C temperature. The resulting reaction mixture was stirred at room temperature for Ih. After completion of the reaction, the reaction mixture was concentrated under reduce pressure to obtain the residue. The obtained residue was suspended in saturated aq. NaHCOs solution (50mL) and extracted with DCM (3 x 50mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford title compound as a brown solid (0.270g, 0.76mmol, Quantitative yield). LCMS: (ACQUITY PDA and QDA detector, UCO4_FAR1): m / z 352.1 (M+H)+(ESI +ve), RT = 2.05 min, 85.4%, 200 - 400nm. HPLC : (Agilent Technologies. 1260 Series, Infinity-II, HP10 TFAR1) : RT = 8.16 min, 86.4%, 200-400nm.1H NMR (400 MHz, DMSO) : δ 7.62 (d, J = 8.8 Hz, 2H), 6.66 (d, J = 8.8 Hz, 2H),6.50 (s, 2H), 2.58 (s, 3H).19F NMR (400 MHz, DMSO) : 5 -133.92_-134.02 (m, 2F), -139.52_- 139.62 (m, 2F).Intermediate 1: Synthesis of N-(piperidin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amineStep 1: Synthesis of tert-butyl 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-l- carboxylate
[0575] In a sealed tube vial, 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (1.0 g, 6.512 mmol) was dissolved in Isopropyl alcohol (15 ml) at room temperature. To the above stirred solution was added tert-butyl 4-aminopiperidine-l -carboxylate (1.3 g, 6.512 mmol) and stirred for another 5 minutes. DIPEA (2 mL, 11.722 mmol) was added and the reaction vial was sealed and heated at 90°C for 48h. After completion (as monitored by TLC), the reaction mixture was concentrated under reduced pressure to yield a solid brown residue. The crude was purified by flash silica gel chromatography. Title compound was eluted at 80-100% EtOAc / Hexanes and obtained as a light brown solid (1.0 g, 3.154 mmol, 50%). LCMS (Method-C): Retention Time: 1.318 min, 100%, 290 nm, ES (+ve): 318.4 [M+H]+Step-2: Synthesis of N-(piperidin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
[0576] To a stirred solution of tert-butyl 4-((7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)piperidine-l -carboxylate (0.700 g, 2.208 mmol) in DCM (20 mL), was added TFA (10 mL) at 0°C under N2. The reaction mixture was stirred at 0°C for 30 min and gradually brought to RT. The reaction was stirred at RT for 2h or until complete consumption of starting material. After completion, the reaction mixture was diluted with Toluene (20 mL) and co-evaporated with Toluene under reduced pressure to obtain a colorless viscous liquid. The crude was further triturated with 10% Diethyl Ether / Pentane to obtain the desired product as an off-white solid (0.460 g, 2.119 mmol, 96%). LCMS (Method-F): Retention Time 3.22 min, 98%, 275nm, ES(+ve): 218.2 [M+H]+Intermediate 2: Synthesis of (R)-N-(azepan-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amineStep-1: Synthesis of tert-butyl(R)-4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)azepane-l- carboxylate
[0577] In a sealed vial, tert-butyl (R)-4-aminoazepane-l -carboxylate (250 mg, 1.630 mmol) was dissolved in 1,4 Dioxane (5.0 mL) at room temperature. 4-chloro-7H-pyrrolo[2,3- d]pyrimidine (419 mg, 1.96 mmol) was added to the above solution and stirred for another 5 minutes. DIPEA (0.4 mL, 2.44 mmol) was added and the reaction vial was sealed and heated at 80 °C for 4 hours. After completion (as monitored by TLC), the reaction mixture was concentrated to afford crude. The resulting crude was purified by normal phase column chromatography. Product was eluted at 70 % Ethyl acetate in Hexanes. Combined pure fraction was concentrated under reduced pressure to obtain title compound as an off white solid (300 mg, 0.906 mmol, 55%). LCMS (Method-C): Retention Time: 1.43 min, 100%, 202 nm, ES (+ve): 332.2 [M+H]+Step-2: Synthesis of (R)-N-(azepan-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
[0578] To a stirred solution tert-butyl (R)-4-((7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)azepane-l -carboxylate (300 mg, 0.906 mmol) in DCM (5.0 mL), TFA (0.5 mL) was added at 0 °C under Nitrogen atmosphere. The reaction mixture was stirred at 0 °C for 30 minutes and gradually brought to room temperature. The reaction was stirred at room temperature for 4 hours. After completion, the reaction mixture was diluted with Toluene (5 mL) and co-evaporated with Toluene (2 x 5 mL) under reduced pressure to obtain a colorless viscous liquid. The crude product was further triturated with 10% Diethyl ether in Pentane to obtain title compound as a yellow solid (180 mg, 0.623 mmol, 86%). The crude product was used for next step without further purification. LCMS (Method- J): Retention Time: 5.01 min, 98%, 242 nm, ES (+ve): 232.2 [M+H]+Intermediate 3: Synthesis of (S)-N-(azepan-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
[0579] Prepared by the method of Intermediate 2, using tert-butyl (S)-4-aminoazepane-l- carboxylate (1.393 g, 6.511 mmol). Yield (500 mg, crude).Intermediate 4: Synthesis of (ls,4s)-Nl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)cyclohexane-l,4- diamineStep-1: Synthesis of tert-butyl ((ls,4s)-4-((7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)cyclohexyl)carbamate
[0580] In a sealed tube vial, 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (1.0 g, 6.511 mmol) was dissolved in n-Butanol (10 mL) at room temperature. To the above stirred solution was added tert- butyl ((ls,4s)-4-aminocyclohexyl)carbamate (1.393 g, 6.511 mmol) and stirred for another 5 minutes. DIPEA (2.2 mL, 13.020 mmol) was added, and the reaction vial was sealed and heated at 120 °C for 16 hours. After completion (as monitored by TLC), the reaction mixture was quenched with Water (30 mL). The aqueous layer was extracted with Ethyl acetate (3 x 50 mL). The combined organic layer was evaporated under reduced pressure to afford crude product. The crude residue was purified by silica gel flash chromatography and pure compound was eluted at 10% Ethyl acetate in n-Hexanes to obtain title compound as off white solid (1.700 g, 8.146 mmol, 80%). LCMS (Method-C): Retention Time: 1.347 min, 100%, 230 nm, ES (+ve): 332.46 [M+H]+Step-2: Synthesis of (ls,4s)-Nl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)cyclohexane-l,4-diamine
[0581] To a stirred solution of tert-butyl ((ls,4s)-4-((7H-pyrrolo[2,3-d]pyrimidin-4- yl)amino)cyclohexyl)carbamate (1.0 g, 3.017 mmol) in DCM (10 mL), was added TFA (3 mL) at 0 °C under Nitrogen atmosphere. The reaction mixture was stirred at 0 °C for 30 minutes and gradually brought to room temperature. The reaction was stirred at room temperature for 2 hours. After completion, the reaction mixture was diluted with Toluene (5 mL) and co-evaporated with Toluene under reduced pressure to obtain title compound as off white solid (800 mg, crude). The crude was used for next step without column purification.1H NMR (400 MHz, DMSO-d6): δ 1.81 (s, 5H), 1.92-1.91 (m, 3H), 3.29 (s, 1H), 4.07 (s, 1H), 7.02 (s, 1H), 7.39 (s, 1H), 7.97 (s, 2H), 8.35 (s, 1H), 8.90 (s, 1H), 12.53 (bs, 1H).Intermediate 5: Synthesis of l-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)piperidin-4-amineStep-1: Synthesis of tert-butyl (l-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)piperidin-4-yl)carbamate
[0582] In a 250 mL RBF, a solution of tert-butyl (l-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)piperidin-4-yl)carbamate (10.0 g, 31.500 mmol) in DMF (100 ml) was cooled to 0 °C under Nitrogen atmosphere. NaH (60% in mineral oil) (1.512 g, 63.010 mmol) was added portion wise and the reaction mixture was stirred for 15 minutes at 0 °C. 2-(Trimethylsilyl)ethoxymethyl chloride (5.251 g, 31.500 mmol) was added dropwise. The reaction mixture was gradually brought to room temperature and stirred at room temperature for 4 hours. After completion, the reaction mixture was diluted with cold Water (200 mL) and the aqueous layer was extracted with Ethyl acetate (3 x 100 mL). The combined organic phase was dried over Sodium sulfate and evaporated under reduced pressure to get crude product. The crude residue was purified by basic alumina chromatography and pure compound was eluted at 7% MeOH in DCM to obtain title compound as a brown liquid (5.0 g, 11.160 mmol, 35%). LCMS (Method-C): Retention Time: 1.807 min, 97%, 290 nm, ES(+ve): 448.3 [M+H]+Step-2: Synthesis of l-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)piperidin-4-amine
[0583] To a stirred solution of tert-butyl (l-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H- pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl)carbamate (5.0 g, 11.160 mmol) in DCM (50 mL), 4M HC1 in Dioxane (25 mL) was added at 0 °C under Nitrogen atmosphere. The reaction mixture was stirred at 0 °C for 30 minutes and gradually brought to room temperature. The reaction was stirred at room temperature for 2 hours. After completion, the reaction mixture was evaporated under reduced pressure to obtain a yellow solid. The crude residue was purified by basic alumina chromatography and pure compound was eluted at 7% MeOH in DCM to obtain title compound as a brown liquid (2.400 g, 6.905 mmol, 62%). LCMS (Method-C): Retention Time 1.403 min, 100%, 220 nm, ES(+ve): 348.4 [M+H]+Intermediate 6: Synthesis of l-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3- d]pyrimidizetidinen-4-yl)azetidin-3-amineNHBoc NHBocCl O 4M HOl inH M Dioxane, DCM,Step-1: Synthesis of tert-butyl (l-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3- d]pyrimidizetidinen-4-yl)azetidin-3-yl)carbamate
[0584] In a sealed tube vial 4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3- d]pyrimidine (1.0 g, 3.523 mmol) was dissolved in Dioxane (15 mL) at room temperature. To the above stirred solution, tertzetidine-butyl azeti din-3 -ylcarbamate (0.728 g, 4.228 mmol) was added and the reaction mixture was stirred for another 5 minutes. DIPEA (1.366 g, 10.569 mmol) was then added and the reaction vial was sealed and heated at 110 °C for 12 hours. After completion (as monitored by TLC), the reaction mixture was concentrated under reduced pressure to yield a white solid residue. The crude was purified by silica gel flash chromatography. Pure compound was eluted at a gradient of 20-100% Ethyl acetate in Hexanes to obtain title compound as light brown solid (1.0 g, 2.383 mmol, 68%). LCMS (Method-C): Retention Time: 1.706 min, 100%, 230 nm, ES(+ve): 420.04 [M+H]+Step-2: Synthesis of l-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3- d]pyrimidizetidinen-4-yl)azetidin-3-amine
[0585] In a 25 mL RBF, tert-butyl (l-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3- d]pyrimidizetidinen-4-yl)azetidin-3-yl)carbamate (0.5 g, 1.191 mmol) was dissolved in DCM (5 mL). The solution was cooled to 0 °C and 4.0 M HC1 in Dioxane (7.5 mL) was added dropwise. The reaction mixture was gradually brought to room temperature and stirred at room temperature for 45 minutes. After completion, the reaction mixture was azeotroped with Toluene (3 x 5 mL) to obtained a brown solid (0.600 g, crude). The crude was used in the next step without column purification. LCMS (Method-C): Retention Time: 1.376 min, 100%, 290 nm, ES(+ve): 320.21 [M+H]+Intermediate 7: Synthesis of 4-(4-(methylamino)piperidin-l-yl)-lH-pyrrolo[2,3-b]pyridine- 5-carboxamide
[0586] Prepared by an analogous procedure to Intermediate 2 using 4-chloro-lH-pyrrolo[2,3- b]pyridine-5-carboxamide (275 mg, 1.402 mmol) and tert-butyl methyl(piperidin-4-yl)carbamate (301 mg, 1.402 mmol). Yield (150 mg, 0.545 mmol, 98%). LCMS (Method-F): Retention Time 0.258 min, 100%, 254 nm, ES (+ve): 274.2 [M+H]+Intermediate 8: Synthesis of l-(6-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H- pyrrolo[2,3-d]pyrimidin-4-yl)-3-methylazetidin-3-amineStep-1: Synthesis of tert-butyl (l-(6-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H- pyrrolo[2,3-d]pyrimidin-4-yl)-3-methylazetidin-3-yl)carbamate
[0587] Prepared by the method of Intermediate 2, Step 1 using 4,6-dichloro-7-((2- (trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine (400 mg, 1.256 mmol) and tert- butyl (3-methylazetidin-3-yl)carbamate hydrochloride (336 mg, 1.508 mmol). After completion, the reaction mixture was diluted with Water (10 mL) and the aqueous layer was extracted with Ethyl acetate (3 x 20 mL). The combined organic phases were dried over anhydrous Sodium sulfate. The crude residue was purified by flash silica gel chromatography. Pure compound was eluted at 50% Ethyl acetate in Hexanes to obtain title compound as light yellow solid (600 mg, 1.282 mmol, 100%). LCMS (Method-C): Retention time: 2.077 min, 99.96 %, 280 nm, ES (+ve): 468.4 / 470.3 [M+H]+.Step-2: Synthesis of l-(6-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl)-3-methylazetidin-3-amine
[0588] Prepared by the method of Intermediate 5, Step 2 using tert-butyl (l-(6-chloro-7-((2- (trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-3-methylazeti din-3- yl)carbamate (600 mg, 1.282 mmol). The crude residue was triturated with n-Pentane (2 x 10 mL) to obtain title compound as white solid (500 mg, crude). The crude was used for the next stepwithout column purification. LCMS (Method-C): Retention Time: 1.756 min, 91.02%, 225 nm, ES(+ve): 368.26 [M+H]+Intermediate 9: Synthesis of (8-(l-methyl-6-(trifluoromethyl)-lH- bzetidineenzo[d]imidazol-5-yl)indolizin-3-yl)(piperazin-l-yl)methanoneStep-1: Synthesis of ethyl 8-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)indolizine-3- carboxylate
[0589] To a stirred solution of ethyl 8-bromoindolizine-3 -carboxylate (10.0g, 37.45mmol) in 1,4-dioxane (1000mL) were added potassium acetate (11.01g, 112.36mmol) and Bis(pinacolato)diboron (14.27g, 56.17mmol) at room temperature. The reaction mixture was purged with N2 gas For 15-20mins. followed by the addition of PdC12(dppf)DCM (3.056g, 3.74mmol) at room temperature. The reaction mixture was stirred at 85°C for 4h. After completion of reaction, the reaction mixture was cooled to room temperature, diluted with hexane (900mL) and filtered through the celite bed and washed with hexane (2 x 300mL). The filtrate was concentrated under reduced pressure to obtain the crude. The obtained crude was purified by column chromatography, eluted with 100% hexane to afford title compound as an off-white solid (14.0g, quantitative yield). LCMS: (ACQUITY PDA and QDA detector, UC05 FAR1): m / z 316.4 (M+H)+(ESI +ve), RT = 3.03min, 79.4%, 200- 400nm.Step-2: Synthesis of ethyl 8-(l-methyl-6-(trifluoromethyl)-lH-benzo[d]imidazol-5- yl)indolizine-3-carboxylate
[0590] To a stirred solution of 5-bromo-l-methyl-6-(trifluoromethyl)-lH-benzo[d]imidazole(WO2021084765 Al) (4.0g, 36.36mmol) in mixture of 1,4-di oxane: water (8:2, 1000mL) wereadded sodium carbonate (4.57g, 43.16mmol) and ethyl 8-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)indolizine-3-carboxylate (6.79g, 21.586mmol) at room temperature. The reaction mixture was purged with N2 gas For 10-15mins. followed by the addition of PdCh(dppf) (1.05g, 1.43mmol) at room temperature. The reaction mixture was stirred at 90°C for 4h. After completion of reaction, the reaction mixture was cooled to room temperature, diluted with water (400mL) and extracted with ethyl acetate (3 x 400mL). The combined organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The obtained crude was purified by column chromatography, eluted with 100% ethyl acetate in hexane to afford title compound as an off-white solid (6.0g, 15.50mmol, 54% yield). LCMS: (ACQUITY PDA and QDA detector, UC05_FARl): m / z 388.4 (M+H)+(ESI +ve), RT = 2.37min, 98.6%, 200- 400nm.Step-3: Synthesis of tert-butyl 4-(8-(l-methyl-6-(trifluoromethyl)-lH-benzo[d]imidazol-5- yl)indolizine-3-carbonyl)piperazine-l-carboxylate
[0591] To a stirred solution of tert-butyl piperazine- 1 -carboxylate (1.45g, 7.75mmol) in toluene (lOmL) were added TEA (0.782g, 7.75mmol) and trimethylaluminum (4.5mL, 9.04mmol, 2.0M in toluene) at 0°C temperature. The reaction mixture was stirred at 0°C temperature for 30 min under N2 atm followed by addition of ethyl 8-(l-methyl-6-(trifluoromethyl)-lH- benzo[d]imidazol-5-yl) indolizine-3 -carboxylate (1.0g, 2.58mmol) in toluene (5mL). The reaction mixture was stirred at 90°C temperature for Ih. After completion of the reaction, the reaction mixture was cooled to room temperature and diluted with sat. NaHCO3(100mL). The resulting suspension was extracted with ethyl acetate (3xl00mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford the title compound as a brown liquid (4.51g, 8.55mmol, Quantitative). LCMS: UC05 FAR1, RT- 2.336 ESI-MS: measured m / z 528.5 [M+l]+.Step-4: Synthesis of (8-(l-methyl-6-(trifluoromethyl)-lH-benzo[d]imidazol-5-yl)indolizin- 3-yl)(piperazin-l-yl)methanone
[0592] To a stirred solution of tert-butyl 4-(8-(l-methyl-6-(trifluoromethyl)-lH- benzo[d]imidazol-5-yl)indolizine-3-carbonyl)piperazine-l-carboxylate (4.5g, 8.53mmol) in DCM (25mL) was added 4M HC1 in 1,4-dioxane (30mL) at room temperature. The reaction mixture was stirred at room temperature for 2h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure and basified using saturated aq. NaHCO3(30mL). The resulting suspension was extracted with ethyl acetate (3x300mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford the title compound as a brown solid (2.5g, 5.85mmol, Quantitative). LCMS: UC05 FAR1, RT- 1.499 ESLMS: measured m / z 428.5, [M+l]+.Intermediate 10: Synthesis of N-(2-aminoethyl)-8-(l-methyl-6-(trifluoromethyl)-lH- benzo [d] imidazol-5-yl)indolizine-3-carboxamideStep-1: Synthesis of 8-(l-methyl-6-(trifluoromethyl)-lH-benzo[d]imidazol-5-yl)indolizine- 3-carboxylic acid
[0593] To a stirred solution of ethyl 8-(l-methyl-6-(trifluoromethyl)-lH-benzo[d]imidazol-5- yl)indolizine-3 -carboxylate (Intermediate 9, Step 2) (1.0g, 2.58mmol) in mixture of EtOH and water (8:2, lO.OmL) was added NaOH (0.31g, 7.75mmol) at room temperature. The reaction mixture was stirred at 70°C for 3h. After completion of the reaction, the reaction mixture was cooled to room temperature and concentrated under reduce pressure to obtain the residue. The obtained residue was acidified with IN HC1 solution (25mL) to obtain the precipitate.Step-2: Synthesis of tert-butyl (2-(8-(l-methyl-6-(trifluoromethyl)-lH-benzo[d]imidazol-5- yl)indolizine-3-carboxamido)ethyl)carbamate
[0594] To a stirred solution of 8-(l-methyl-6-(trifluoromethyl)-lH-benzo[d]imidazol-5- yl)indolizine-3 -carboxylic acid (0.6g, 1.67mmol) in THF (lOmL) were sequentially added tert- butyl (2-aminoethyl)carbamate (0.534g, 3.34mmol), TEA (0.506g, 5.01mmol) and T3P (0.797g, 2.50mmol) at 0°C temperature. The resulting reaction mixture was stirred at room temperature for Ih. After completion of the reaction, the reaction mixture was diluted with water (80mL) and extracted with ethyl acetate (80mL X 2). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain the crude. The obtained crude material was purified by reverse phase column chromatography, eluted with 70-80% MeCN using 0.1% FA in water to afford the title compound as an off-white solid (0.35g, 0.69mmol, 42% yield). LCMS: (ACQUITY PDA and QDA detector, UC05 FAR1): m / z 502.2 (M+H)+(ESI +ve), RT = 2.14 min, 79.5%, 200 - 400nm.Step-3: Synthesis of N-(2-aminoethyl)-8-(l-methyl-6-(trifluoromethyl)-lH- benzo[d]imidazol-5-yl)indolizine-3-carboxamide
[0595] To a stirred solution of tert-butyl (2-(8-(l-methyl-6-(trifluoromethyl)-lH- benzo[d]imidazol-5-yl)indolizine-3-carboxamido)ethyl)carbamate (0.35g, 0.69mmol) in DCM (5mL) was added 4M HC1 in 1,4-di oxane (4mL) at 0°C temperature. The reaction mixture was stirred at room temperature for Ih. After completion of the reaction, the reaction mixture wasconcentrated under reduced pressure to afford the title compound as a green solid (0.31, 0.7, Quantitative yield). LCMS: (ACQUITY PDA and QDA detector, UC05 FAR1): m / z 402.2 (M+H)+(ESI +ve), RT = 1.49 min, 79.5%, 200 - 400nm.Intermediate 11: Synthesis of N-(3-aminopropyl)-8-(l-methyl-6-(trifluoromethyl)-lH- benzo[d]imidazol-5-yl)indolizine-3-carboxamide hydrochlorideStep-1: Synthesis of tert-butyl (3-(8-(l-methyl-6-(trifluoromethyl)-lH-benzo[d]imidazol-5- yl)indolizine-3-carboxamido)propyl)carbamate
[0596] To a stirred solution of 8-(l-methyl-6-(trifluoromethyl)-lH-benzo[d]imidazol-5- yl)indolizine-3 -carboxylic acid (Intermediate 10, Step 1) (0.5g, 1.39mmol) in DMF (5.0mL) were added DIPEA (0.71mL, 4.17mmol) and HATU (0.79g, 2.08mmol) at 0°C temperature. The resulting reaction mixture was stirred at room temperature for 15minutes followed by addition of tert-butyl (3-aminopropyl)carbamate (0.36g, 2.08mmol). The reaction mixture was stirred at room temperature for 15 minutes. After completion of the reaction, the reaction mixture was diluted with ice cold water (100mL) and extracted with ethyl acetate (2x70mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain the crude. The obtained crude was purified by reverse phase column chromatography, eluted with 63% MeCN in water (using 0.1% formic acid as modifier) to afford the title compound as off white solid (0.15g, 0.29mmol, 21% yield). LCMS: (ACQUITY PDA and QDA detector, UC05 FAR1): m / z 516.3 (M+l)+(ESI +ve), RT = 2.19 min, 98.8 %, 200 - 400nm.Step-2: Synthesis of N-(3-aminopropyl)-8-(l-methyl-6-(trifluoromethyl)-lH- benzo [d] imidazol-5-yl)indolizine-3-carboxamide hydrochloride
[0597] Prepared by the method of Intermediate 10, Step 3 using tert-butyl (3-(8-(l-methyl-6- (trifluoromethyl)-lH-benzo[d]imidazol-5-yl)indolizine-3-carboxamido)propyl)carbamate(0.15g, 0.29mmol). The obtained crude was triturated with / / -hexane to afford the title compound as brown solid (0.18g, 0.43mmol, quantitative yield). LCMS: (ACQUITY PDA and QDA detector, UC05_FARl): m / z 416.3 (M+l)+(ESI +ve), RT = 1.46 min, 98.7 %, 200 - 400nm.Intermediate 12: Synthesis of (2-(aminomethyl)azetidin-l-yl)(8-(l-methyl-6- (trifluoromethyl)-lH-benzo[d]imidazol-5-yl)indolizin-3-yl)methanoneStep-1: Synthesis of tert-butyl ((l-(8-(l-methyl-6-(trifluoromethyl)-lH-benzo[d]imidazol-5- yl)indolizine-3-carbonyl)azetidin-2-yl)methyl)carbamate
[0598] Prepared by the method of Intermediate 11, Step 1 using tert-butyl (azetidin-2- ylmethyl)carbamate (0.544g, 2.92mmol). The obtained crude material was purified by reverse phase column chromatography, eluted with 70-80% MeCN in water to afford the title compound as an off-white solid (0.5g, 0.9mmol, 48% yield). LCMS: (ACQUITY PDA and QDA detector, UC05 FAR1): m / z 528.3 (M+H)+(ESI +ve), RT = 2.26 min, 93.3%, 200 - 400nm.Step-2: Synthesis of (2-(aminomethyl)azetidin-l-yl)(8-(l-methyl-6-(trifluoromethyl)-lH- benzo [d] imidazol-5-yl)indolizin-3-yl)methanone
[0599] To a stirred solution of tert-butyl ((l-(8-(l-methyl-6-(trifluoromethyl)-lH- benzo[d]imidazol-5-yl)indolizine-3-carbonyl)azetidin-2-yl)methyl)carbamate (0.440g,0.83mmol) in DCM (lOmL) was added TFA (4mL) at 0°C temperature. The reaction mixture was stirred at room temperature for Ih. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure to afford the title compound as a blue sticky solid (0.6g, 1.40mmol, Quantitative yield). LCMS: (ACQUITY PDA and QDA detector, UC05 FAR1): m / z 428.2 (M+H)+(ESI +ve), RT = 1.51 min, 98.3%, 200 - 400nm.Intermediate 13: Synthesis of (4-aminophenyl)(8-(l-methyl-6-(trifluoromethyl)-lH- benzo [d] imidazol-5-yl)indolizin-3-yl)methanoneStep-1: Synthesis of 3-bromo-2-methyl-l-(2-(4-nitrophenyl)-2-oxoethyl)pyridin-l-ium bromide salt
[0600] To a stirred solution of 2-bromo-l-(4-nitrophenyl)ethan-l-one (20.0g, 81.95mmol) in THF (200mL) was added 3-bromo-2-methylpyridine (28.2g, 163.90mmol) at room temperature. The reaction mixture was heated at 80°C for 32h. After completion of the reaction, the reaction mixture was cooled to room temperature. The resulting suspension was filtered and washed with hexane. The resulting solid was dried under vacuum to afford title compound as an off-white solid (28.0g, 67.65mmol, 83% yield). LCMS: (ACQUITY PDA and QDA detector, UC05_FARl): m / z 335.1 (M)+(ESI +ve), RT = 1.32 min, 77.1%, 200 - 400nm.Step-2: Synthesis of (8-bromoindolizin-3-yl)(4-nitrophenyl)methanone
[0601] Dimethyl sulphate (34.12g, 270.58mmol) was dissolved in DMF (21mL) at room temperature and heated at 80°C temperature for 2h. The reaction mixture was cooled to room temperature. In a separate vessel 3-bromo-2-methyl-l-(2-(4-nitrophenyl)-2-oxoethyl)pyridin-l- ium bromide salt (14g, 33.82mmol) was dissolved in in DMF (21mL) at room temperature. The reaction mixture was cooled to 0°C temperature. A solution of dimethyl sulphate in DMF was added to the reaction mixture at 0°C temperature. The reaction mixture was stirred for Ih at room temperature followed by addition of DIPEA (23.52mL, 135.29mmol) over a period of Ih. After completion of the reaction, the reaction mixture was poured into ice-cold water to precipitate out the product. The obtained precipitate was filtered off and washed with hexane to afford the title compound a...
Claims
CLAIMSWhat is claimed is:
1. A compound having a structure of F ormula (A) :Formula (A) or a salt thereof, wherein,X1is absent or O;X is absent, O, or NRA;Q1is Rxor L-G;Q2is L-G or Y2;Y2is a blocking group (e.g., a group that directs (e.g., covalent and / or irreversible) binding (of a cysteine residue) of a protein to a position other than Y2);Rxis substituted or unsubstituted alkyl or NRyRz;RA, Ry, and Rzare each independently hydrogen or substituted or unsubstituted alkyl;L is a linker; andG is an organic residue; wherein one and only one of Q1or Q2is L-G.
2. A compound having a structure of Formula (I):Formula (I) or a salt thereof, wherein,X is absent, O, or NRA;RAis hydrogen or substituted or unsubstituted alkyl;Y is a blocking group (e.g., a group that directs (e.g., covalent and / or irreversible) binding (of a cysteine residue) of a protein to a position other than Y2);L is a linker; andG is a protein-binding ligand (e.g., a radical of a compound that interacts with a protein or a mutant thereof, comprising one or more cyclic group wherein the one or more cyclic groups are individually linked by one or more linker).
3. The compound of claim 1, wherein Q1is not substituted or unsubstituted methoxy phenyl.
24. The compound of claim 1 or 2, wherein X is O.
5. The compound of any one of the preceding claims, wherein at least one of X1or X2is O.
6. The compound of any one of the preceding claims, wherein Y2is not halo.
7. The compound of any one of the preceding claims, wherein Y2is not fluoro.
8. The compound of any one of the preceding claims, wherein Y2is hydrogen, CN, NO2, hydroxy, substituted or unsubstituted amino (e.g., -NRxaRya-, where Rxais hydroxy and Ryais hydrogen or), substituted or unsubstituted alkyl (e.g., fluoroalkyl), substituted or unsubstituted alkoxy (e.g., fluoroalkoxy), or substituted or unsubstituted heteroalkyl (e.g., alkylamine substituted with oxo and / or hydroxy)).
9. The compound of any one of the preceding claims, wherein Y2is hydrogen, CN, NO2, or substituted alkyl (e.g., alkyl substituted with halo (e.g., fluoroalkyl (e.g., methyl substituted with one, two, or three fluoro))).
10. The compound of any one of the preceding claims, wherein Y2is hydrogen, CN, NO2, or CF3.
11. The compound of any one of the preceding claims, wherein Y2is CN, NO2, or CF3.
12. The compound of any one of the preceding claims, wherein Y2is CN or NO2.
13. The compound of any one of the preceding claims, wherein the compound (e.g., covalently and / or irreversibly) interacts with a protein or a mutant thereof (e.g., a cysteine residue of the protein or the mutant thereof) at a position other than Y2(e.g., a position ortho or meta to Y2).
214. The compound of any one of the preceding claims, wherein Y is a group that directs (e.g., covalent and / or irreversible) binding (e.g., of a cysteine residue) of a protein (e.g., BTK, EGFR, FGFR, AUKRA, KIT, BMX, KRAS, TEAD, JAK3) or a mutant thereof to a position other than Y2(e.g., a position ortho or meta to Y2).
15. The compound of any one of the preceding claims, wherein when Y2is H, thiol, substituted thioether, substituted alkoxy (e.g., fluoroalkoxy), substituted amino, or NO2, the compound (e.g., covalently and / or irreversibly) interacts with a protein or a mutant thereof(e.g., a cysteine residue of the protein or the mutant thereof) at a position other than Y2(e.g., a position ortho or meta to Y2).
16. The compound of any one of the preceding claims, wherein the compound does not covalently bind with (e.g., the thiol of) GSH (e.g., at Y2 or a position ortho or meta to Y2).
17. The compound of any one of the preceding claims, wherein G comprises one or more cyclic groups wherein the one or more cyclic groups are individually linked by one or more linker.
18. The compound of any one of the preceding claims, wherein G comprises an optionally substituted cyclic group, optionally substituted with one or more L’-G’, wherein each L’ is individually selected from a linker and is connected to another G’.
19. The compound of any one of the preceding claims, wherein G comprises an optionally substituted cyclic group, optionally substituted with -(L’-G’)nL’-G’, wherein n is 0 to 4.
20. The compound of claim 19, wherein n is 1 to 3.
21. The compound of any one of the preceding claims, wherein G or G’ is a radical of a compound that interacts with a protein (e.g., BTK, EGFR, FGFR, AUKRA, KIT, BMX, KRAS, TEAD, JAK3) or a mutant thereof.
22. The method or pharmaceutical composition of any one of the preceding claims, wherein G or G’ is amino, hydroxyl, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, alkoxy, or comprises one or more cyclic groups wherein the one or more cyclic groups are individually linked by one or more linker.
23. The method or pharmaceutical composition of any one of the preceding claims, wherein G or G’ comprises one or more cyclic groups wherein the one or more cyclic groups are individually linked by one or more linker.
24. The compound of any one of the preceding claims, wherein G or G’ comprises a substituted or unsubstituted carbocycle.
25. The compound of any one of the preceding claims, wherein G or G’ is a substituted carbocycle.
26. The compound of any one of the preceding claims, wherein G or G’ comprises a substituted or unsubstituted heterocycle.
27. The compound of claim 26, wherein G or G’ is a substituted heterocycle.
28. The compound of claim 27, wherein G or G’ is a substituted or unsubstituted N- heterocycle.
29. The compound of any one of the preceding claims, wherein G or G’ comprises one or more (e.g., one, two, or three) nitrogen atoms (e.g., within its (e.g., fused) ring system).
30. The compound of any one of the preceding claims, wherein G or G’ comprises one or more (e.g., fused) rings.
31. The compound of any one of the preceding claims, wherein G or G’ is aromatic or partially aromatic.
32. The compound of any one of the preceding claims, wherein G or G’ comprises one or more (e.g., one, two, or three) substituted or unsubstituted (e.g., fused) aromatic ring(s).
33. The compound of any one of the preceding claims, wherein G or G’ comprises two or more substituted or unsubstituted aromatic or partially aromatic rings, each aromatic or partially aromatic ring independently being a carbocycle or a heterocycle.
34. The compound of any one of the preceding claims, wherein G or G’ comprises one or more substituted or unsubstituted carbocycle and one or more substituted or unsubstitued heterocycle, each of the one or more substituted or unsubstituted carbocycle and the one or more substituted or unsubstitued heterocycle independently being linked (e.g., fused) to a substituted or unsubstituted carbocycle or a substituted or unsubstitued heterocycle by a bond.
35. The compound of any one of the preceding claims, wherein G or G’ comprises two (or more) substituted or unsubstituted heteroaromatic rings, the heteroaromatic rings being linked (e.g., fused) by a bond, each heteroaromatic ring being aromatic or partially aromatic.
36. The compound of claim 35, wherein the heteroaromatic rings are selected from the group consisting of benzimidazole, indole, indolizine, pyridine, and pyridopyrimidinone (e.g., pyrido[2,3-d]pyrimidin-2(lH)-one).
37. The compound of any one of the preceding claims, wherein G or G’ has a structure of:
38. The compound of any one of claims 1-36, wherein G or G’ has a structure of:
39. The compound of any one of claims 1-36, wherein G or G’ has a structure of:
40. The compound of any one of claims 1-33, wherein G or G’ comprises two (or more) substituted or unsubstituted phenyl rings, the phenyl being linked by a bond.
41. The compound of claim 40, wherein G or G’ has a structure of:
42. The compound of any one of claims 1-36, wherein G or G’ is or comprises a substituted or unsubsituted quinazoline, a substituted or unsubstituted tetrahydropyridopyrimidine (e.g., 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine), a substituted or unsubsituted quinoline, a substituted or unsubstituted pyridopyrazinone (e.g., pyrido[2,3-b]pyrazin-3(4H)-one), a substituted or unsubstituted benzimidazole, a substituted or unsubstituted pyrrolopyrimidine (e.g., a 7H-pyrrolo[2,3-t / ]pyrimidine), a substituted or unsubstituted pyrazolopyridine (e.g., a pyrazolo[l,5-a]pyridine), or a substituted pyrrolopyridine (e.g., a lH-pyrrolo[2,3-Z>]pyridine).
43. The compound of claim 42, wherein G or G’ is a substituted tetrahydropyridopyrimidine (e.g., 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine).
44. The compound of claim 43, wherein G or G’ has a structure of:
45. The compound of any one of claims 1-34, wherein G or G’ has a structure of:
46. The compound of any one of claims 1-32, wherein G or G’ is a substituted carbocycle.
47. The compound of claim 46, wherein G or G’ is a substituted phenyl.
48. The compound of claim 46 or 47, wherein G or G’ has a structure of:
49. The compound of any one of claims 1-32, wherein G or G’ is a substituted pyridine.
50. The compound of claim 49, wherein G or G’ has a structure of:
51. The compound of any one of claims 1-32, wherein G or G’ is a substituted pyrazole.
52. The compound of claim 51, wherein G or G’ has a structure of:
53. The compound of any one of claims 1-32, wherein G or G’ is a substituted or unsubsituted quinazoline or a substituted pyrazolopyrimidine (e.g., lH-pyrazolo[3,4-d]pyrimidine).
54. The compound of claim 53, wherein G or G’ has a structure of:
55. The compound of claim 53, wherein G or G’ has a structure of:
56. The compound of claim 53, wherein G or G’ has a structure of:
57. The compound of claim 53, wherein G or G’ has a structure of:
58. The compound of any one of claims 1-32, wherein G or G’ is a substituted pyrrolopyridine (e.g., a lH-pyrrolo[2,3-Z>]pyridine).
59. The compound of claim 58, wherein G or G’ has a structure of:
60. The compound of any one of claims 1-32, wherein G or G’ is an unsubstituted pyrrolopyrimidine (e.g., a 7H-pyrrolo[2,3-t / ]pyrimidine).
61. The compound of claim 60, wherein G or G’ has a structure of:
62. The compound of any one of claims 1-32, wherein G or G’ is a substituted pyrazolopyridine (e.g., a pyrazolo[l,5-a]pyridine).
63. The compound of claim 62, wherein G or G’ has a structure of:
64. The compound of any one of claims 1-32, wherein G or G’ is a substituted benzimidazole.
65. The compound of claim 64, wherein G or G’ has a structure of:
66. The compound of any one of the preceding claims, wherein L or L’ is a bond, amino, substituted or unsubstituted alkyl(ene), substituted or unsubstituted alkoxy, substituted or unsubstituted heteroalkyl(ene), substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl.
67. The compound of any one of the preceding claims, wherein L or L’ is amino, substituted or unsubstituted heteroalkyl(ene), or substituted or unsubstituted heterocyclyl.
68. The compound of any one of the preceding claims, wherein L or L’ comprises one or more N atom(s).
69. The compound of any one of the preceding claims, wherein L or L’ is amino.
70. The compound of any one of the preceding claims, wherein L or L’ is -NR2-, where R2is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted carbocyclyl.
71. The compound of any one of the preceding claims, wherein L or L’ is -NH- or -NCH3-.
72. The compound of any one of the preceding claims, wherein L or L’ is substituted or unsubstituted alkylamine.
73. The compound of claim 72, wherein L or L’ is methylamine, ethylamine, propylamine, or butylamine.
74. The compound of any one of claims 1-69, wherein L or L’ is -NR3R4-, where R3is substituted or unsubstituted alkyl(ene), substituted or unsubstituted heteroalkyl(ene), substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocycyl andR4is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted carbocyclyl.
75. The compound of claim 74, wherein L or L’ is -NH(heterocyclyl)-.
76. The compound of claim 75, wherein L or L’ is -NH(azetidinyl)-.
77. The compound of any one of claims 1-68, wherein L or L’ is substituted or unsubstituted heterocyclyl.
78. The compound of any one of claims 1-68, wherein L or L’ is -NR5R6-, -NR5R6-NR7-, - NR5R6-C(O)-, -NR5R6-CH2NR7-, -NR5R6-CH2NR7C(O)-, -C(O)NR5R6-NR7-, or - C(O)NR5R6CH2-NR7-, where R5and R6are taken together to form a substituted or unsubstituted heterocyclyl, and R7is H, substituted or unsubstituted alkyl (e.g., alkyl substituted with oxo), or alkoxy.
79. The compound of claim 78, wherein -NR5R6- is substituted or unsubstituted piperazinyl (e.g., piperazinyl substituted with methyl), substituted or unsubstituted piperidinyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted azepanyl, or diazepanyl (e.g., 1,4-diazepanyl).
80. The compound of claim 78, wherein -NR5R6- is substituted or unsubstituted piperidinyl or substituted or unsubstituted azetidinyl and -NR7- is -NH-, -NCH3-, -NC(O)CH3-, or - NCH2CH2OCH3-.
81. The compound of claim 78, wherein L or L’ is -NR5R6-C(O)- and -NR5R6- is unsubstituted 1,4-diazepanyl.
82. The compound of claim 78, wherein L or L’ is -C(O)NR5R6-NR7-, -NR5R6- is unsubstituted piperidinyl or unsubstituted pyrrolidinyl, and -NR7- is -NH-.
83. The compound of claim 78, wherein L or L’ is -NR5R6-CH2NR7C(O)-, -NR5R6- is unsubstituted pyrrolidinyl, and -NR7- is -NH-.
84. The compound of claim 78, wherein L or L’ is -NR5R6-CH2NR7-, -NR5R6- is unsubstituted azetidinyl or azepanyl, and -NR7- is -NH-.
85. The compound of claim 78, wherein L or L’ is -NR5R6-CH2NR7C(O)-, -NR5R6- is unsubstituted azetidinyl, and -NR7- is -NH-.
86. The compound of claim 78, wherein L or L’ is substituted or unsubstituted piperazinyl (e.g., piperazinyl substituted with methyl) or substituted or unsubstituted piperidinyl.
87. The compound of any one of the preceding claims, wherein L or L’ comprises two N atom(s) (e.g., (substituted or unsubstituted) diaminoalkyl, (substituted or unsubstituted) diamino-cycloalkyl, (substituted or unsubstituted) amino-heterocyclyl (e.g., the heterocyclyl being nitrogen containing), (substituted or unsubstituted) heterocyclyl (e.g., containing 2 nitrogen atoms), the heterocyclyl being optionally fused or spirocyclic).
88. The compound of any one of the preceding claims, wherein L or L’ is or comprises -C(O)- diaminoalkyl-, each amino group of the diaminoalkyl being independently unsubstituted or substituted, such as being substituted with methyl.
89. The compound of any one of the preceding claims, wherein L or L’ comprises one or more (e.g., fused or spirocyclic) rings.
90. The compound of any one of the preceding claims, wherein L or L’ is or comprises a spirocyclic ring, such as l,7-diazaspiro[4.5]decane.
91. The compound of any one of the preceding claims, wherein L or L’ is or comprises substituted or unsubstituted phenyl.
92. The compound of claim 91, wherein L or L’ is or comprises substituted phenyl, the phenyl being substituted with substitued halo, cyano, amino, alkylamino, heteroalkyl (e.g., substituted alkanolamine or substituted diaminoalkyl), -N-(substituted heterocyclyl), or substituted heterocyclyl, such as wherein the substituted heterocyclyl is piperidinyl or pyrrolidinyl substituted with amino or alkylamine.
93. The compound of claim 91 or 92, wherein L or L’ is -NH-(unsubstituted phenyl)-, -NH- (unsubstituted phenyl)-C(O)-, -NH-(substituted phenyl)-C(O)-, -NH-(unsubstituted phenyl)-C(O)NH-, or-NH-(substituted phenyl)-C(O)NH-.
94. The compound of any one of claims 91-93, wherein L or L’ is:
95. The compound of any one of claims 1-66, wherein L or L’ is a bond.
96. A compound represented by a structure of Table 2A, Table 2B, Table 2C, or Table 2D.
97. A pharmaceutically acceptable composition comprising a compound of any one of the preceding claims, or a salt thereof, and one or more pharmaceutically acceptable excipients.
98. A protein modified with a compound of any one of the preceding claims, or a salt thereof, wherein the compound forms a covalent bond with a sulfur atom of a cysteine residue of the protein.
99. A method of modifying (e.g., attaching to and / or degrading) a polypeptide with a compound, comprising contacting the polypeptide with a compound of any one of the preceding claims, or a salt thereof, to form a covalent bond with a sulfur atom of a cysteine residue of the polypeptide.
100. A method of binding a compound to a polypeptide (e.g., a protein), comprising contacting the polypeptide with a compound of any one of the preceding claims, or a salt thereof.
101. A method of disrupting a polypeptide (e.g. the function thereof), comprising contacting the polypeptide with a compound of any one of the preceding claims, or a salt thereof.
102. A method of modifying a polypeptide with a compound, comprising contacting the polypeptide with the compound of any one of the preceding claims, or a salt thereof.
103. The method of any one of claims 99-102, wherein the compound contacts the polypeptide intracellularly (e.g., in an individual).
104. A method for (e.g., selectively) modifying a polypeptide (e.g., a protein) with a compound of any one of claims 1-96, the method comprising contacting the polypeptide with the compound, the compound having reduced reactivity with glutathione (GSH).
105. A method for (e.g., selectively) modifying a polypeptide (e.g., a protein) in the presence of glutathione (GSH) with a compound of any one of claims 1-96, the method comprising contacting the polypeptide with the compound (e.g., to form a covalent bondwith (e.g., a sulfur atom of a cysteine residue of) the polypeptide) without the compound substantially covalently binding to GSH (e.g., as demonstrated by the lack of covalent binding of GSH to the compound).
106. A method for (e.g., selectively) modifying a polypeptide (e.g., a protein) in the presence of glutathione (GSH) with a compound of any one of claims 1-96, the method comprising contacting the polypeptide with the compound, wherein the compound is selective for the polypeptide relative to GSH.
107. The method of any one of the preceding claims, wherein the polypeptide covalently binds to the compound (e.g., wherein the polypeptide comprises a thiol (e.g., a cysteine residue) that covalently binds to the compound).
108. The method of any one of the preceding claims, wherein the polypeptide contacts (e.g., covalently binds) the compound in the absence of covalent binding of GSH to the compound.
109. The method of any one of the preceding claims, wherein the compound is selective for (e.g., covalent) binding to the polypeptide relative to GSH.
110. The method of any one of the preceding claims, wherein the compound is selective for the polypeptide relative to GSH at a ratio of at least 10: 1 (e.g., 20: 1 or more, 50: 1 or more, 100: 1 or more, 500: 1 or more, 1000: 1 or more).
111. The method of any one of the preceding claims, wherein the compound has an ICso for the polypeptide of at least 10 μM and a GSH half life of greater than about 10 minutes (e.g., ICso of at least 1 μM and a GSH half life of greater than about 10 minutes (e.g., IC50 of at least 0.1 μM and a GSH half life of greater than about 100 minutes)).
112. The method of any one of the preceding claims, wherein the compound is at least 2-fold (e.g., 2-fold or more, 5-fold or more, 10-fold or more, 25-fold or more) selective for the polypeptide relative to GSH.
113. The method of any one of the preceding claims, wherein the polypeptide is Bruton’s tyrosine kinase (BTK), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), aurora kinase A (AURKA), proto-oncogene c-KIT (KIT), or BMX non-receptor tyrosine kinase (BMX), transcriptional enhancer factor TEF (TEAD), Janus kinase 3 (JAK3), KRAS, or a mutant thereof.
114. The method of any one of the preceding claims, further comprising inhibiting, deactivating, or degrading the polypeptide.
115. A pharmaceutical composition comprising a compound of any one of the preceding claims, the compound having reduced reactivity with GSH.
116. A pharmaceutical composition comprising a compound of any one of the preceding claims, wherein the compound is selective for a polypeptide (e.g., a protein) relative to glutathione (GSH).
117. A pharmaceutical composition that is (e.g., at least partially) stable to glutathione (GSH), the composition comprising a compound of any one of the preceding claims.
118. The pharmaceutical composition of any one of claims 115-117, wherein the pharmaceutical composition is (e.g., at least partially) stable to glutathione (GSH) in the presence of a polypeptide.
119. The pharmaceutical composition of any one of claims 115-118 wherein the compound is selective for the polypeptide over GSH.
120. The pharmaceutical composition of any one of claims 115-119, wherein the compound is selective for the polypeptide relative to GSH at a ratio of at least 10: 1 (e.g., 20: 1 or more, 50: 1 or more, 100: 1 or more, 500: 1 or more, 1000: 1 or more).
121. The pharmaceutical composition of any one of claims 115-120, wherein the compound is selective for the polypeptide relative to GSH at a ratio of about 10: 1 to about 100: 1.
122. The pharmaceutical composition of any one of claims 115-121, wherein the polypeptide comprises Bruton’s tyrosine kinase (BTK), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), aurora kinase A (AURKA), proto-oncogene c-KIT (KIT), BMX non-receptor tyrosine kinase (BMX), transcriptional enhancer factor TEF (TEAD), Janus kinase 3 (JAK3), KRAS, or a mutant therof.
123. The method or pharmaceutical composition of any one of the preceding claims, wherein the compound does not covalently bind with (e.g., the thiol of) GSH.
124. The method or pharmaceutical composition of any one of the preceding claims, wherein the compound is represented by a structure of Table 2A, Table 2B, Table 2C, or Table 2D.
Citation Information
Patent Citations
Pharmaceutical compositions comprising tetrafluorobenzenesulphonamide derivatives
GB1025314A
Substituted benzene compounds as antiproliferative and cholesterol lowering agents
WO1999010320A1
Fluorinated benzenesulfonamides as inhibitors of carbonic anhydrase
WO2014062044A1
Organic polymers as photocatalysts
WO2020047042A1
Benzenesulfonamide derivatives and uses thereof
WO2022106902A2
